[go: up one dir, main page]

US20080260655A1 - Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses - Google Patents

Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses Download PDF

Info

Publication number
US20080260655A1
US20080260655A1 US12/025,547 US2554708A US2008260655A1 US 20080260655 A1 US20080260655 A1 US 20080260655A1 US 2554708 A US2554708 A US 2554708A US 2008260655 A1 US2008260655 A1 US 2008260655A1
Authority
US
United States
Prior art keywords
composition
agent
petrolatum
foam
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/025,547
Other languages
English (en)
Inventor
Dov Tamarkin
Doron Friedman
Enbal Ziv
Meir Eini
Tal Berman
Jorge Danziger
Rita KEYNAN
David Schuz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vyne Pharmaceuticals Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/940,290 external-priority patent/US20080206155A1/en
Priority to US12/025,547 priority Critical patent/US20080260655A1/en
Application filed by Individual filed Critical Individual
Assigned to FOAMIX LTD. reassignment FOAMIX LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHUZ, DAVID, KEYNAN, RITA, DANZIGER, JORGE, EINI, MEIR, FRIEDMAN, DORON, TAMARKIN, DOV, ZIV, ENBAL, BERMAN, TAL
Publication of US20080260655A1 publication Critical patent/US20080260655A1/en
Priority to AU2009211147A priority patent/AU2009211147A1/en
Priority to EP09707299A priority patent/EP2257276A2/fr
Priority to CA2714015A priority patent/CA2714015C/fr
Priority to PCT/IB2009/005032 priority patent/WO2009098595A2/fr
Priority to US12/778,591 priority patent/US8795635B2/en
Priority to US14/189,559 priority patent/US9682021B2/en
Assigned to FOAMIX PHARMACEUTICALS LTD. reassignment FOAMIX PHARMACEUTICALS LTD. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: FOAMIX LTD.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A61K2800/31—Anhydrous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Definitions

  • Petrolatum in its various forms has a number of useful attributes for use in topical foamable pharmaceutical and cosmetic compositions. They are inherently stable and inert, which are clearly desirable characteristics. They are also able to moisturize and soften the skin and in appropriate amounts can act as a protective or barrier layer and can form a barrier to water, which can, for example, solubilize or cause destabilization of some active ingredients. By careful design and appropriate formulation of petrolatum compositions they can act to improve drug delivery to the skin; provide a protective environment for the drug and yet remain resistant to being washed off unintentially.
  • Aliphatic alcohols in foam compositions promote fast drying and thereby attempt to address the sticky feeling left by many topical formulations after application; however, alcohols, and in particular short chain alcohols like methyl, ethyl and isopropyl alcohols are defatting agents and may cause skin to become dry and cracked. Also, the presence of such alcohols generates alcoholic foam that is thermal sensitive and quick breaking, e.g., it collapses readily upon contact with a surface upon exposure to body temperature environment. Although certain compositions based on petrolatum are known they are, for example, designed to form an occlusive layer in the presence of active pharmaceutical agents that are not soluble in the water or oil phase.
  • silicone oil is an essential and main component and it is used to try and overcome the greasy feeling of petrolatum. Silicones can have substantial disadvantages in foamable compositions and foams especially in significant levels.
  • Alcohol is known to impair the integrity of the skin barrier, dry the skin and cause skin irritation.
  • the incidence skin irritation (burning, itching and stinging) can be very high.
  • a safe foam vehicle which will overcome the evident skin drying and irritation caused by alcohol, is warranted, especially where sensitive skin, mucosa, or body cavity membranes are being targeted.
  • foam compositions that possess a lesser degree of thermal sensitivity, thus being more useful for the treatment of large skin areas are desired.
  • Foamable compositions that produce foams, which are soft are desirable especially with improved stability.
  • a foamable vehicle that is suitable for use as a base for delivery of not merely one type of active pharmaceutical ingredient (API) but is adaptable for use with one or more API's from a wide range of different types of API's with relatively minimal or minor adjustment to the vehicle. For example, by altering the amount of a component or by the addition of a buffer that provides a pH at which the API is stable as would be appreciated by a person skilled in the art.
  • API active pharmaceutical ingredient
  • This application relates to petrolatum-based foamable vehicles, pharmaceutical compositions and resultant foams.
  • the petrolatum-based foamable vehicles, pharmaceutical compositions and resultant foams are non-aqueous.
  • petrolatum-based foamable vehicles, pharmaceutical compositions and resultant foams have low water content.
  • the application further relates to such compositions and to such resultant foams that are non-silicone and or are non-alcoholic or substantially so.
  • a prime concept covered herein is that petrolatum as a hydrophobic carrier is a main ingredient and is at least about 50% of the foamable carrier alone or in combination with a solvent substantially miscible therein for example a hydrophobic oil.
  • the percentage of petrolatum is more than about 60%.
  • the foamable carrier is non-aqueous and the petrolatum is at least about 25% and is in combination with a solvent substantially miscible therein such that together they are at least about 80% and the carrier is substantially free of silicone oil.
  • substantially free it is meant that the silicone oil content in the composition is less than about 1%.
  • the foamable carrier is substantially non-aqueous or has low water content and the petrolatum is more than about 50% or more than about 55% and preferably more than about 60%.
  • substantially non-aqueous or low water content it is meant that the amount of water if present in the composition is small and is less than about 26%, preferably less than about 16% and more preferably less than about 13%.
  • proportion of water is relatively very small by selective use of appropriate and compatible surfactants it can be possible to produce both water in oil and also oil in water petrolatum emulsion compositions. Whilst these carriers are intended to be without lower or short chain alcohols, where an API is provided as an alcoholic extract, such small amount of alcohol is permitted in the compositions. In certain embodiments, such lower alcohol content is reduced or essentially eliminated by evaporation upon warming.
  • the petrolatum based carriers comprise one or more active pharmaceutical ingredients (API's).
  • API's active pharmaceutical ingredients
  • the formulations are designed to carry homogeneously large ranges of API's from microgram levels to up to about 33% of the composition.
  • Some API's are stable in one kind of environment whilst others require a different environment.
  • many steroids are known to undergo rearrangement at high pH, and are more stable in acidic formulations whilst vitamin D and its derivatives fare better in a basic medium. So adding an acidic modulating agent such as an acidic buffer, or fatty acid helps prevent steroid degradation whilst the addition of a basic modulating agent, such as a basic buffer or triethanolamine is useful to maintain acceptable stability for vitamin D and derivatives.
  • the formulations described herein offer waterless and substantially waterless or low water content variations and an appropriate carrier may be selected for an API depending on its sensitivity and reactivity in the presence and absence of relatively small amounts of water. Whilst the carrier compositions described herein may be useful carriers for API's some are not compatible in the same formulations and may react or breakdown.
  • the formulations described are suitable for use in dual or multi chamber foam delivery devices, where each chamber delivers an API which if stored with the API's in the other chamber(s) would have broken down.
  • the carrier in the first chamber is substantially waterless and the carrier in the second chamber is waterless.
  • the carrier is basically the same in each chamber although some minor variations such as to pH or artificial pH or in the presence of one or more preservatives, stabilizers, antioxidants, and the like may be made to reflect the specific requirements of the API.
  • the formulations contain a foam agent.
  • the foam agent is selected from the group consisting of a surfactant, a surfactant combination, a foam adjuvant and combinations thereof.
  • the quality may be improved by addition of a polymeric agent.
  • the polymeric agent may preferably have some surfactant-like properties or help to ameliorate the tacky greasy properties of petrolatum.
  • the foamable composition is a non-aqueous, non-alcoholic foamable composition that includes a foamable carrier and at least one liquefied or compressed gas propellant.
  • the foamable carrier includes (1) a petrolatum or mixtures thereof at a concentration of about 25% to about 95% by weight; (2) a solvent substantially miscible in the petrolatum at a concentration of about 0% to about 70% by weight; and (3) at least one foam agent selected from the group consisting of a surfactant, a surfactant system, a foam adjuvant and combinations thereof; at a concentration of about 0.1% to about 20% by weight.
  • the petrolatum is present in the foamable carrier at a concentration of at least about 50% by weight.
  • the petrolatum is present in the foamable carrier at a concentration of at least about 25% by weight and the solvent and petrolatum are together present in the foamable carrier at a concentration of least about 55% by weight; or (ii) the amount of petrolatum is about the same as or in excess of the solvent and, together, the solvent and petrolatum are present in the foamable carrier at a concentration of at least about 80%.
  • the ratio of the foamable carrier to the propellant is 100:10 to 100:35.
  • the composition is substantially free of silicone. The composition is stored in a pressurized container or aerosol container and upon release expands to form a breakable foam.
  • the foamable composition is a non-aqueous, non-alcoholic foamable composition that includes a foamable carrier and at least one liquefied or compressed gas propellant.
  • the foamable carrier includes (1) a petrolatum or mixtures thereof at a concentration of about 50% to about 95% by weight; (2) a solvent substantially miscible in the petrolatum at a concentration of about 0% to about 45% by weight; (3) at least one foam agent selected from the group consisting of a surfactant, a surfactant system; a foam adjuvant and combinations thereof at a concentration of about 0.1% to about 20% by weight; and (4) an effective amount of an active pharmaceutical agent.
  • the ratio of the foamable carrier to the propellant ranges from about 100:10 to about 100:35.
  • the composition is substantially free of silicone. Moreover, the composition is resistant to centrifugation at 1000 rpm for about 10 minutes; is flowable or flowable to a degree and or is shakable or substantially so when stored in a pressurized container or an aerosol container and upon release expands to form a breakable foam having no substantial or sustained cooling affect and having a foam hardness in the range of about 5 g to about 100 g.
  • the foamable composition is a low water content, non-alcoholic foamable composition that includes a foamable carrier and at least one liquefied or compressed gas propellant.
  • the foamable carrier includes (1) a petrolatum or mixtures thereof at a concentration of about 25% to about 95% by weight; (2) a solvent substantially miscible in the petrolatum at a concentration of 0% to about 70% by weight; (3) at least one foam agent selected from the group consisting of a surfactant, a surfactant system, a foam adjuvant and combinations thereof; at a concentration of about 0.1% to about 20% by weight; and (4) water at a concentration of up to about 26% by weight.
  • the petrolatum is present in the foamable carrier at a concentration of at least about 50% by weight.
  • the petrolatum is present in the foamable carrier at a concentration of at least about 25% by weight and the solvent and petrolatum are together present in the foamable carrier at a concentration of least about 55% by weight; or (ii) the amount of petrolatum is about the same as or in excess of the solvent and, together, the solvent and petrolatum are present in the foamable carrier at a concentration of at least about 80%.
  • the ratio of the foamable carrier to the propellant ranges from about 100:10 to about 100:35.
  • the composition is substantially free of silicone.
  • the foamable composition is stored in a pressurized container or aerosol container and upon release expands to form a breakable foam.
  • the foamable composition is a low water content, non-alcoholic foamable composition that includes a foamable carrier and at least one liquefied or compressed gas propellant.
  • the foamable carrier includes (1) a petrolatum or mixtures thereof at a concentration of about 50% to about 95% by weight; (2) a solvent substantially miscible in the petrolatum at a concentration of about 0% to about 45% by weight; (3) at least one foam agent selected from the group consisting of a surfactant, a surfactant system; a foam adjuvant and combinations thereof at a concentration of about 0.1% to about 20% by weight; and (4) an effective amount of an active pharmaceutical agent.
  • the solvent is water and is present in the carrier at a concentration of about 0.1% to about 26% by weight.
  • the ratio of the foamable carrier to the propellant ranges from about 100:10 to about 100:35.
  • the composition is substantially free of silicone.
  • the composition is resistant to centrifugation at 1000 rpm for about 10 minutes and is flowable or flowable to a degree and or is shakable or substantially so when stored in a pressurized container or aerosol container and upon release expands to form a breakable foam having no substantial or sustained cooling affect and having a foam hardness in the range of about 5 g to about 100 g
  • a substantially non-aqueous, non-alcoholic, non-silicone foamable carrier composition comprising:
  • the amount of petrolatum is in excess of about 50% and there is present an amount of solvent substantially miscible therein between about 0.1% to about 45%. Preferably it is in excess of about 55% and the range is about 0.1% to about 40% and more preferably in excess of about 60% and the range is about 0.1% to about 35%.
  • a substantially non-aqueous, non-alcoholic non-silicone foamable carrier composition comprising:
  • the formulations and foams are non-aqueous, non-silicone and non-alcoholic (being in the absence of a lower alcohol). In one or more other embodiments the formulations and foams have at least two of the three features listed.
  • Foamable non-aqueous compositions are described that are non-aqueous or essentially so, are stable and able to provide some of the main attributes of a petrolatum ointment or cream in a topical foamable formulation and which can deliver a substantially uniform and stable foam without the use of an alcohol in the formulation.
  • non-aqueous or “essentially non-aqueous” it is meant that the compositions contain at most incidental and trace amounts of water. In one embodiment, the water content is very small being about less than about 5%.
  • without alcohol or “non-alcoholic” it is intended to exclude the use of lower or short chain alcohols.
  • These compositions comprise petrolatum.
  • the petrolatum phase is the main phase or is a major element of the carrier.
  • the formulations can also ameliorate or overcome to a degree the look and feel of a greasy material. These compositions can provide an improved delivery system over ointments and creams.
  • the foamable non-aqueous compositions are flowable or flowable to a degree and or are shakable and can expand to produce a good quality foam without the propellant having a significant cooling effect.
  • the foamable non-aqueous compositions produce foams that are soft or with an improved softness.
  • pharmaceutically effective amounts of one or more active pharmaceutical ingredients are incorporated into the foamable non-aqueous composition.
  • an active ingredient is distributed homogeneously in the composition are described.
  • substantial amounts of an active ingredient are distributed homogeneously in the composition.
  • foamable non-aqueous compositions are provided in which the solvent comprises a propellant, which evaporates on expansion to produce a foam.
  • the foamable non-aqueous composition is suitable for use as a base for delivery for API's, which are by their nature emulsion destabilizers, micelle destabilizers or interphase destabilizers, with relatively minimal or minor adjustment to the vehicle or in the method of preparation.
  • API's which are by their nature emulsion destabilizers, micelle destabilizers or interphase destabilizers, with relatively minimal or minor adjustment to the vehicle or in the method of preparation.
  • Pharmaceutical salts for example, are in general emulsion destabilizers.
  • foamable non-aqueous compositions are described that improve the solubility and/or deliverability of the active pharmaceutical to a target skin, mucosa or body cavity area and/or provide an improved delivery system over ointments and creams.
  • the present invention relates to non-aqueous, non-alcoholic, non-silicone, foamable carriers and pharmaceutical and cosmetic compositions comprising at least, a hydrophilic carrier comprising petrolatum or mixtures thereof with a solvent substantially miscible therein, a surfactant, and a propellant with and without the addition of an active agent.
  • a hydrophilic carrier comprising petrolatum or mixtures thereof with a solvent substantially miscible therein, a surfactant, and a propellant with and without the addition of an active agent.
  • the present invention relates to non-aqueous, non-alcoholic, non-silicone, foamable carriers and pharmaceutical and cosmetic compositions comprising at least, a hydrophilic carrier comprising petrolatum or mixtures thereof with a solvent substantially miscible therein, a surfactant, and a propellant, with and without the addition of an active agent, wherein the foam produced by the carrier or pharmaceutical composition when packaged in an aerosol container and released has a foam hardness in the range of about 5 g to about 100 g.
  • hardness level is towards the lower part of the range reflecting relative softness.
  • the resultant foam is applied to a surface it does not have any cooling or significant cooling effect.
  • the present invention relates to non-aqueous, non-alcoholic, non-silicone foamable carriers and pharmaceutical and cosmetic compositions comprising a petrolatum or mixtures thereof with a solvent substantially miscible therein, a surfactant, and a propellant, which can hold substantial amounts of active agents and still produce a good quality stable breakable foam.
  • relatively high viscosity is a viscosity of at least about 20,000 CPs. In some embodiments, relatively high viscosity is a viscosity of at least about 50,000 CPs. In some embodiments, relatively high viscosity is a viscosity of at least about 100,000 CPs.
  • the present invention also relates to non-aqueous, non-alcoholic, non-silicone, foamable carriers and pharmaceutical and cosmetic compositions comprising a petrolatum or mixtures thereof with a solvent substantially miscible therein, a surfactant, a propellant, wherein the propellant dissolves in the composition and which when stored in a pressurized canister rapidly expands on release to produce a breakable foam.
  • the present invention also relates to non-aqueous, non-alcoholic, non-silicone, foamable carriers and pharmaceutical and cosmetic compositions comprising a petrolatum or mixtures thereof with a solvent substantially miscible therein, a surfactant, a propellant, wherein the propellant dissolves in the composition.
  • the present invention also relates to non-aqueous, non-alcoholic, non-silicone, foamable based pharmaceutical compositions comprising petrolatum with a solvent substantially miscible therein, a surfactant, a propellant, and an active agent wherein the active agent is insoluble and is distributed uniformly in the composition or, wherein the composition or a phase thereof is able at least to a very limited degree to solubilize the active agent or wherein the composition or a phase of the composition is able to a degree to solubalize the active agent.
  • the hydrophobic carrier or composition does not in certain aspects contain a non-propellant organic co-solvent.
  • the present invention relates to non-aqueous, non-alcoholic, non-silicone, foamable compositions wherein each composition is flowable or flowable to a degree and or is shakable or substantially shakable when stored in an aerosol container and upon release expands to form a breakable foam that effectively delivers petrolatum with a solvent substantially miscible therein, at a concentration of from about 25% to about 95% by weight of the foam.
  • the amount of petrolatum is about more than about 35% and more preferably the amount of petrolatum is more than about 50% or more than about 55% or more than about 60%.
  • the present invention relates to a non-aqueous, non-alcoholic, non-silicone, foamable carrier composition
  • a non-aqueous, non-alcoholic, non-silicone, foamable carrier composition comprising:
  • the solvent substantially miscible in petrolatum is from about 1% to about not more than 68% by weight of the composition, preferably about not more than 55%, more preferably about not more than 45% by weight of the composition.
  • the present invention further relates to said compositions additionally comprising one or more additional active agents.
  • the present invention also relates to a non-aqueous, non-alcoholic, non-silicone, foamable pharmaceutical or cosmetic composition
  • a non-aqueous, non-alcoholic, non-silicone, foamable pharmaceutical or cosmetic composition comprising:
  • the solvent substantially miscible in petrolatum or mixtures thereof is a hydrophobic solvent or an unctuous additive.
  • the solvent is an oil, preferably a therapeutically active oil.
  • the present invention relates to said composition comprising one or more therapeutically active oils.
  • oil acts to soften and increase the fluidity of the petrolatum or mixtures thereof but on the other hand it significantly and substantially complicates the formulation and the selection of surfactants and other solvents and or foam adjuvants and or propellants appropriate to achieve a foam of quality.
  • the solvent comprises a mineral oil. In other embodiments the solvent comprises a therapeutic oil.
  • the gas propellant and its amount can be significant in improving the characteristics of the foam.
  • the propellant may itself be a solvent with respect to the foamable composition even though ultimately the propellant disappears from the composition upon release as it expands to form a breakable foam.
  • the gas propellant comprises n butane.
  • the gas propellant comprises a mixture of n-butane, isobutane and propane.
  • the mixture may be varied as a man skilled in the art would appreciate.
  • the foamable cosmetic or pharmaceutical composition is non-flammable, wherein said gas propellant contains hydrofluorocarbon.
  • non-aqueous formulations are also generally applicable to the low water content or substantially non-aqueous formulations herein with where necessary appropriate changes as would be appreciated by a man of the art.
  • the compositions further described below may also be waterless but without substantial amounts of a hydrophobic oil or where the compositions described below contain some small amount of water the compositions are formulated as an emulsion as opposed to a single phase.
  • the compositions above refer to a solvent which is substantially miscible in petrolatum
  • the compositions below are primarily concerned with hydrophilic or polar solvents.
  • Other embodiments by way of example are specifically described below.
  • Petrolatum foamable compositions wherein the petrolatum phase is the main phase of the composition that are shakable and can expand to produce a good quality foam without the propellant having a significant cooling effect are described and can provide an improved delivery system over ointments and creams.
  • Petrolatum foamable and non-aqueous petrolatum foamable compositions in which the petrolatum phase is the main phase of the composition and contains an active ingredient distributed homogeneously in the composition are described. These compositions provide an improved delivery system over ointments and creams.
  • petrolatum foamable compositions are provided without a cosolvent in which the petrolatum phase is the main phase of the composition and contains substantial amounts of an active ingredient distributed homogeneously in the composition.
  • petrolatum foamable compositions are provided in which the solvent is a propellant, which evaporates on expansion to produce a foam.
  • the petrolatum phase is the main phase of the composition and can contain substantial amounts of an active ingredient distributed homogeneously in the composition.
  • a foamable petrolatum composition is suitable for use as a base for delivery of not merely one type of API but is adaptable for use with one or more API's from a wide range of different types of API's with relatively minimal or minor adjustment to the vehicle. For example, by altering the amount of a component or by the addition of a buffer that provides a pH at which the API is stable as would be appreciated by a person skilled in the art.
  • the present invention also relates to stable non-alcoholic foamable petrolatum based carriers and pharmaceutical and cosmetic compositions comprising a petrolatum or mixtures thereof, a surfactant, a propellant, with and without a solvent wherein the propellant dissolves in the composition and which when stored in a pressurized canister rapidly expands on release to produce a breakable foam.
  • the present invention also relates to stable non-alcoholic foamable petrolatum based carriers and pharmaceutical and cosmetic compositions comprising a petrolatum or mixtures thereof, a surfactant, a propellant, with and without a solvent wherein the propellant dissolves in the composition and which are resistant to creaming at 3000 rpm for at least 10 minutes.
  • the present invention also relates to stable non-alcoholic foamable petrolatum based pharmaceutical and cosmetic compositions comprising petrolatum mixtures.
  • the present invention also relates to stable non-alcoholic foamable petrolatum based pharmaceutical compositions comprising petrolatum, a surfactant, a solvent, a propellant, and an active agent wherein the active agent is insoluble and is distributed uniformly in the composition which does not contain a non propellant organic cosolvent.
  • the present invention also relates to stable non-alcoholic foamable pharmaceutical emulsion compositions comprising petrolatum, a surfactant, a solvent, a propellant, and an active agent, wherein the composition or a phase thereof is able at least to a very limited degree to solubilize the active agent; and or so that the composition does not comprise a non propellant organic cosolvent.
  • the present invention also relates to stable non-alcoholic foamable petrolatum based pharmaceutical compositions comprising a petrolatum or mixtures thereof, a surfactant, a solvent, a propellant, and an active agent wherein the composition or a phase of the composition is able to a degree to solubalize the active agent.
  • the present invention relates to stable non-alcoholic foamable petrolatum based compositions wherein each composition is shakable or substantially shakable stored in an aerosol container and upon release expands to form a breakable foam that effectively delivers petrolatum at a concentration of about 50% to about 95% by weight of the foam.
  • petrolatum is delivered at a concentration of at least about 55%, and more preferably at least about 60%.
  • the present invention relates to stable non-alcoholic foamable petrolatum based compositions wherein each composition is flowable or flowable to a degree when stored in an aerosol container and upon release expands to form a breakable foam that effectively delivers petrolatum at a concentration of about 50% to about 95% by weight of the foam.
  • the present invention relates to a stable non-alcoholic foamable carrier composition
  • a stable non-alcoholic foamable carrier composition comprising:
  • the present invention further relates to said compositions comprising in addition a solvent, preferably water or a hydrophilic solvent.
  • a solvent preferably water or a hydrophilic solvent.
  • the solvent is about not more than 40% by weight of the composition.
  • the present invention relates to a stable non-alcoholic foamable pharmaceutical or cosmetic composition
  • a stable non-alcoholic foamable pharmaceutical or cosmetic composition comprising:
  • the present invention further relates to said composition comprising one or more additional therapeutically active oils.
  • the active agent is an alcoholic extract, an aqueous extract or an aqueous alcoholic extract.
  • the amount of water or lower alcohol is permitted to the extent necessary to deliver an effective amount of the API.
  • these substantially non-aqueous formulations and foams are also non-silicone and or non-alcoholic or substantially so.
  • the present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering a therapeutically effective amount of the herein-mentioned compositions to an afflicted target site.
  • the present invention further provides a method of treating, alleviating or preventing a nappy rash of mammalian subject, comprising administering a therapeutically effective amount of the herein-mentioned compositions to an afflicted target site.
  • the petrolatum based composition contains Zinc Oxide as an API for use against or to treat or prevent minor skin irritations (e.g., burns, cuts, poison ivy, rash, particularly diaper or nappy rash).
  • the compositions described herein are ideal for carrying effective high concentrations of API.
  • the present invention further provides a use of any of the herein-mentioned compositions for the manufacture of a medicament for treating, alleviating or preventing a disorder of a mammalian subject in need thereof.
  • the present invention further provides a use of any of the herein-mentioned compositions for the manufacture of a medicament for treating, alleviating or preventing nappy rash of a mammalian subject in need thereof.
  • any of the foregoing methods of treatment may be applied by providing a first pharmaceutical composition in a first foam canister and a second pharmaceutical composition in a second canister.
  • the contents of each canister may be applied individually in an appropriate sequence or at the same time.
  • the canisters may be part of a dual or multi chamber foam delivery device.
  • FIGS. 1 a and 1 b are pictures of two elevations (vertical and horizontal) of a waterless oil relatively low petrolatum carrier composition with Aluminum starch octenyl succinate (“ASOS”) comprising a propellant, which shows that the formulation is homogeneous and liquid.
  • ASOS Aluminum starch octenyl succinate
  • FIGS. 2 a and 1 b are pictures of two elevations (vertical and horizontal) of a waterless carrier high petrolatum oil carrier composition comprising a propellant, which shows that the formulation is homogeneous and liquid.
  • the formulation is presented in Example 2.
  • FIG. 3 is a picture of a waterless carrier composition comprising a propellant, which shows that the propellant is dissolved in the petrolatum of the composition and appears as a single translucent phase.
  • the present invention provides safe and effective foamable petrolatum based pharmaceutical and cosmetic vehicles and compositions. More particularly, it provides non-aqueous, non-alcoholic, non-silicone or essentially so, foamable petrolatum based pharmaceutical or cosmetic carriers and compositions in which a petrolatum or mixtures thereof is the largest single component or is a substantial or major component by weight in the carrier or composition.
  • the present invention further provides low water content foamable petrolatum based pharmaceutical or cosmetic carriers in which a petrolatum or mixture thereof is the largest single component or is a substantial or major component by weight in the carrier or composition.
  • the vehicle or composition further comprises at least one surfactant or surfactant system.
  • the vehicle or composition further comprises at least one propellant wherein the composition is stored in an aerosol container and upon release expands to form a foam.
  • the carrier or composition further comprises one or more active agents which may be insoluble, at least soluble to a very limited degree or soluble in the composition or a phase thereof.
  • the formulations may have present a small amount of water (i.e., incidental or trace amounts of water). In one embodiment, the formulations have less than about 5% water content. In one embodiment, the formulations have less than about 4% water content. In one embodiment, the formulations have less than about 3% water content. In one embodiment, the formulations have less than about 2% water content. In one embodiment, the formulations have less than about 1% water content. In one or more embodiments where the composition is has low water content or is essentially non-aqueous it may contain a small amount of water and in certain aspects the carrier or composition does not contain a non propellant organic co-solvent.
  • the present invention also relates to foamable petrolatum based pharmaceutical and cosmetic compositions comprising petrolatum mixtures.
  • foamable petrolatum based pharmaceutical and cosmetic compositions comprising petrolatum mixtures.
  • a low melting point petrolatum is mixed with a petrolatum with a higher melting point.
  • the major petrolatum is the lower molecular weight petrolatum.
  • the petrolatum is mixed in a ratio for example, of about 5:1; 4:1; 3:1; 2:1; or 1:1 of lower melting point to higher melting point petrolatum.
  • the ratio of mixture can be of higher melting point to lower melting point.
  • a softer type of petrolatum is utilized on its own or in a mixture.
  • the foamable carriers described herein are suitable for use as a base for delivery of not merely one type of API but are adaptable for use with one or more API's from a wide range of different types of API's with relatively minimal or minor adjustment to the carrier, for example, by altering the amount of a component, as would be appreciated by a person skilled in the art.
  • pH applies to aqueous environments in one or more embodiments the presence of a buffer or pH agent can also help to provide a stable environment for an active agent.
  • the buffer or pH agent is provided in an effective amount that provides a pH at which the API is stable.
  • chelating agents, antioxidants and anti-ionization agents may also be usefully added
  • a foamable vehicle or carrier that is suitable for use as a base for delivery for API's, which are by their nature destabilizes, with relatively minimal or minor adjustment to the vehicle or in the method of preparation.
  • Pharmaceuticals that have a hydrophobic region may be absorbed at least partially by the hydrophobic carrier compositions.
  • non-aqueous, non-alcoholic, non-silicone, foamable carrier composition comprising:
  • the foamable carriers and compositions described herein are resistant to centrifugation at 1000 rpm for at least 10 minutes, for example, when the petrolatum concentration is relatively high.
  • non-aqueous, non-alcoholic, non-silicone, foamable carrier composition comprising:
  • a breakable foam is thermally stable or substantially so, yet breaks under sheer force.
  • the breakable foam is not “quick breaking”, i.e., it does not readily collapse upon exposure to body temperature environment. Sheer-force breakability of the foam is clearly advantageous over thermally induced breakability, (due to, for example, the presence of alcohol) since it allows comfortable application and well directed administration to the target area.
  • ‘Shakability’ in the context herein means that the composition contains some or sufficient flow to allow the composition to be mixed or remixed on shaking. By shakable it indicates that some motion or movement of the formulation can be sensed when the canister containing the formulation is shaken or is firmly shaken.
  • non-aqueous, non-alcoholic, non-silicone, foamable carrier composition comprising:
  • the foamable carriers and compositions described herein are stored in an aerosol container and upon release expands to form a breakable foam having a foam hardness in the range of about 5 g to about 100 g.
  • the foam hardness is in the range of about 10 g to about 90 g or more preferably about 15 g to about 55 g.
  • the petrolatum or mixture thereof influences foam hardness such that the foam produced is soft.
  • Softness especially with stability improves usability. If the foam, for example, is intended upon application to form a barrier, the attribute of softness should be adjusted, balanced, increased or reduced with the need to provide an effective barrier. A little less softness can be achieved, for example, by adding a proportion of petrolatum with a higher melting point or increasing the amount of waxy or solid surfactant. Alternatively it may be achieved by reducing the amount of solvent or liquid surfactant. To the extent liquid surfactant is reduced it may be compensated by increasing solid or waxy surfactant or by addition of foam adjuvants.
  • petrolatum or mixtures thereof is between about 57% to about 90% by weight of the foamable carrier (i.e., prior to the addition of propellant).
  • petrolatum or mixtures thereof is preferably between about 57% to about 82% by weight of the foamable carrier.
  • the surfactant or surfactant system is preferably between about 3% to about 15% by weight of the foamable carrier (i.e., prior to the addition of propellant).
  • the ratio between the petrolatum and solvent is determined according to the desirable level of petrolatum and the importance of the solvent from one or more non limiting aspects including, therapeutic effect, liquefying effect, hardness, resistance to centrifugation, enhancing solubility or penetration, and taking into account appropriate and desirable pharmacologic and safety properties of the product.
  • the solvent to petrolatum ranges between about 3:1 and about 1:100, for example, about 3:1, about 2:1, about 1:1, about 1:2, about 1:3, about 1:4, about 1:5 about, about 1:10; about 2:25, about 1:15, about 2:35, about 1:20, about 2:45 and about 1:25, about 1:30; about 1:40 about 1:50; about 1:60; about 1:70; about 1:80; about 1:90; about 1:100 preferably between about 1:15 to about 1:60.
  • the solvent is a PPG alkyl ether, preferably PPG15 stearyl ether.
  • the solvent is a combination of an oil and a PPG alkyl ether.
  • the oil comprises a light mineral oil and the ether comprises PPG15 stearyl ether.
  • the surfactant or combination of surfactants is selected from one or more of the group consisting of ceteth20, steareth 2, steareth 20, glucose methyl stearate, methyl glucose sesquistearate, Span 20, Span 80, Tween 20, and Tween 80.
  • the combination of surfactants is a complex emulgator.
  • the foam adjuvant is selected from one or more of the group consisting of oleyl alcohol, behenyl alcohol, and cetostearyl alcohol.
  • the foam adjuvant is selected from one or more of the group consisting of cetyl alcohol, and stearyl alcohol.
  • the surfactant and its amount is selected so that the composition is sufficiently shakable so that substantially uniform foam extrusion is possible.
  • the amount of solid or waxy surfactant is increased the shakability of the formulation reduces until a limitation point is reached where the formulation becomes non shakable and unsuitable. To this extent the maximum effective amount of surfactant that may be used may be limited by the need for shakability.
  • the surfactant and its amount is selected so that the composition is sufficiently flowable so that substantially uniform foam extrusion is possible.
  • the amount of solid or waxy surfactant is increased the flowability of the formulation reduces until a limitation point is reached where the formulation becomes non flowable and unsuitable To this extent, the maximum effective amount of surfactant that may be used may be limited by the need for some flowability.
  • the composition may be marginally shakable or apparently non shakable but nevertheless is flowable or flowable to a degree that it can flow under the pressure of the propellant through an aerosol valve to expand and form a good quality foam.
  • This exception may be due to one or more of a number of factors such as, the high viscosity, the softness, the lack of crystals, the pseudoplastic or semi pseudo plastic nature of the composition and the dissolution of the propellant into the petrolatum.
  • an inverse canister system without a dip tube may be preferred and is ideal for formulations which are flowable to a degree but are apparently or marginally non shakable.
  • the propellant or mixtures thereof and amounts thereof are selected so that the composition is sufficiently shakable so that substantially uniform foam extrusion is possible.
  • An aspect of this embodiment is the property of the propellant to form a single phase with petrolatum.
  • the propellant or mixtures thereof and amounts thereof are selected so that the composition is sufficiently flowable so that substantially uniform foam extrusion is possible.
  • An aspect of this embodiment is the property of the propellant to form a single or homogeneous phase with petrolatum.
  • propellant and the surfactant or surfactant system and their amounts are selected so that the composition is sufficiently shakable so that substantially uniform foam extrusion is possible.
  • propellant and the surfactant or surfactant system and their amounts are selected so that the composition is sufficiently flowable so that substantially uniform foam extrusion is possible.
  • the propellant is preferably between about 5% to about 30% by weight of the composition.
  • the propellant is preferably between about 8% to about 20% by weight of the composition.
  • the propellant is in a sufficient amount to expel the composition from the canister upon actuation to form a foam but is not sufficient to have a cooling effect on application of the foam to the skin.
  • the foam produced from the composition or carrier is capable of remaining substantially unchanged after at least one freeze thaw cycle.
  • the degree of solubility of the active agent is slightly, sparingly or more soluble.
  • the degree of solubility of the active agent is very slightly soluble.
  • the carrier or composition does not comprise a non propellant organic co-solvent.
  • the active ingredient may be a cosmetic agent or a placebo.
  • the carrier composition may itself be useful for the treatment prevention or amelioration of various general skin and cosmetic complaints such as aging, atopic dermatitis, contact dermatitis and radiation or burn injury and the like.
  • composition further comprises one or more additional active agents.
  • active agents compliment each other or may have a synergistic effect.
  • In one or more embodiments comprises one or more additional therapeutically active oils.
  • the foamable cosmetic or pharmaceutical composition is non-flammable, wherein said gas propellant contains hydrofluorocarbon.
  • a method of treating, alleviating or preventing a disorder of mammalian subject comprising administering a therapeutically effective amount of the above-mentioned compositions to an afflicted target site.
  • a method of treating, alleviating or preventing nappy rash in a mammalian subject comprising administering a therapeutically effective amount of the above-mentioned compositions to an afflicted target site.
  • compositions for use in the manufacture of a medicament.
  • the petrolatum may alone or in combination with a stabilizing agent or vica versa may help to ameliorate, counteract, or overcome undesirable effects and drawbacks of an API, such as destabilization, precipitation or breakdown.
  • the stabilizing agent can also assist or improve the skin feeling.
  • Non limiting examples are polymeric agent such as ASOS, an alkyl lactate such as C-12 to C-15 alkyl lactate, a cellulose like carboxymethyl cellulose sodium and microcrystalline cellulose or methocel and xantham gum.
  • the polymeric agent comprises ASOS.
  • foamable petrolatum based compositions that are stable and able to provide some of the main attributes of a petrolatum composition when delivered as a topical substantially uniform and stable foam and without the use of an alcohol in the formulation.
  • foamable petrolatum based compositions that are stable and able to provide some of the main attributes of a petrolatum composition when delivered as a topical substantially uniform and stable foam with barrier properties and without the use of a volatile alcohol and or a volatile silicone in the formulation.
  • the barrier properties are enhanced or improved by the refatting qualities of the solvent substantially miscible in the petrolatum.
  • a foamable pharmaceutical composition is provided also incorporating an added hydrophobic solvent, for example, as a look and feel enhancer, solubility enhancer or deliverability enhancer.
  • a foamable pharmaceutical composition is provided also incorporating an added polar solvent, for example, as penetration enhancer, solubility enhancer or deliverability enhancer.
  • an added polar solvent for example, as penetration enhancer, solubility enhancer or deliverability enhancer.
  • the enhancer is selected to be substantially miscible in the composition.
  • the polar solvent or the potent solvent is in a small amount.
  • non-aqueous solvents which preferably are added in small amounts are solvents such as polyethylene glycol (PEG), isosorbide derivatives, such as dimethyl isosorbide, propylene gycol (PG), hexylene glycol and glycerin, diethylene glycol monoethyl ether, a liquid polyethylene glycol, glycofurol, tetrahydrofurfuryl alcohol, polyethyleneglycol, ether, DMSO, a pyrrolidone, N-methylpyrrolidones, N-Methyl-2-pyrrolidone, 1-Methyl-2-pyrrolidinone, ethyl proxitol, dimethylacetamide, a PEG-type surfactant, an alpha hydroxy acid, lactic acid and glycolic acid, hexylene glycol, benzyl alcohol, DMSO, glycofurol and ethoxydiglycol (transcutol),
  • solvents such as polyethylene glycol (P
  • non-aqueous solvent is monooctanoin.
  • a foamable pharmaceutical composition wherein the ratios of surfactant, petrolatum and added polar solvent as penetration enhancer are selected or adapted to provide a selected pharmacological or safety property.
  • a foamable pharmaceutical composition is provided also incorporating a polymeric agent.
  • the polymeric agent whilst it is believed to be non essential can be useful in improving foam characteristics including hardness, viscosity, and feel.
  • the polymeric agent is selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent and can be from about 0.01% to about 5% by weight.
  • the pharmaceutical or cosmetic foamable product is non-flammable.
  • the foamable composition is non-alcoholic or alcohol free, i.e., free of short chain alcohols.
  • Short chain alcohols having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butaneol, iso-butaneol, t-butaneol and pentanol, are considered less desirable solvents or polar solvents due to their skin-irritating effect.
  • the composition is substantially alcohol-free and can includes less than about 5% final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1%. Where the active ingredient is provided in an alcoholic extract then in such limited circumstances the alcoholic content may be up to about 8%.
  • Non-limiting benefits include:
  • the ratio between the stabilizing agent or polymeric agent and petrolatum is determined according to the desirable level of petrolatum and taking into account appropriate and desirable pharmacologic and safety properties of the product.
  • the stabilizing agent to petrolatum ranges between about 1:5 and about 1:100, for example, about 1:5, about 2:15, about 1:10, about 2:25, about 1:15, about 2:35, about 1:20, about 2:45 and about 1:25, about 1:30; about 1:40 about 1:50; about 1:60; about 1:70; about 1:80; about 1:90; about 1:100 preferably between about 1:15 to about 1:60.
  • non-aqueous formulations are also generally applicable to the low water content formulations herein with where necessary appropriate changes as would be appreciated by a man of the art.
  • the non limiting examples given in the Summary also apply here.
  • the previous section may be read and applied to these formulations with these points in mind.
  • Other embodiments by way of example are specifically described below.
  • the present invention relates to stable non-alcoholic foamable petrolatum based carriers and pharmaceutical and cosmetic emulsion compositions comprising a petrolatum or mixtures thereof, a surfactant, and a propellant and in certain cases a solvent, with and without the addition of an active agent, wherein the foam produced by the carrier or pharmaceutical composition when packaged in an aerosol container and released has a foam hardness in the range of about 5 g to about 100 g.
  • the foam hardness in the range of about 5 g to about 100 g.
  • some of the compositions show hardness measurements in the upper range and yet have a relatively soft feeling.
  • the present invention relates to stable non-alcoholic foamable petrolatum based carriers and pharmaceutical and cosmetic emulsion compositions with very high viscosity measurements prior to addition of the propellant.
  • the pre foam formulation can have a wide range of viscosity from about 500,000 to about 12,000 CP or less. For example, from about 500,000 to about 300,000, from about 400,000 to about 150,000; from about 375,000 to about 225,000; from about 225,000 to about 75,000; from about 125,000 to about 12,000 or less.
  • the present invention also relates to stable non-alcoholic foamable petrolatum based pharmaceutical and cosmetic compositions comprising petrolatum mixtures. It was discovered that by combining appropriate amounts of different types of petrolatum foams which are able to mimic the barrier properties of petrolatum ointments and particularly petrolatum based barrier creams for nappy rash.
  • a low melting point petrolatum is mixed with a petrolatum with a higher melting point.
  • the major petrolatum is the lower molecular weight petrolatum.
  • the petrolatum is mixed in a ratio for example, of about 5:1; 4:1; 3:1; 2:1; or 1:1 of lower melting point to higher melting point petrolatum. In some embodiments the ratio of mixture can be of higher melting point to lower melting point.
  • a foamable vehicle that is suitable for use as a base for delivery of not merely one type of active pharmaceutical ingredient (API) but is adaptable for use with one or more API's from a wide range of different types of API's with relatively minimal or minor adjustment to the vehicle.
  • API active pharmaceutical ingredient
  • a foamable vehicle that is suitable for use as a base for delivery of not merely one type of active pharmaceutical ingredient (API) but is adaptable for use with one or more API's from a wide range of different types of API's with relatively minimal or minor adjustment to the vehicle.
  • API active pharmaceutical ingredient
  • the present invention relates to a stable non-alcoholic foamable pharmaceutical or cosmetic composition
  • a stable non-alcoholic foamable pharmaceutical or cosmetic composition comprising:
  • the foam hardness is in the range of about 10 g to about 90 g or more, preferably about 30 g to about 85 g.
  • the surfactant or surfactant system is preferably between about 1% to about 10% by weight of the composition prior to the addition of propellant.
  • the surfactant and its amount is selected so that the composition is sufficiently shakable so that substantially uniform foam extrusion is possible.
  • the maximum effective amount of surfactant that may be used may be limited by the need for shakability.
  • the surfactant and its amount is selected so that the composition is sufficiently flowable so that substantially uniform foam extrusion is possible.
  • the maximum effective amount of surfactant that may be used may be limited by the need for some flowability.
  • the propellant is preferably between about 10% to about 30% by weight of the composition.
  • the propellant is preferably between about 14% to about 26% by weight of the composition.
  • the active ingredient may be partially insoluble in a phase of the emulsion. In other embodiments it may be insoluble in a phase.
  • a stabilizing agent may alone or in combination with petrolatum help to ameliorate, counteract, or overcome undesirable effects and drawbacks of an API, such as destabilization, on an emulsion vehicle, on a phase, on micelles or on an interphase.
  • the stabilizing agent comprises a polymeric agent such as ASOS, an alkyl lactate such as C-12 to C-15 alkyl lactate, carboxymethyl cellulose sodium and microcrystalline cellulose or methocel and xantham gum.
  • a combination of surfactants, a metal starch, and an alkyl lactate can be used to achieve a stable foam.
  • the foamable composition can be an emulsion, or microemulsion, or nanoemulsion.
  • these low water content formulations and foams are also non-silicone and or non-alcoholic or substantially so.
  • Solvent and optional ingredients are added to complete the total mass of the foamable carrier to 100%.
  • Formulation of foam is a very delicate balance between the functional inactive ingredients, excipients, which contribute to bubble size, viscosity, hardness look and feel and stability.
  • the Foam Formulation should during its intended life or use period be liquid and shakable in the canister, otherwise it will not flow easily and completely towards and through the valve.
  • the composition In the context of high levels of petrolatum foamable formulations it is possible as an exception for the composition to be marginally or apparently non shakable whilst the composition has a sufficient degree of flowability under pressure of the propellant that it is possible to obtain a good quality of foam.
  • Stability of compositions of petroleum and solvents substantiality miscible therein together with surfactants and other additives is desired. Testing for aging as reflected by creaming or phase separation whilst normally considered in the realm of emulsions may also be used to explore waterless compositions.
  • the concept of creaming in waterless single phase compositions may be artificial and not accurately applicable and requires investigation. Resistance to creaming or phase separation can be determined by taking a sample and subjecting it to a significant G force through centrifugation to simulate accelerated aging.
  • Waterless compositions in which petrolatum is the main component may have some inherent resistant to “creaming” or phase separation because of the physical properties of petrolatum.
  • improved physical stability may be obtained by an appropriate choice of product viscosity through use of different blends of petrolatum together with one or more solvents substantially miscible in petrolatum plus a surfactant or surfactant system optionally in combination with stabilizing agents and or viscoelastic agents, which can provide suitable rheology whilst retaining the requirements of shakability or at least flowability.
  • solvents and the surfactants used can have a considerable influence on rheology, shakability and flowability.
  • Emulsions in which petrolatum is the main single component or is the main component may be inherently resistant to creaming because of the physical properties of petrolatum.
  • foamable emulsion compositions it has been discovered that improved physical stability is obtained by an appropriate choice of product viscosity through use of different blends of petrolatum plus a surfactant or surfactant system optionally in combination with stabilizing agents and or viscoelastic agents, which can provide suitable rheology whilst retaining the requirements of shakability or at least flowability and by controlling droplet size.
  • creaming it is meant that an upper layer forms.
  • the creaming value is defined as the relative volume of the creamed phase and the total volume the sample.
  • the expression used for calculation of the creaming volume is as follows:
  • Creaming values are between 1% and 99%, accordingly. 100% means “no creaming” which is the desirable best score. 0% (Zero value) indicates phase separation and is the worst score.
  • the formulation is capable of physically withstanding to a substantial degree at least one of centrifugation at about 1000 rpm for non-aqueous formulations and at about 3000 rpm for emulsions for about 10 minutes in each case; or one, or possibly more freeze thaw cycles; or a period of time at an elevated temperature of say 30° C. or say 40° C. for say about one month; or a prolonged period of time at room temperature for say about three months.
  • the formulations can withstand 3 months at 30° C. or 40° C. and or 6 months at room temperature.
  • composition should exhibit pseudoplastic rheological behavior.
  • compositions can be stabilized.
  • agents, surfactants and solvent in a petrolatum base composition to facilitate biocompatibility and to achieve the appropriate balance of physical properties, it is possible to prepare formulations that are resilient to aging when subjected to centrifugation which could be extrapolated to reflect a reasonable stable shelf life.
  • Petrolatum is known by various names including yellow soft paraffin, yellow petrolatum, mineral jelly; and petroleum jelly.
  • Petrolatum is a purified mixture of semisolid saturated hydrocarbons having the general formula C n H 2n+2 , and is obtained from petroleum.
  • the hydrocarbons consist mainly of branched and unbranched chains although some cyclic alkanes and aromatic molecules with paraffin side chains may also be present.
  • Some forms may contain a suitable stabilizer (antioxidant). It is mainly used as an emollient and ointment base in topical pharmaceutical formulations creams and transdermal applications.
  • Therapeutically, sterile gauze dressings containing petrolatum may be used for nonadherent wound dressings.
  • Petrolatum is additionally widely used in cosmetics and in some food applications. It is odorless, and tasteless.
  • the rheological properties of petrolatum are determined by the ratio of the unbranched chains to the branched chains and cyclic components of the mixture.
  • Petrolatum contains relatively high amounts of branched and cyclic hydrocarbons, in contrast to paraffin, which accounts for its softer character and makes it an ideal ointment base.
  • a petrolatum or a petrolatum mixture is selected such that it has a quality of relative softness.
  • Petrolatum is an inherently stable material. On exposure to light any impurities present may be Oxidation may be inhibited by the inclusion of a suitable antioxidant such as butylated hydroxyanisole, butylated hydroxytoluene, or alpha tocopherol.
  • a suitable antioxidant such as butylated hydroxyanisole, butylated hydroxytoluene, or alpha tocopherol.
  • petrolatum Various grades of petrolatum are commercially available, which vary in their physical properties depending upon their source and refining process. Petrolatum obtained from different sources may therefore behave differently in a formulation.
  • White petrolatum is a preferred petrolatum for use in cosmetics and pharmaceuticals, Additives, such as microcrystalline wax, may be used to add body to petrolatum.
  • the petrolatum used in the present invention was examined microscopically and no wax crystallization was observed.
  • the petrolatum selected shows no tendency to wax crystallization.
  • the petrolatum based foamable carriers and compositions are free or substantially free of wax crystallization.
  • the petrolatum based foamable carriers and compositions are free or substantially free of wax crystallization when the petrolatum level is about 50% to about 95% by weight in the composition before the addition of propellant.
  • MMP Inc state in their sales booklet on SofineticTM LMP (Rev 02/05 KVB) that they conducted studies with varying grades of petroleum USP to avoid formation of wax crystals in emulsions containing 20% petrolatum and that MMP's supersoft grade incorporated into low emulsifier content formulations containing 20% petroleum has been shown to eliminate undesirable crystallization of wax. They further state that when compared to similar compositions made with a higher melting point grade of petrolatum the SofineticTM LMP exhibited no tendency to wax crystallization.
  • petrolatum relates to any fatty substance, having Theological properties and meting temperature patterns in the same range as described above for petrolatum.
  • a “unctuous additive” as used herein refers to a greasy, fatty, waxy or oily material, including liquids, semi solids and solids which can be mixed with petrolatum to alter refine or improve the petrolatum based compositions.
  • a small, moderate medium or lager amount of one or more unctuous additive may be blended with petrolatum provided the petrolatum remains the single largest component of the composition.
  • the unctuous additive can be the major component of the blend with petrolatum. Even if not the main component the properties of petrolatum at the levels of about at least 25% in the present invention it may still have a major or dominating influence on the composition.
  • unctuous additives may also have a role in effecting the solubility of an API. Unexpectedly it has been noted that in certain cases where an oil is combined with petrolatum the resultant foam has a significantly lower density.
  • Non limiting examples of unctuous additives that may be used in the pharmaceutical composition may be natural or synthetic or a synthetic derivative and, include higher aliphatic hydrocarbons, animal or vegetable fats, greases and oils, waxes, and combinations thereof.
  • specific non limiting examples are higher aliphatic hydrocarbons, mineral jelly and fractions thereof, paraffin, squalane, ceresin, mineral oil and the like.
  • waxes include beeswax, carnauba wax, microcrystalline wax, candililla wax, berry wax, montan wax, polyethylene wax and ethylene vinyl acetate (EVA) copolymers spermaceti, lanolin, wool wax, wool fat, wax blend, solid paraffin, oxidized wax, waxy solids or waxy semi-solids, synthetic wax's and the like.
  • EVA ethylene vinyl acetate
  • non limiting specific examples of the animal or vegetable fats and oils include, triglycerides, olive oil, almond oil, avocado oil, borage oil, castor oil, cocoa butter, palm oil, turtle oil, cod-liver oil, whale oil, beef tallow, butter fat, shea butter, shorea butter, and the like.
  • the above-described unctuous additive may be used alone or in combination with petrolatum.
  • high melting point hydrocarbons such as petrolatum can be occlusive when applied to the skin.
  • petrolatum in concentrations of more than 25% preferably more than 50% to about 95% prior to the addition of propellant is included in the compositions.
  • petrolatum and petrolatum mixtures may also be combined with one or more hydrophobic solvents or carriers, which are materials suitable for use to blend with or act as a carrier for the petrolatum emollients. They may also have a further role in effecting the solubility of an API.
  • the hydrophobic solvents or carriers are ester oils.
  • ester oils include isopropyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, octyldodecyl myristate, di-isopropyl adipate, isocetyl myristate, di-isopropyl sebacate, and the like.
  • the hydrophobic solvents or carriers are higher alcohols.
  • the higher alcohols include cetyl alcohol, oleyl alcohol, isostearyl alcohol, octyldodecanol and the like.
  • hydrophobic solvents or carriers are liquid oils originating from vegetable, marine or animal sources.
  • suitable liquid oil includes saturated, unsaturated or polyunsaturated oils.
  • the unsaturated oil may be olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils or mixtures thereof, in any proportion.
  • Suitable hydrophobic solvents or carriers also include polyunsaturated oils containing poly-unsaturated fatty acids.
  • the unsaturated fatty acids are selected from the group of omega-3 and omega-6 fatty acids.
  • examples of such polyunsaturated fatty acids are linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
  • GLA gamma-linoleic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • the hydrophobic solvent can include at least 3% preferably at least 6% of an oil selected from omega-3 oil, omega-6 oil, and mixtures thereof.
  • oils that possess therapeutically beneficial properties are termed as “therapeutically active oil.”
  • essential oils Another class of hydrophobic solvents or carriers is the essential oils, which are also considered therapeutically active oils, and which contain active biologically occurring molecules and, upon topical application, exert a therapeutic effect.
  • essential oils include rosehip oil, which contain retinoids and is known to reduce acne and post-acne scars, and tea tree oil, which possess antibacterial, antifungal and antiviral properties.
  • Silicone oils also may be used and are desirable due to their known skin protective and occlusive and antifriction properties. Moreover they may mask to some extent the tacky greasy feeling of petrolatum on the skin.
  • Suitable silicone oils include non-volatile silicones, such as polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers, polydimethylsiloxanes (dimethicones) and poly(dimethylsiloxane)-(diphenyl-siloxane) copolymers. Silicone oils are also considered therapeutically active oil, due to their barrier retaining and protective properties. However, silicone oils are not essential.
  • silicones are foam defoamers and therefore if included are ideally used in relatively small amounts, such as less than about 5% if there is more than 50% petrolatum, and in other cases where the petrolatum is under about 50% then the silicones should be less than about 1%. To counteract to some extent the defoaming properties extra surfactant and or foam adjuvant may be usefully added. If volatile silicones are used they evaporate from the skin and effect the deposited composition and can interfere with its occlusive properties and may cause dryness. In a preferred embodiment there is no silicone or less than 1%. When the level of petrolatum is at least about 50% or more then higher levels of silicone may be used.
  • a further class of hydrophobic solvents or carriers includes hydrophobic liquids, selected from the family of organic liquids described as “emollients.” Emollients possess a softening or soothing effect, especially when applied to body areas, such as the skin and mucosal surfaces.
  • Suitable emollients include isopropyl myristate, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, cetyl acetate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, propylene glycol ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, octyl dodecanol, suc
  • the petrolatum based foamable carrier and composition comprises a hydrophobic solvent in a moderate or larger amount.
  • a polypropylene glycol alkyl ether is a liquid, water-insoluble propoxylated fatty alcohol, having the molecular formula of RO(CH 2 CHOCH 3 ) n ; wherein “R” is a straight-chained or branched C 4 to C 22 alkyl group; and “n” is in the range between 4 and about 50.
  • PPG alkyl ethers are organic liquids that function as skin-conditioning agent in pharmaceutical and cosmetic formulations. They possess exceptional emollient effect, side by side with enhanced solvency properties, which facilitates solubilization of active agents in a composition comprising a PPG alkyl ether. PPG alkyl ethers offer the following advantages when used as a component in the foamable composition:
  • Exemplary PPG alkyl ethers include PPG-2 butyl ether, PPG-4 butyl ether, PPG-5 butyl ether, PPG-9 butyl ether, PPG-12 butyl ether, PPG-14 butyl ether, PPG-15 butyl ether, PPG-16 butyl ether, PPG-17 butyl ether, PPG-18 butyl ether, PPG-20 butyl ether, PPG-22 butyl ether, PPG-24 butyl ether, PPG-26 butyl ether, PPG-30 butyl ether, PPG-33 butyl ether, PPG-40 butyl ether, PPG-52 butyl ether, PPG-53 butyl ether, PPG-10 cetyl ether, PPG-28 cetyl ether, PPG-30 cetyl ether, PPG-50 cetyl ether, PPG-30 isocetyl ether, PPG-4 lauryl ether, PPG-7 lauryl ether, PPG
  • Preferred PPG alkyl ethers according to the present invention include PPG-15 stearyl ether (also known as Earlamol E®, Unichema), PPG-2 butyl ether, PPG-9-13 butyl ether and PPG-40 butyl ether.
  • PPG alkyl ethers can be incorporated in the foamable composition in a concentration preferably between about 1% and about 20%, more preferably between about 3% and about 15%.
  • PPG alkyl ethers also reduce the degree of inflammability of a foam, as demonstrated in a standard inflammability test according to European Standard prEN 14851, titled “Aerosol containers. According to this standard, a product is considered inflammable if a stable flame appears following ignition, which is at least 4 cm high and which is maintained for at least 2 seconds.
  • the concentration of the PPG alkyl ether is sufficient to reduce the degree of inflammability, of a composition when compared with the same composition without the PPG alkyl ether.
  • the composition further contains a surface-active agent.
  • Surface-active agents include any agent linking oil and water in the composition, in the form of emulsion.
  • a surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil. HLB is defined for non-ionic surfactants. The HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics.
  • Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions.
  • the HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average).
  • a single surfactant may suffice.
  • a combination of two or more surfactants is desired.
  • Reference to a surfactant in the specification can also apply to a combination of surfactants or a surfactant system. As will be appreciated by a person skilled in the art which surfactant or surfactant system is more appropriate is related to the vehicle and intended purpose. In general terms a combination of surfactants is usually preferable where the vehicle is an emulsion.
  • a combination of surfactants can be significant in producing breakable forms of good quality.
  • a surfactant or combination of surfactants can also be significant in producing breakable forms of good quality.
  • the generally thought considerations for HLB values for selecting a surfactant or surfactant combination are not always binding for emulsions and that good quality foams can be produced with a surfactant or surfactant combination both where the HLB values are in or towards the lipophilic side of the scale and where the HLB values are in or towards the hydrophilic side of the scale.
  • the composition contains a single surface active agent having an HLB value between about 2 and 9, or more than one surface active agent and the weighted average of their HLB values is between about 2 and about 9. Lower HLB values may in certain embodiments be more applicable.
  • the composition contains a single surface active agent having an HLB value between about 9 and about 19, or more than one surface active agent and the weighted average of their HLB values is between about 9 and about 19.
  • HLB values In a waterless or substantially waterless environment a wide range of HLB values may be suitable.
  • a wide range of HLB values giving about an average mid range can be achieved with combinations of two, three or more surfactants.
  • the following provides an average of 9.36:
  • the composition contains a non-ionic surfactant.
  • non-ionic surfactants include a polysorbate, polyoxyethylene (20) sorbitan monostearate, sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, sorbitan laurate; a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59; a polyoxyethylene alkyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, steareths such as steareth 2, brij 21, brij 721, brij 38, brij 52, brij 56 and brij W1, behenyl alcohol; a sucrose ester, a partial ester of sorbitol and its anhydrides, sorbitan monolaurate, sorbitan monolaurate,
  • surfactants are selected which can provide a close packed surfactant layer.
  • combinations of at least two surfactants are selected.
  • they should be complex emulgators and more preferably they should both be of a similar molecular type; for example, a pair of ethers, like steareth 2 and steareth 21, or a pair of esters, for example, PEG-40 stearate and polysorbate 80.
  • the surfactants can be ethers.
  • POE esters cannot be used and a combination of sorbitan laurate and sorbitan stearate or a combination of sucrose stearic acid ester mixtures and sodium laurate may be used. All these combinations due to their versatility and strength may also be used satisfactorily and effectively with ether formulations, although the amounts and proportion may be varied according to the formulation and its objectives as will be appreciated by a man of the art.
  • dextrin derivative surfactants prepared by the reaction of the propylene glycol polyglucosides with a hydrophobic oxirane-containing material of the glycidyl ether are highly biodegradable. [Hong-Rong Wang and Keng-Ming Chen, Colloids and Surfaces A: Physicochemical and Engineering Aspects Volume 281, Issues 1-3, 15 Jun. 2006, Pages 190-193].
  • Non-limiting examples of non-ionic surfactants that have HLB of about 7 to about 12 include steareth 2 (HLB ⁇ 4.9); glyceryl monostearate/PEG 100 stearate (Av HLB ⁇ 11.2); stearate Laureth 4 (HLB ⁇ 9.7) and cetomacrogol ether (e.g., polyethylene glycol 1000 monocetyl ether). More exemplary stabilizing surfactants which may be suitable for use in the present invention are found below.
  • PEG-Fatty Acid Diester Surfactants Chemical name Product example name HLB PEG-4 dilaurate Mapeg .RTM. 200 DL (PPG), 7 Kessco .RTM.PEG 200 DL (Stepan), LIPOPEG 2-DL (Lipo Chem.) PEG-4 distearate Kessco .RTM. 200 5 DS (Stepan.sub) PEG-32 dioleate Kessco .RTM. PEG 1540 DO 15 (Stepan) PEG-400 dioleate Cithrol 4DO series (Croda) >10 PEG-400 disterate Cithrol 4DS series (Croda) >10 PEG-20 glyceryl oleate Tagat .RTM. O (Goldschmidt) >10
  • Polyglycerized Fatty Acids such as: Chemical name Product example name LB Polyglyceryl-6 dioleate Caprol .RTM. 6G20 (ABITEC); 8.5 PGO-62 (Calgene), PLUROL OLEIQUE CC 497 (Gattefosse)Hodag
  • PEG-Sorbitan Fatty Acid Esters Chemical name Product example name HLB PEG-20 sorbitan Tween 40 (Atlas/ICI), Crillet 2 16 monopalmitate (Croda) PEG-20 sorbitan Tween-60 (Atlas/ICI), Crillet 3 15 monostearate (Croda) PEG-20 sorbitan Tween-80 (Atlas/ICI), Crillet 4 15 (Croda) PEG-20 sorbitan Tween-80 (Atlas/ICI), Crillet 4 15 (Croda)
  • Sorbitan Fatty Acid Ester Surfactants Chemical name Product example name HLB Sorbitan monolaurate Span-20 (Atlas/ICI), Crill 1 8.6 (Croda), Arlacel 20 (ICI) Sorbitan monopalmitate Span-40 (Atlas/ICI), Crill 2 6.7 (Croda), Nikkol SP-10 (Nikko) Sorbitan monooleate Span-80 (Atlas/ICI), Crill 4 4.3 (Croda), Crill 50 (Croda) Sorbitan monostearate Span-60 (Atlas/ICI), Crill 3 4.7 (Croda), Nikkol SS-10 (Nikko)
  • the surface active agent is a complex emulgator in which the combination of two or more surface active agents can be more effective than a single surfactant and provides a more stable emulsion or improved foam quality than a single surfactant.
  • the complex emulgator comprises a combination of surfactants wherein there is a difference of about 4 or more units between the HLB values of the two surfactants or there is a significant difference in the chemical nature or structure of the two or more surfactants.
  • a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed, at a ratio of between 1:8 and 8:1, or at a ratio of 4:1 to 1:4, wherein the HLB of the combination of emulsifiers is preferably between about 5 and about 18.
  • the surface active agent is selected from the group of cationic, zwitterionic, amphoteric and ampholytic surfactants, such as sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
  • the surfactant is a surfactant or surfactant combination is capable of or which tends to form liquid crystals.
  • the at least one surface active agent is solid, semi solid or waxy.
  • the composition contains a non-ionic surfactant.
  • the composition includes a mixture of non-ionic surfactants as the sole surface active agent.
  • the foamable composition includes a mixture of at least one non-ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1.
  • the non-ionic to ionic surfactant ratio is greater than about 6:1, or greater than about 8:1; or greater than about 14:1, or greater than about 16:1, or greater than about 20:1.
  • surface active agent comprises a combination of a non-ionic surfactant and an ionic surfactant, at a ratio of between 1:1 and 20:1.
  • the surface-active agent includes mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), prepared from sucrose and esters of fatty acids or by extraction from sucro-glycerides.
  • sucrose esters include those having high monoester content, which have higher HLB values.
  • the carrier or composition comprises a solvent substantially miscible in petrolatum.
  • the carrier or composition comprises a hydrophobic solvent in petrolatum wherein preferably the solvent is an unctuous additive or an oil.
  • the carrier or composition comprises an emulsion.
  • the carrier or composition comprises water in petrolatum emulsion.
  • the carrier or composition comprises a unique solvent in petrolatum emulsion wherein the solvent is a non-aqueous solvent.
  • the carrier or composition comprises a unique hydrophillic solvent in petrolatum emulsion.
  • non-aqueous solvent examples include solvents such as polyethylene glycol (PEG), isosorbide derivatives, such as dimethyl isosorbide, propylene gycol (PG), hexylene glycol and glycerin, diethylene glycol monoethyl ether, a liquid polyethylene glycol, glycofurol, tetrahydrofurfuryl alcohol, polyethyleneglycol, ether, DMSO, a pyrrolidone, N-methyl pyrrolidones, N-Methyl-2-pyrrolidone, 1-Methyl-2-pyrrolidinone, ethyl proxitol, dimethylacetamide, a PEG-type surfactant, an alpha hydroxy acid, lactic acid and glycolic acid, hexylene glycol, benzyl alcohol, DMSO, glycofurol and ethoxydiglycol (transcutol), butylene glycol
  • PEG polyethylene glycol
  • the non-aqueous solvent is monooctanoin.
  • the carrier or composition comprises a unique hydrophillic solvent in petrolatum emulsion, wherein the hydrophilic solvent is selected from a liquid polyethylene glycol, a propylene glycol or dimethyl isosorbide.
  • the stabilizing agent may help to ameliorate, counteract, or overcome undesirable effects and drawbacks of using an petrolatum emollient.
  • the stabilizing agent can be, a polymer or a polymeric agent; more specifically it can be an alkyl lactate for example a C12-15 alkyl lactate, a metal starch for example ASOS or similar polymeric derivatives; a hydrophobic starch; a microcrystalline cellulose; a cellulose ether and or long chain polysaccharide; a (alpha-tocopheryl polyethylene glycol succinate); polyoxyethylene alkyl ethers and crosslinked polyacrylic acid polymers and the like.
  • an alkyl lactate for example a C12-15 alkyl lactate
  • a metal starch for example ASOS or similar polymeric derivatives
  • a hydrophobic starch a microcrystalline cellulose
  • a cellulose ether and or long chain polysaccharide a (alpha-tocopheryl polyethylene glycol succinate); polyoxyethylene alkyl ethers and crosslinked polyacrylic acid polymers and the like.
  • modulating agent is used to describe an agent which can improve the stability of or stabilize a foamable carrier or composition and or an active agent by modulating the effect of a substance or residue present in the carrier or composition.
  • the modulating agent is used in a water in oil (petrolatum) emulsion. In one or more other embodiments the modulating agent is used in a unique waterless emulsion.
  • the substance or residue may for example be acidic or basic and potentially alter pH in an emulsion environment or it may be one or more metal ions which may act as a potential catalyst in an emulsion environment.
  • the substance or residue may for example be acidic or basic and potentially alter an artificial pH in a waterless or low water content environment or it may be one or more metal ions which may act as a potential catalyst in a waterless or low water content environment.
  • the modulating agent is used to describe an agent which can affect pH in an aqueous solution.
  • the agent can be any of the known buffering systems used in pharmaceutical or cosmetic formulations as would be appreciated by a man of the art. It can also be an organic acid, a carboxylic acid, a fatty acid an amino acid, an aromatic acid, an alpha or beta hydroxyl acid an organic base or a nitrogen containing compound.
  • the API can also affect pH.
  • the modulating agent is used to describe an agent, which is a chelating or sequestering or complexing agent that is sufficiently soluble or functional in the solvent to enable it to “mop up” or “lock” metal ions.
  • modulating agent is used to describe an agent which can effect pH in an aqueous solution
  • modulating agent more particularly means an acid or base or buffer system or combinations thereof, which is introduced into or is present in and acts to modulate the ionic or polar characteristics and any acidity or basesity balance of (i) a waterless or low water content or (ii) an emulsion carrier, composition, foamable carrier or foamable composition or resultant foam described herein.
  • the substance or residue can be introduced into the formulation from any one or more of the ingredients, some of which themselves may have acidic or basic properties.
  • the polymer or solvent may contain basic residues in which case it may be desirable or beneficial to add an acid.
  • the surfactant may contain some acid residues in which case the addition of a base may be desirable and beneficial.
  • more than one ingredient may contain residues which may ameliorate or compound their significance. For example, if one ingredient provided weak acid residues and another ingredient provided stronger acid residues, the pH in an emulsion environment should be lower. In contrast, if one residue was acidic and the other basic the net effect in the formulation maybe significantly reduced.
  • the active ingredient may favor an acidic pH or more significantly may need to be maintained at a certain acidic pH otherwise it may readily isomerize, chemically react or breakdown, in which case introducing acidic components such as an acidic polymer might be of help.
  • sufficient modulating agent is added to achieve a pH in which the active agent is preferably stable.
  • sufficient modulating agent is added to achieve an artificial pH in which the active agent is preferably stable.
  • Waterless medium can be polar and protic yet it does not conform to classical ionic behavior.
  • the chelating agent is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), hydroxyethylenediaminetriacetic acid (HEDTA), nitrilotriacetic acid (NTA), O,O′-bis(2-aminoethyl)ethyleneglycol-N,N,N′,N′-tetraacetic acid (EGTA), trans-1,2-diaminocyclohexane-N,N,N′,N′-tetraacetic acid (CyDTA) or a pharmaceutically acceptable salt thereof (normally as a sodium salt), more preferably EDTA, HEDTA and their salts; most preferably EDTA and its salts.
  • EDTA ethylenediaminetetraacetic acid
  • DTPA diethylenetriaminepentaacetic acid
  • HEDTA hydroxyethylenediaminetriacetic acid
  • NTA nitrilotriacetic acid
  • the modulating agent may also be a preservative or an antioxidant or an ionization agent.
  • Any preservative, antioxidant or ionization agents suitable for pharmaceutical or cosmetic application may be used.
  • Non limiting examples of antioxidants are tocopherol succinate, propyl galate, butylated hydroxy toluene and butyl hydroxy anisol as well as a whole range of flavanoids such as quercitin and rutin.
  • Ionization agents may be positive or may be negative depending on the environment and the active agent or composition that is to be protected. Ionization agents may for example act to protect or reduce sensitivity of active agents.
  • Non limiting examples of positive ionization agents are benzyl conium chloride, and cetyl pyridium chloride.
  • Non limiting examples of negative ionization agents are sodium lauryl sulphate, sodium lauryl lactylate and phospholipids.
  • a humectant is a substance that helps retain moisture and also prevents rapid evaporation.
  • Non limiting examples are propylene glycol, propylene glycol derivatives, glycerin, hydrogenated starch hydrosylate, hydrogenated lanolin, lanolin wax, D manitol, sorbitol, sodium 2-pyrrolidone-5-carboxylate, sodium lactate, sodium PCA, soluble collagen, dibutyl phthalate, and gelatin.
  • the humectant is preferably a hydrophobic humectant.
  • a moisturizer is a substance that helps retain moisture or add back moisture to the skin.
  • examples are allantoin, petrolatum, urea, lactic acid, sodium PCV, glycerin, shea butter, caprylic/capric/stearic triglyceride, candelilla wax, propylene glycol, lanolin, hydrogenated oils, squalene, sodium hyaluronate and lysine PCA.
  • the moisturizer is preferably a hydrophobic moisturizer.
  • Pharmaceutical compositions may in one or more embodiments usefully comprise in addition a humectant or a moisturizer or combinations thereof.
  • a “polar solvent” is an organic solvent, typically soluble in both water and oil. Certain polar solvents, for example propylene glycol and glycerin, possess the beneficial property of a humectant.
  • the polar solvent is a humectant.
  • the polar solvent is a polyol.
  • Polyols are organic substances that contain at least two hydroxy groups in their molecular structure.
  • the polar solvent contains an diol (a compound that contains two hydroxy groups in its molecular structure), such as propylene glycol (e.g., 1,2-propylene glycol and 1,3-propylene glycol), butaneediol (e.g., 1,4-butaneediol), butaneediol (e.g., 1,3-butaneediol and 1,4-butenediol), butynediol, pentanediol (e.g., 1,5-pentanediol), hexanediol (e.g., 1,6-hexanediol), octanediol (e.g., 1,8-octanediol), neopentyl glycol,
  • diol a compound that
  • polar solvents include pyrrolidones, (such as N-methyl-2-pyrrolidone and 1-methyl-2-pyrrolidinone), dimethyl isosorbide, 1,2,6-hexapetriol, dimethyl sulfoxide (DMSO), ethyl proxitol, dimethylacetamide (DMAc) and alpha hydroxy acids, such as lactic acid and glycolic acid.
  • pyrrolidones such as N-methyl-2-pyrrolidone and 1-methyl-2-pyrrolidinone
  • dimethyl isosorbide 1,2,6-hexapetriol
  • DMSO dimethyl sulfoxide
  • DMAc dimethylacetamide
  • alpha hydroxy acids such as lactic acid and glycolic acid.
  • the polar solvent is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature, including PEG200 (MW (molecular weight) about 190-210 kD), PEG300 (MW about 285-315 kD), PEG400 (MW about 380-420 kD), PEG600 (MW about 570-630 kD) and higher MW PEGs such as PEG 4000, PEG 6000 and PEG 10000 and mixtures thereof.
  • PEG200 MW (molecular weight) about 190-210 kD
  • PEG300 MW about 285-315 kD
  • PEG400 MW about 380-420 kD
  • PEG600 MW about 570-630 kD
  • higher MW PEGs such as PEG 4000, PEG 6000 and PEG 10000 and mixtures thereof.
  • Polar solvents are known to enhance the penetration of active agent into the skin and through the skin, and therefore, their inclusion in the composition can be desirable, despite their undesirable skin drying and irritation potential.
  • Lower molecular weight alcohols can sometimes be more potent as a solvent, for example by extracting lipids from the skin layers more effectively, which characteristic can adversely affect the skin structure and cause dryness and irritation. Therefore the selection of lower molecular weight alcohols is ideally avoided.
  • the foamable composition includes a potent solvent, in addition to or in place of one of the hydrophobic solvents, polar solvents or emollients of the composition.
  • a potent solvent is a solvent other than mineral oil that solubilizes a specific active agent substantially better than a hydrocarbon solvent such as mineral oil or petrolatum.
  • a potent solvent solubilizes the active agent 5 fold better than a hydrocarbon solvent; or even solubilizes the active agent 10-fold better than a hydrocarbon solvent.
  • the composition includes at least one active agent in a therapeutically effective concentration; and at least one potent solvent in a sufficient amount to substantially solubilize the at least one active agent in the composition.
  • substantially soluble means that at least 95% of the active agent has been solubilized, i.e., 5% or less of the active agent is present in a solid state.
  • the concentration of the at least one potent solvent is more than about 40% of the at least one solvent of the composition; or even more than about 60%.
  • Non-limiting examples of pairs of active agent and potent solvent include: Betamethasone valerate: Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1% in glycofurol; Hydrocortisone butyrate: Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1% in glycofurol; Metronidazole: Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1% in dimethyl isosrbide; Ketoconazole: Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1% in glycofurol, propylene glycol and dimethyl isosrbide; Mupirocin: Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1% in glycofurol, hexylene glycol, dimethyl isosorbide, propylene glycol and polyethylene glycol 400 (PEG 400); Meloxicam, a nonsteroidal anti-inflammatory agent: Practically insoluble in mineral oil ( ⁇ 0.001%); soluble in propylene glyco
  • a non-limiting exemplary list of solvents that can be considered as potent solvents includes polyethylene glycol, propylene glycol, hexylene glycol, butaneediols and isomers thereof, glycerol, benzyl alcohol, DMSO, ethyl oleate, ethyl caprylate, diisopropyl adipate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, isosorbide derivatives, such as dimethyl isosorbide, glycofurol and ethoxydiglycol (transcutol) and laurocapram.
  • the present invention provides a method of designing a stable petrolatum foamable composition by selecting at least one active agent; and identifying a solvent that solubilizes the active agent substantially better than mineral oil or petrolatum, for example, solubilizes the active agent 5-fold better or even 10-fold better than a hydrocarbon solvent such as mineral oil or petrolatum.
  • the method may further include adjusting the type and concentration of surfactant and gelling agent to provide a foamable composition.
  • the active agent has a degree of solubility in solvent, in petrolatum, in the emulsion or a phase thereof and a potent solvent is used to increase the solubility, in one or both phases, in the interphase or in the foam.
  • the active agent has a limited degree of solubility in solvent, in petrolatum, in the emulsion or a phase thereof and a potent solvent is used to increase the solubility, in one or both phases, in the interphase or in the foam.
  • a potent solvent in a foam composition provides an improved method of delivering poorly soluble therapeutic agents to a target area. It is known that low drug solubility results in poor bioavailability, leading to decreased effectiveness of treatment. Foam compositions, for which the solvent includes a potent solvent, increase the levels of the active agent in solution and thus, provide high delivery and improved therapy.
  • Potent solvents as defined herein, are usually liquid. Formulations comprising potent solvents and active agents are generally disadvantageous as therapeutics, since their usage involves unwanted dripping and inconvenient method of application; resulting in inadequate dosing. Surprisingly, the foams, which are drip-free, provide a superior vehicle for such active agents, enabling convenient usage and accurate effective dosing.
  • the foamable pharmaceutical composition may additionally include a potent solvent or a mixture of two or more of the above solvents selected from the group of hydrophobic solvents, silicone oils, emollients, polar solvents and potent solvents in an appropriate proportion as would be appreciated to a person skilled in the art and preferably in relatively small amounts.
  • a potent solvent or a mixture of two or more of the above solvents selected from the group of hydrophobic solvents, silicone oils, emollients, polar solvents and potent solvents in an appropriate proportion as would be appreciated to a person skilled in the art and preferably in relatively small amounts.
  • the foamable composition contains a polymeric agent.
  • the polymeric agent serves to stabilize the foam composition and to control drug residence in the target organ.
  • the polymeric agent is ASOS, carboxymethyl cellulose/microcrystalline cellulose, Arlacel 2121, or methocel and xantham gum.
  • More exemplary polymeric agents are classified below in a non-limiting manner.
  • a given polymer can belong to more than one of the classes provided below.
  • the composition includes a gelling agent.
  • a gelling agent controls the residence of a therapeutic composition in the target site of treatment by increasing the viscosity of the composition, thereby limiting the rate of its clearance from the site.
  • Many gelling agents are known in the art to possess mucoadhesive properties.
  • the gelling agent can be a natural gelling agent, a synthetic gelling agent and an inorganic gelling agent.
  • Exemplary gelling agents that can be used in accordance with one or more embodiments include, for example, naturally-occurring polymeric materials, such as locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, starch, chemically modified starches and the like, semi-synthetic polymeric materials such as cellulose ethers (e.g.
  • Further exemplary gelling agents include the acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers.
  • Non-limiting examples include Carbopol® 934, Carbopol® 940, Carbopol® 950, Carbopol® 980, Carbopol® 951 and Carbopol® 981.
  • Such agents can function as stabalisers in one or more embodiments and as delivery enhancers in one or more other embodiments.
  • the gelling agent includes inorganic gelling agents, such as silicone dioxide (fumed silica).
  • Mucoadhesive/bioadhesion has been defined as the attachment of synthetic or biological macromolecules to a biological tissue.
  • Mucoadhesive agents are a class of polymeric biomaterials that exhibit the basic characteristic of a hydrogel, i.e. swell by absorbing water and interacting by means of adhesion with the mucous that covers epithelia.
  • Compositions may contain a mucoadhesive macromolecule or polymer in an amount sufficient to confer or partially to confer bioadhesive properties, although these substances may by their nature, increase the tackiness of a composition so this will be taken into account in preparing compositions.
  • the bioadhesive macromolecule can enhance delivery of biologically active agents on or through the target surface.
  • the mucoadhesive macromolecule may be selected from acidic synthetic polymers, preferably having an acidic group per four repeating or monomeric subunit moieties, such as poly(acrylic)- and/or poly(methacrylic) acid (e.g., Carbopol®, Carbomer®), poly(methylvinyl ether/maleic anhydride) copolymer, and their mixtures and copolymers; acidic synthetically modified natural polymers, such as carboxymethylcellulose (CMC); neutral synthetically modified natural polymers, such as (hydroxypropyl)methylcellulose; basic amine-bearing polymers such as chitosan; acidic polymers obtainable from natural sources, such as alginic acid, hyaluronic acid, pectin, gum tragacanth, and karaya gum; and neutral synthetic polymers, such as polyvinyl alcohol or their mixtures.
  • acidic synthetic polymers preferably having an acidic group per four repeating or monomeric subunit moieties, such as
  • mucoadhesive polymers includes natural and chemically modified cyclodextrin, especially hydroxypropyl- ⁇ -cyclodextrin. Such polymers may be present as free acids, bases, or salts, usually in a final concentration of about 0.01% to about 0.5% by weight. Many mucoadhesive agents are known in the art to also possess gelling properties.
  • the polymeric agent contains a film-forming component, although these substances may also by their nature, increase the tackiness of a composition so this will be taken into account in preparing compositions.
  • the film-forming component may include a water-insoluble alkyl cellulose or hydroxyalkyl cellulose.
  • Exemplary alkyl cellulose or hydroxyalkyl cellulose polymers include ethyl cellulose, propyl cellulose, butyl cellulose, cellulose acetate, hydroxypropyl cellulose, hydroxybutyl cellulose, and ethylhydroxyethyl cellulose, alone or in combination.
  • a plasticizer or a cross-linking agent may be used to modify the polymer's characteristics.
  • esters such as dibutyl or diethyl phthalate, amides such as diethyldiphenyl urea, vegetable oils, fatty acids and alcohols such as oleic and myristyl acid may be used in combination with the cellulose derivative.
  • the polymeric agent includes a phase change polymer, which alters the composition behavior from fluid-like prior to administration to solid-like upon contact with the target mucosal surface.
  • phase change results from external stimuli, such as changes in temperature or pH and exposure to specific ions (e.g., Ca 2+ ).
  • phase change polymers include poly(N-isopropylamide) and Poloxamer 407®.
  • the polymeric agent is present in an amount in the range of about 0.01% to about 5.0% by weight of the foam composition. In one or more embodiments, it is typically less than about 1 wt % of the foamable composition.
  • a therapeutically effective foam adjuvant is included in the foamable compositions to increase the foaming capacity of surfactants and/or to stabilize the foam.
  • the foam adjuvant agent includes fatty alcohols having 15 or more carbons in their carbon chain, such as cetyl alcohol and stearyl alcohol (or mixtures thereof).
  • fatty alcohols are myristyl alcohol (C14), arachidyl alcohol (C20), behenyl alcohol (C22), 1-triacontanol (C30), as well as alcohols with longer carbon chains (up to C50).
  • Fatty alcohols derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, are especially well suited as foam adjuvant agents.
  • the amount of the fatty alcohol required to support the foam system is inversely related to the length of its carbon chains.
  • Foam adjuvants, as defined herein are also useful in facilitating improved spreadability and absorption of the composition.
  • the foam adjuvant agent includes fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof.
  • fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof.
  • fatty acids having 16 or more carbons in their carbon chain such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic
  • a combination of a fatty acid and a fatty ester is employed.
  • the carbon atom chain of the fatty alcohol or the fatty acid may have a double bond.
  • a further class of foam adjuvant agent includes a branched fatty alcohol or fatty acid.
  • the carbon chain of the fatty acid or fatty alcohol also can be substituted with a hydroxyl group, such as 12-hydroxy stearic acid.
  • a property of the fatty alcohols and fatty acids used in context of the composition is related to their therapeutic properties per se.
  • Long chain saturated and mono unsaturated fatty alcohols e.g., stearyl alcohol, erucyl alcohol, arachidyl alcohol and behenyl alcohol (docosanol) have been reported to possess antiviral, antiinfective, antiproliferative and anti-inflammatory properties (see, U.S. Pat. No. 4,874,794).
  • Longer chain fatty alcohols e.g., tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol, etc.
  • tetracosanol hexacosanol
  • heptacosanol heptacosanol
  • octacosanol triacontanol, etc.
  • Long chain fatty acids have also been reported to possess anti-infective characteristics.
  • the active agent is encapsulated in particles, microparticles, nanoparticles, microcapsules, spheres, microspheres, nanocapsules, nanospheres, liposomes, niosomes, polymer matrix, nanocrystals or microsponges.
  • composition may further optionally include a variety of formulation excipients, which are added in order to fine-tune the consistency of the formulation, protect the formulation components from degradation and oxidation and modify their consistency.
  • formulation excipients may be selected, for example, from stabilizing agents, antioxidants, humectants, moisturizers, preservatives, colorant and odorant agents and other formulation components, used in the art of formulation.
  • Aerosol propellants are used to generate and administer the foamable composition as a foam.
  • the total composition including propellant, foamable compositions and optional ingredients is referred to as the foamable carrier.
  • the propellant makes up about 3% to about 25% (w/w) of the foamable carrier or composition.
  • suitable propellants include volatile hydrocarbons such as butane, propane, isobutane, and fluorocarbon gases or mixtures thereof.
  • the propellant is 1681, which is a mixture of three gas propellants propane, isobutene and butane.
  • AP 70 which is a mixture of propane, isobutene and butane with a higher pressure. In some circumstances the propellant may be up to 35%.
  • the total composition including propellant, foamable compositions and optional ingredients is referred to as the foamable composition.
  • the propellant is not included in the 100% but is instead added to the 100% since the propellant is essentially discharged into the atmosphere upon expulsion of the formulation.
  • Such propellants include, but are not limited to, hydrofluorocarbon (HFC) propellants, which contain no chlorine atoms, and as such, fall completely outside concerns about stratospheric ozone destruction by chlorofluorocarbons or other chlorinated hydrocarbons.
  • HFC hydrofluorocarbon
  • Exemplary non-flammable propellants according to this aspect include propellants made by DuPont under the registered trademark Dymel, such as 1,1,1,2 tetrafluorethane (Dymel 134), and 1,1,1,2,3,3,3 heptafluoropropane (Dymel 227).
  • HFCs possess Ozone Depletion Potential of 0.00 and thus, they are allowed for use as propellant in aerosol products.
  • foamable emulsions including HFC as the propellant can be improved in comparison with the same composition made with a hydrocarbon propellant.
  • foamable compositions comprise a combination of a HFC and a hydrocarbon propellant such as n-butane or mixtures of hydrocarbon propellants such as propane, isobutane and butane.
  • a hydrocarbon propellant such as n-butane or mixtures of hydrocarbon propellants such as propane, isobutane and butane.
  • a composition includes one or more additional components.
  • additional components include but are not limited to anti perspirants, anti-static agents, buffering agents, bulking agents, conservational agents, chelating agents, cleansers, colorants, conditioners, deodorants, diluents, dyes, emollients, fragrances, hair conditioners, humectants, pearlescent aids, perfuming agents, permeation enhancers, pH-adjusting agents, preservatives, protectants, skin penetration enhancers, softeners, solubilizers, sunscreens, sun blocking agents, sunless tanning agents, viscosity modifiers, ionization agents, and antioxidants like flavonoids and phenolics.
  • a specific additional component may have more than one activity, function or effect.
  • the additional component is a pH adjusting agent or a buffering agent.
  • Suitable buffering agents include but are not limited to acetic acid, adipic acid, calcium hydroxide, citric acid, glycine, hydrochloric acid, lactic acid, magnesium aluminometasilicates, phosphoric acid, sodium carbonate, sodium citrate, sodium hydroxide, sorbic acid, succinic acid, tartaric acid, and derivatives, salts and mixtures thereof.
  • Sodium metabisulfite is used as an antioxidant in (primarily acidic) pharmaceutical formulations, at concentrations of 0.01-1.0% w/v., preparations and can also be used as a preservative having some antimicrobial activity at though for alkaline preparations, sodium sulfite is usually preferred
  • active agents useful herein can in some instances provide more than one benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit the active agent to that particular application or applications listed.
  • composition comprises an active agent that provides therapeutic or cosmetic activity.
  • Non-limiting examples of active agents include an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, a steroidal anti-inflammatory agent, a nonsteroidal anti-inflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, a steroid, a vasoactive agent, a vasoconstrictor, a vasodilator, vitamin A, a vitamin A derivative, a retinoid, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, alpha-tocopheryl polyethylene glycol succinate, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a burn healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid,
  • the active agent may be vitamin D or a derivative such as calcipotriol or calcitriol.
  • the vitamin D or derivative is used in combination with a steroid. Due to the different environmental requirements of the two types of API's it is very difficult to produce formulations that are both chemically and physically stable. In certain embodiments there are provided chemically and physically stable formulations containing one or both active agents. Nevertheless, in certain other preferred embodiments the active agents are in separate formulations and are delivered by means of a multichamber or dual chamber device. Alternatively they can be expelled manually simultaneously or consecutively from two separate canisters directed to the same target site.
  • the active agent may be an extract or tincture of one or more beneficial agents that have beneficial properties, for example, when applied to the skin, a body surface, a body cavity or a mucosal surface.
  • the extract can be, for example, alcoholic, hydroalcoholic, propelyne glycol, glycerine, dry, press, cold, hot, liquid carbon dioxide, oil or other process known in the art.
  • the extract or tincture may comprise of substances of animal, plant, (such as herb, fruit, vegetable) mineral or other origin. Nonlimiting examples are proteins, polypepeptides, sugars, hyularonic acid, and coal tar.
  • Herbal extracts may be from any known therapeutic herb, as listed for example in Herbal Medicines, London: Pharmaceutical Press Electronic Version 2006 or in the American Herbal Association electronic publication Herbal gram or in German Commission E., such as, angelica, calendula, celery, coltsfoot, comfrey, dandelion, jamaica dogwood, kava, marshmallow, prickly ash, northern prickly ash, southern senna, valerian, agrimony, aloe vera, alfalfa, artichoke, avens, bayberry, bloodroot, blue flag, bogbean, boldo, boneset, broom, buchu, burdock, burnet, calamus, calendula, cascara, centaury, cereus, chamomile, german chamomile, roman chamomile, cinnamon, clivers, cohosh, black, cohosh, blue, cola, corn silk, couchgrass, cowslip, damiana, de
  • the extract may contain, for example, an aqueous, polar, hydrophobic or potent solvent as will be appreciated by a person of ordinary skill in the art.
  • the active agent is an anti-infective agent, selected from an antibiotic agent, an antibacterial agent, an anti-fungal agent, an anti-viral agent and an anti-parasite agent.
  • the antibacterial drug can be active against gram positive and gram-negative bacteria, protozoa, aerobic bacteria and anaerobic ones.
  • the antibiotic agent is selected from the classes consisting of beta-lactam antibiotics, synthetic and semi-synthetic penicillin's, aminoglycosides, ansa-type antibiotics, anthraquinones, antibiotic azoles, antibiotic glycopeptides, macrolides, antibiotic nucleosides, antibiotic peptides, antibiotic polyenes, antibiotic polyethers, quinolones, fluoroquinolnes, antibiotic steroids, cyclosporines, sulfonamides, tetracycline, chloramphenicol, dicarboxylic acids, such as azelaic acid, salicylates, antibiotic metals, oxidizing agents, substances that release free radicals and/or active oxygen, cationic antimicrobial agents, quaternary ammonium compounds, biguanides, triguanides, bisbiguanides and analogs and polymers thereof and naturally occurring antibiotic compounds.
  • beta-lactam antibiotics synthetic and semi-synthetic penicillin's, aminoglycosides, ans
  • Additional antibacterial agents which are non-specific, include strong oxidants and free radical liberating compounds, such as hydrogen peroxide, bleaching agents (e.g., sodium, calcium or magnesium hypochloride and the like), iodine, chlorohexidine and benzoyl peroxide.
  • strong oxidants and free radical liberating compounds such as hydrogen peroxide, bleaching agents (e.g., sodium, calcium or magnesium hypochloride and the like), iodine, chlorohexidine and benzoyl peroxide.
  • the antifungal agent can be an azole compound.
  • exemplary azole compounds include azoles selected from the group consisting of azoles, diazoles, triazoles, miconazole, ketoconazole, clotrimazole, econazole, mebendazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, thiabendazole, tiaconazole, fluconazole, itraconazole, ravuconazole and posaconazole.
  • Additional exemplary antifungal agents include griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B, potassium iodide, flucytosine (5FC) and any combination thereof at a therapeutically effective concentration.
  • the active agent is an anti-viral agent.
  • Any known antiviral agent, in a therapeutically effective concentration, can be incorporated in the foam composition.
  • Exemplary antiviral agents include, but not limited to, acyclovir, famciclovir, gancyclovir, valganciclovir and abacavir.
  • the active agent is an anti-inflammatory or anti-allergic agent.
  • Anti-inflammatory agents can be selected from the group of corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), anti-histamines, immunosuppressant agents, immunomodulators; and any combination thereof at a therapeutically effective concentration.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • immunosuppressant agents immunomodulators; and any combination thereof at a therapeutically effective concentration.
  • Non-limiting examples of corticosteroids include hydrocortisone, hydrocortisone acetate, desonide, betamethasone valerate, clobetasone-17-butyrate, flucinonide, fluocinolone acetonide, alcometasone dipropionate, mometasone furoate, prednicarbate, triamcinolone acetonide, betamethasone-17-benzoate, methylprednisolone aceponate, betamethasone dipropionate, halcinonide, triamcinolone acetonide, halobetasol and clobetasol-17-propionate.
  • a second class of anti-inflammatory agents which is useful in the foam, includes the nonsteroidal anti-inflammatory agents (NSAIDs).
  • NSAIDs nonsteroidal anti-inflammatory agents
  • Specific non-steroidal anti-inflammatory agents useful in the composition invention include, but are not limited to, oxicams, such as piroxicam, isoxicam, tenoxicam, sudoxicam; salicylates, such as salicylic acid, ethyl salicylate, methyl salycilate, aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal; scetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepir
  • Antiallergic active agents include antihistamine compounds, including, in a non limiting manner, thylenediamines, such as pyrilamine (mepyramine), antazoline and methapyrilene; tripelennamine phenothiazines, such as promethazine, methdilazine and trimeprazine; ethanolamines, such as diphenhydramine, bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenylpyraline, doxylamine and phenyltoxamine; piperazines, such as cyclizine, buclizine, chlorcyclizine, hydroxyzine, meclizine and thiethylperazine; alkylamines, such as brompheniramine, pyrrobutamin, desbrompheniramine, tripolidine, dexchlorpherniramine, chlorpheniramine; dimethindene and pheniramine; and piperid
  • composition may also comprise an anti-inflammatory or antiallergic agent, wherein said agent reduces the occurrence of pro-inflammatory cytokines or inhibits the effect of pro-inflammatory cytokines.
  • Immunosuppressant agents, immunoregulating agents and immunomodulators are chemically or biologically derived agents that modify the immune response or the functioning of the immune system (as by the stimulation of antibody formation or the inhibition of white blood cell activity).
  • Immunosuppressant agents and immunomodulators include, among other options, cyclic peptides, such as cyclosporine, tacrolimus, tresperimus, pimecrolimus, sirolimus (rapamycin), verolimus, laflunimus, laquinimod and imiquimod.
  • the active agent is a topical anesthetic.
  • topical anesthetic drugs include, but not limited to, benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine, and phenol. Mixtures of such anesthetic agents may be synergistically beneficial.
  • the active agent is a “keratolytically active agent.”
  • keratolytically active agent refers herein to a compound, which loosens and removes the stratum corneum of the skin, or alters the structure of the keratin layers of the skin.
  • Suitable keratolytically active agents include phenol and substituted phenolic compounds. Such compounds are known to dissolve and loosen the intracellular matrix of the hyperkeratinized tissue. Dihydroxy benzene and derivatives thereof have been recognized as potent keratolytic agents. Resorcinol (m-dihydroxybenzene) and derivatives thereof are used in anti-acne preparations. Hydroquinone (p-dihydroxybenzene), besides its anti-pigmentation properties, is also keratolytic.
  • Vitamin A and its derivatives such as retinoic acid, isoretinoic acid, retinol and retinal are another preferred class of keratolytically active agents.
  • keratolytically active agents include alpha-hydroxy acids, such as lactic acid and glycolic acid and their respective salts and derivatives; and beta-hydroxy acids, such as Salicylic acid (o-hydroxybenzoic acid) and its salts and pharmaceutically acceptable derivatives, which typically possess anti-inflammatory, as well as keratolytic, activity.
  • alpha-hydroxy acids such as lactic acid and glycolic acid and their respective salts and derivatives
  • beta-hydroxy acids such as Salicylic acid (o-hydroxybenzoic acid) and its salts and pharmaceutically acceptable derivatives, which typically possess anti-inflammatory, as well as keratolytic, activity.
  • Salicylic acid o-hydroxybenzoic acid
  • pharmaceutically acceptable derivatives which typically possess anti-inflammatory, as well as keratolytic, activity.
  • another class of preferred keratolytically active agents includes urea and its derivatives.
  • the active agent is a retinoid.
  • Retinoids include, for example, retinol, retinal, all-trans retinoic acid and derivatives, isomers and analogs thereof.
  • Etretinate, actiretin, isotretinoin, adapalene and tazarotene are further examples of said retinoid isomers and analogs.
  • the active agent is a vitamin D 3 analogue such as calcipotriol, tacalcitol, maxacalcitol, and calcitriol with calcipotriol being especially preferred.
  • Vitamin D 3 analogues and derivatives are known to degrade at low pH levels. The waterless compositions can protect against or retard such degredation.
  • the active agent is vitamin D 3 or an analogue or a derivative thereof, and there is a concern that there are some potential residues which could effect the agent in the composition or following application to the skin or a body cavity could cause breakdown a neutralizing or stabilizing agent might additionally be added which could be a suitable pH adjuster or buffer.
  • the active agent is an insecticide or an insect repellent agent.
  • the active agent is an anti cancer agent.
  • the active agent is a photodynamic therapy (PDT) agent.
  • PDT agents can be modified porphyrins, chlorins, bacteriochlorins, phthalocyanines, naphthalocyanines, pheophorbides, purpurins, m-THPC, mono-L-aspartyl chlorin e6, bacteriochlorins, phthalocyanines, benzoporphyrin derivatives, as well as photosensitizer precursors, such as aminolevulinic acid (ALA).
  • ALA aminolevulinic acid
  • the active agent is an agent useful in the treatment of burns, wounds, cuts and ulcers.
  • the foam compositions may comprise a combination of anti-infective agents (against bacteria, fungi and/or viruses), anti-inflammatory agents (steroidal and/or NSAIDs) and pain relieving components.
  • the active agent can also be used as an absorption and bioavailability enhancer for other drugs and vitamins, for example TPGS that forms its own micelles can aid e.g. amprenavir and vitamin D respectively.
  • the active agent has some degree of solubility in water.
  • some degree of solubility it is understood to include API's that are described by the US or European Pharmacopoeia as being slightly soluble, sparingly soluble, soluble, freely soluble or very soluble. Both describe the approximate ranges of parts of solvent (volume) required for 1 part (per gram) of solute as less than 1 for very soluble; from 1-10; for freely soluble, from 10-30 for soluble; from 30 to 100 for sparingly soluble; and from 100 to 1000 for slightly soluble. Additionally, the phrase may include the terms partly soluble and miscible.
  • Non limiting examples of substances that have some degree of solubility in water are acyclovir, azelaic acid, allantoin, ammonium lactate, benzoyl peroxide, caffeine, calcipotriol, ciclopirox olamine, clindamycin hydrochloride, clindamycin phosphate, clindamycin palmitate hydrochloride, coal tar, cyanocobalamine, diclofenac sodium, gentamycin sulphate, lactic acid, glycyrrhizinic acid, map (magnesium ascorbyl phosphate), minoxidil, mupirocin, salicylic acid, terbinafine, urea, fusidic acid, a hydrocortisone, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, a clobetasol, a halobetasol, a batamethsone; halobetasol and clobetasol-17
  • the active agent has a limited degree of solubility in water.
  • a limited degree of solubility it is understood to include API's that are described by the US or European Pharmacopoeia as being very slightly soluble.
  • the approximate range of parts of solvent (volume) required for 1 part (per gram) of solute is from 1000 to 10000 for very slightly soluble.
  • the active agent has some degree of solubility in an petrolatum emollient. So any agent that by its nature is hydrophobic may qualify, such as permethrin and tetracaine.
  • the active agent has some degree of solubility in a composition in one or more of the water phase, the oil phase, or the interphase or the foam.
  • a composition in one or more of the water phase, the oil phase, or the interphase or the foam For example, beamethasone valerate has been stated to be practically insoluble in water. However, it has been surprisingly found that it is soluble in the water phase of a foamable composition in a pharmaceutically effective amount for topical application.
  • foam compositions are suitable for the further application as “cosmeceutical” preparation (cosmetic products with therapeutic benefit), to treat “cosmetic” skin disorders, such as aging skin, wrinkles, hyperpigmentation (melasma, chloasma, freckles, etc.), scaly skin and other skin undesirable properties.
  • cosmetic cosmetic products with therapeutic benefit
  • skin disorders such as aging skin, wrinkles, hyperpigmentation (melasma, chloasma, freckles, etc.), scaly skin and other skin undesirable properties.
  • CTFA Cosmetic Ingredient Handbook describes a wide variety of non-limiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions. Examples of these ingredient classes include: abrasives, absorbents, aesthetic components such as fragrances, pigments, colorings/colorants, essential oils, astringents, etc.
  • anti-acne agents e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate
  • anti-acne agents e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate
  • anti-microbial agents e.g., iodopropyl butylcarbamate
  • antioxidants e.g., iodopropyl butylcarbamate
  • binders biological additives, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film formers or materials, e.g., polymers, for aiding the film-forming properties and substantivity of the composition (e.g., copolymer
  • the active agent is an agent useful in the treatment of acne, wrinkles and scars.
  • useful anti-acne actives include resorcinol, sulfur, salicylic acid and salicylates, alpha-hydroxy acids, nonsteroidal anti-inflammatory agents, benzoyl peroxide, retinoic acid, isoretinoic acid and other retinoid compounds, adapalene, tazarotene, azelaic acid and azelaic acid derivatives, antibiotic agents, such as erythromycin and clyndamycin, zinc salts and complexes, and combinations thereof, in a therapeutically effective concentration.
  • Exemplary anti-wrinkle/anti-atrophy active agents suitable for use in the compositions include sulfur-containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives; thiols; hydroxy acids (e.g., alpha-hydroxy acids such as lactic acid and glycolic acid and their derivatives and salts; or beta-hydroxy acids such as salicylic acid and salicylic acid salts and derivatives), urea, hyaluronic acid, phytic acid, lipoic acid; lysophosphatidic acid, skin peel agents (e.g., phenol, resorcinol and the like), vitamin B3 compounds (e.g., niacinamide, nicotinic acid and nicotinic acid salts and esters, including non-vasodilating esters of nicotinic acid (such as tocopheryl nicotinate), nicotinyl amino acids, nicotinyl alcohol esters of carboxylic
  • the active agent is an anti-oxidant or a radical scavenger.
  • Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, lipoic acid, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydr
  • polyunsaturated fatty acids containing omega-3 and omega-6 fatty acids (e.g., linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are beneficial in the treatment of psoriasis and other skin inflammation conditions.
  • omega-3 and omega-6 fatty acids e.g., linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
  • GLA gamma-linoleic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • a skin protective foam is provided, wherein the hydrophobic carrier comprises in full or in part, an organic
  • the active agent is a self-tanning active Agent, such as dihydroxyacetone.
  • the active agent comprises solid matter or particulate matter, i.e., material that is not soluble in the liquid carrier composition of the foamable composition.
  • solid matter shall mean material that is not soluble in the foamable composition more than 10% of the concentration intended to be included in said foamable composition.
  • metallic oxides such as titanium dioxide, zinc oxide, zirconium oxide, iron oxide
  • silicon containing materials such as silicone oxide and talc
  • carbon for example in the form of amorphous carbon or graphite
  • insoluble oxidizing agents such as benzoyl peroxide, calcium and magnesium hypochlorite
  • metallic Silver metallic Silver
  • cosmetic scrub materials including, for example meals of strawberry seeds, raspberry seeds, apricot seeds, sweet almond, cranberry seeds; and pigments.
  • the solid is substantially uniformly dispersed as a suspension in the composition, wherein the composition is formulated so that the resultant foam when applied topically to a target will form an effective barrier and the composition does not comprise a non propellant organic cosolvent.
  • the active agent is selected from the group of solvent, surface active agent, foam adjuvant and gelling agent, which are, on a case-by-case basis, known to possess a therapeutic benefit.
  • At least one or at least two active agents are included in the composition.
  • the reference includes, derivatives, conjugates, analogues, prodrugs, chelates, complexes, ions, isomers, enantimers, and salts thereof.
  • a pharmaceutical or cosmetic composition manufactured using the foamable carrier is very easy to use. When applied onto the afflicted body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
  • the foamable composition can be in the state of (1) solutions; (2) a readily dispersible suspension; or (3) an emulsion. It is stable, having an acceptable shelf life of a year, or at least two years at ambient temperature, as revealed in accelerated stability tests.
  • Polar solvents, hydrophobic carriers and propellants which are a mixture of low molecular weight hydrocarbons, tend to impair the stability of emulsions and to interfere with the formation of a stable foam upon release from a pressurized container. It has been observed, however, that the foamable compositions according to the present invention are surprisingly stable. Following accelerated stability studies, they demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
  • compositions containing semi-solid hydrophobic solvents e.g., white petrolatum, as the main ingredients of the oil phase of the emulsion, exhibit high viscosity and reduced or poor flowability and are not ideal candidates for a foamable composition. It has been found that despite the aforesaid in the compositions s the produce foams, which are surprisingly soft, or with improved stability.
  • the foam can act as a barrier to water soluble irritants and air borne bacteria whilst also providing a vehicle for water soluble active agents.
  • anaerobic bacteria growing under the barrier.
  • an petrolatum emollient can aid API transport through the skin or retard penetration prolonging thereby its action.
  • a pharmaceutical formulation for example with petrolatum can be designed to improve or prolong delivery as is required as will be appreciated by a person skilled in the art.
  • Foam quality can be graded as follows:
  • Grade E excellent: very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery.
  • Grade G good: rich and creamy in appearance, very small bubble size, “dulls” more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery.
  • Grade FG fairly good: a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity.
  • Grade F fair
  • Grade P poor: no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance.
  • Grade VP very poor: dry foam, large very dull bubbles, difficult to spread on the skin.
  • Topically administrable foams are typically of quality grade E or G, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal. Achieving G or E, where petrolatum. a heavy, greasy, tacky substance, is the main or major component is a challenge and achievement. As a consequence of the high levels of petrolatum and its nature, the density of the resultant foams can be significantly higher than with non or low petrolatum foams. With high petrolatum a density of the order of about 0.5 g to about 0.4 g is acceptable. Nevertheless, in certain other embodiments relatively low density petrolatum foams can be achieved having a density below about 0.4 g and preferably with a density of less than about 0.2 g.
  • a further aspect of the foam is breakability.
  • the breakable foam is thermally stable, yet breaks under sheer force. Sheer-force breakability of the foam is clearly advantageous over thermally induced breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
  • composition wherein the foam demonstrates at least eighteen of the following properties:
  • composition wherein the foam provides at least two of the following traits:
  • composition wherein the foam provides at least two of the following traits:
  • Dual and Multi Chamber devices and heads suitable for use with the formulations described herein where a first formulation is stored in a first canister and a second formulation is stored in a second canister are described in U.S. Pat. No. 6,305,578 entitled DEVICE FOR MIXING, FOAMING AND DISPENSING LIQUIDS FROM SEPARATE COMPRESSED-GAS CONTAINERS and in US Publication 2007-0069046 and entitled APPARATUS AND METHOD FOR RELEASING A MEASURE OF CONTENT FROM A PLURALITY OF CONTAINERS all of which are incorporated herein by reference in their entirety. More particularly any of the devices and uses described are applicable herein and are incorporated by reference.
  • the dual chamber device is as described in U.S. Pat. No. 6,305,578 for example,
  • the dual dispenser head is as described in US Publication 2007-0069046 for example:
  • a dispenser head for use with a plurality of containers, comprising:
  • a kit comprising a dual chamber device or dual dispenser head, a first canister comprising a first foamable formulation comprising a first API and a second canister comprising a second foamable formulation comprising a second API wherein each canister is connectable to the said device or head.
  • the first foamable formulation may be any of the stable petrolatum formulations described herein and the second foamable formulation may also be any of the stable petrolatum formulations described herein.
  • the first API is a steroid and the second API is a vitamin D derivative and the each formulation is adapted to carry an effective amount of steroid and vitamin D derivative, respectively, such that each formulation and API is sufficiently chemically and physically stable for pharmaceutical use.
  • foamable compositions are described in: U.S. Publication No. 05-0232869, published on Oct. 20, 2005, entitled NONSTEROIDAL IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0205086, published on Sep. 22, 2005, entitled RETINOID IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0018937, published on Jan. 26, 2006, entitled STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0271596, published on Dec.
  • any of the active ingredients; the solvents; the surfactants; foam adjuvants; polymeric agents, penetration enhancers; preservatives, humectants; moisturizers; and other excipients as well as the propellants and methods listed therein can be applied herein and are incorporated by reference.
  • a “stable foam” is defined herein as a composition, which upon release from an aerosol can, creates a foam mass, which is sustained on a surface for at least one minute, more preferably at least two minutes, and yet more preferably for at least 5 minutes.
  • a period of minutes is regarded as a short term, but nevertheless it allows a good and more than sufficient period of time for a subject to receive foam dispensed on a body surface and to spread it or to transfer it to another region and to spread it.
  • an acceptable foam is one, that does not readily collapse upon dispensing on the skin; spreads easily on a skin surface; at least partially absorbed following rubbing onto the skin, and more preferably, substantially absorbed following rubbing on the skin.
  • an acceptable foam is one, that: creates a pleasant feeling after application; leaves minimal oily residue; and leaves minimal shiny residual look.
  • the petrolatum foam described herein has several advantages, when compared with hydroalcoholic foam compositions.
  • the foamable carrier and the foamable pharmaceutical or cosmetic composition are intended for administration to an animal or a human subject.
  • the composition is intended to treat the skin, a body surface, a body cavity, a deep body cavity, or a mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina, rectum or colon.
  • the composition are useful in treating a patient having any one of a variety of dermatological disorders, which include inflammation as one or their etiological factors (also termed “dermatoses”), such as classified in a non-limiting exemplary manner according to the following groups:
  • Hair follicles and sebaceous glands including acne, rosacea, perioral dermatitis, hypertrichosis (hirsutism), alopecia, including male pattern baldness, alopecia greata, alopecia universalis and alopecia totalis; pseudofolliculitis barbae, keratinous cyst; Scaling papular diseases including psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris; Benign tumors including moles, dysplastic nevi, skin tags, lipomas, angiomas, pyogenic granuloma, seborrheic keratoses, dermatofibroma, keratoacanthoma, keloid; Malignant tumors including basal cell carcinoma, squamous cell carcinoma, malignant melanoma, paget's disease of the nipples, kaposi's sarcom
  • composition is topically applied to a body cavity or mucosal surfaces, including, but not limited to the cranial cavity, the thoratic cavity, the abdominal cavity, the venteral cavity, the vagina, the rectum and penile cavities, the urinary tract, the nasal cavity, the mouth, the eye, the ear the peritoneum, the large and small bowel, the caecum, bladder, and stomach, the cavity between the uterus and the fallopian tubes, the ovaries and other body areas, which may accept topically-applied products.
  • a body cavity or mucosal surfaces including, but not limited to the cranial cavity, the thoratic cavity, the abdominal cavity, the venteral cavity, the vagina, the rectum and penile cavities, the urinary tract, the nasal cavity, the mouth, the eye, the ear the peritoneum, the large and small bowel, the caecum, bladder, and stomach, the cavity between the uterus and the fallopian tubes, the ovaries and other body areas, which may accept topically
  • the composition is suitable to treat conditions of a body cavity and a mucosal membrane, such as post-surgical adhesions, chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix,
  • compositions are also useful in the therapy of non-dermatological disorders by providing transdermal or trans-mucosal delivery of an active agent that is effective against non-dermatological disorders.
  • the disorder is a health abnormality that responds to treatment with a hormone.
  • a typical example of such abnormality is sexual dysfunction in men and women whereby androgen therapy is successfully used to restore sexual function.
  • disorders/medical indications that are in the scope of treatment with a hormone according to the present invention are androgen deficiency, estrogen deficiency, growth disorders, hypogonadism, cancer, vasomotor symptoms, menopausal disorders, vulvar and vaginal atrophy, urethritis, hypoestrogenism, osteoarthritis, osteoporosis, uterine bleeding, Hirsutism, Virilization, ovarian tumors, hypothalamic pituitary unit diseases, testicular tumors, prostate cancer, hypopituitarism, Klinefelter's syndrome, testicular feminisation, orchitectomy, vasomotor symptoms (such as “hot flashes”) associated with the menopause, metabolic abnormalities and mood disturbances.
  • vasomotor symptoms such
  • the water is heated to 70° C.
  • the Oil Phase is prepared by mixing together of all ingredients and heat up to 70° C. Continue mixing until full melting for solid ingredients.
  • the Water phase at 70-75° C. is added to the Oil phase in small portions at 70° C.
  • the emulsification is performed in presence of vigorous agitation continues until PFF uniformity is reached for at least 20 min.
  • the foamable formulation may be produced under nitrogen and under vacuum. Whilst the whole process can be carried out under an oxygen free environment, it can be sufficient to apply a vacuum after heating and mixing all the ingredients to obtain an emulsion or homogenous liquid.
  • the production chamber is equipped to apply a vacuum but if not the formulation can be for example placed in a dessicator to remove oxygen prior to filing and crimping.
  • LFRA100 instrument is used to characterize hardness.
  • a probe is inserted into the test material.
  • the resistance of the material to compression is measured by a calibrated load cell and reported in units of grams on the texture analyzer instrument display.
  • Preferably at least three repeat tests are conducted.
  • the textural characteristics of a dispensed foam can effect the degree of dermal penetration, efficacy, spreadability and acceptability to the user. The results can also be looked at as an indicator of softness. Note: the foam sample is dispensed into an aluminum sample holder and filled to the top of the holder.
  • Collapse time is examined by dispensing a given quantity of foam and photographing sequentially its appearance with time during incubation at 36° C. It is useful for evaluating foam products, which maintain structural stability at skin temperature for at least 1 minute. Thus foams which are structurally stable on the skin for at least one minute are termed “short term stable” compositions or foams.
  • Viscosity is measured with Brookfield LVDV-II+PRO with spindle SC4-25 at ambient temperature and 10, 5 and 1 RPM. Viscosity is usually measured at 10 RPM. However, at about the apparent upper limit for the spindle of ⁇ >50,000 CP, the viscosity at 1 RPM may be measured, although the figures are of a higher magnitude.
  • FTC Freeze Thaw Cycles
  • the amount of active agent present is analyzed in foam expelled from various pressurized canisters containing foam formulations using HPLC. Analysis is carried out at zero time and at appropriate time intervals thereafter.
  • the canisters are stored in controlled temperature incubators at 5° C., at 25° C., at, 40° C. and sometimes at 50° C. At appropriate time intervals canisters are removed and the amount of active agent in the foam sample is measured.
  • Skin hydration is measured using a Corneometer® CM 825 instrument. (Courage+Khazaka, Koln, Germany).
  • the measuring principle of the Corneometer® CM 825 is based on capacitance measurement of dielectric medium. Any change in the dielectric constant due to skin surface hydration alters the capacitance of a measuring capacitor. It can detect even slight changes in the skin hydration level.
  • Foams are made of gas bubbles entrapped in liquid.
  • the bubble size and distribution reflects in the visual texture and smoothness of the foam.
  • Foam bubbles size is determined by dispensing a foam sample on a glass slide, taking a picture of the foam surface with a digital camera equipped with a macro lens. The diameter of about 30 bubbles is measured manually relatively to calibration standard template. Statistical parameters such as mean bubble diameter, standard deviation and quartiles are then determined. Measuring diameter may also be undertaken with image analysis software.
  • the camera used was a Nikon D40X Camera (resolution 10MP) equipped with Sigma Macro Lens (ref: APO MACRO 150 mm F2.8 EX DG HSM). Pictures obtained are cropped to keep a squared region of 400 pixels ⁇ 400 pixels.
  • the light microscope enables observing and measuring particles from few millimeters down to one micron.
  • Light microscope is limited by the visible light wavelength and therefore is useful to measuring size of particles above 800 nanometers and practically from 1 micron (1,000 nanometers).
  • “Shakability” represents the degree to which the user is able to feel/hear the presence of the liquid contents when the filled pressurized canister is shaken. Shaking is with normal mild force without vigorous shaking or excessive force. When the user cannot sense the motion of the contents during shaking the product may be considered to be non shakable. This property may be of particular importance in cases where shaking is required for affecting proper dispersion of the contents.
  • Shakability scoring Good shakability (conforms to required quality specification) 2 Moderate shakability (conforms to required quality specification) 1 Not shakable (fails to meet required quality specification) but may 0 still be flowable and allow foam formation of quality Is substantially not able to pass through valve Block
  • Non-limiting examples of how stock solutions are made up with and without API Other stock solutions may be made using the same methodology by simply varying adding or omitting ingredients as would be appreciated by one of the ordinary skills in the art.
  • Examples 9, 10 and 11 are waterless emulsions of liquid hydrophilic solvents DMI, PEG 400 or Propylene glycol, stabilized in petrolatum base. It has been unexpectedly observed that replacing the water in above water in petrolatum emulsions, yielded high quality foams.
  • PART A- Minimal Ingredients of 60% petrolatum a foam adjuvant a polymer and API 42 Ingredients w/w % Petrolatum (Sofmetic TM 33 LMP) Petrolatum white 27 (Pionier ® 5464) Oleyl alcohol 10 Aluminum Starch 15 Octenyl Succinate Zinc Oxide 15 Total product: 100 Propellant: n-butane 20 Results Viscosity (cP) 249866.7 Viscosity (0.1 RPM cP) 175642.5 Shakability 2 Foam quality Good Color White Odor No odor Density (g/mL) 0.533 collapse >300/G
  • a preferred formulation is one with an average score eg about 60 or more.
  • the study is single blind (study recipient is blinded). Healthy subjects are applied with single dose of formulations as shown in Example A9. Skin hydration is measured using a Corneometer® CM 825 instrument. (Courage+Khazaka, Koln, Germany). The measuring principle of the Corneometer® CM 825 is based on capacitance measurement of dielectric medium. Any change in the dielectric constant due to skin surface hydration alters the capacitance of a measuring capacitor. It can detect even slight changes in the skin hydration level.
  • Skin hydration level is assessed at baseline with the Corneometer® CM 825. The formulations (about 0.075 g) is applied. Corneometers tested skin hydration after 15 mins following application. The skin was then washed and the hydration again measured.
  • Corneometer Results Formulation 45 46 48 49A ZT (Zero 37.5 40.75 34 39 Time) av (4) BEFORE 39.25 32 36.5 30.25 WASHING AFTER 57.25 64 56.5 60.75 WASHING
  • concentrations of active agents in foamable compositions are set out in Table 2.
  • Each active agent is added into, for example, any of the carriers listed in any of the above Examples in a therapeutically effective concentration and amount.
  • the methodology of addition is well known to those of the art.
  • the composition is adjusted in each case so that it is made up to 100% w/w as appropriate by solvent or petrolatum.
  • all the above active agents have a degree of solubility in water or petrolatum or the composition other than clobestol proprionate, which is practically insoluble; tacrolimus, which is insoluble in water; and betamethasone valerate which although has very limited solubility is nevertheless, surprisingly soluble at least to a degree in the compositions, in the water phase.
  • calcipotriol solubility in water is 0.6 ⁇ g/mL.
  • Section B Forms with in Excess of 50% Petrolatum and Oil, without Silicone and with No Water.
  • Betamethasone Valerate BMV
  • Betamethasone Dipropionate Clobetasol Propionate
  • Betamethasone valerate 0.12 Total 100 Results at time point zero: Shakability Good Density [g/mL] 0.103 Foam Quality Good Foam Color White Foam Odor no odor Collapse Time (sec) >300 Assay of Betamethasone valerate 0.116 (% w/w) Results after 2 months at 40° C.: Shakability Good Density [g/mL] 0.112 Foam Quality Good Foam Color White Foam Odor no odor Collapse Time (sec) 190 Assay of Betamethasone valerate 0.115 (% w/w) Results after 3 months at 40° C.: Shakability Good Density [g/mL] 0.108 Foam Quality Good Foam Color White Foam Odor faint odor Collapse Time (sec) 130 Assay of Betamethasone valerate 0.109 (% w/w)
  • Betamethasone dipropionate 0.064 Total 100 Assay of Betamethasone dipropionate (% w/w) Time point zero 0.061 after 2 weeks at 40° C. 0.059
  • the petrolatum mineral oil combination is about at least 78% and the petrolatum is in excess of 50%.
  • 048 049 050 Ingredient % w/w % w/w % w/w Zinc oxide 15 15 15 Petrolatum 73.5 58.5 73.5 (sofmetic) Mineral oil, 5 20 5 light Lecithin Ceteth 20 3 Sorbitan 3 3 stearate PPG 15 stearyl ether GMS 0.5 0.5 0.5 Cetostearyl 3 3 3 alcohol Control 100 100 100 Propellant 8 8 8 AP70
  • compositions are set out in Table 1.
  • Each active ingredient is added into, for example, any of the carriers listed in any of the above Examples in a therapeutically effective concentration and amount.
  • the methodology of addition is well known to those of the art.
  • the composition is adjusted in each case so that it is made up to 100% w/w by either a solvent or petrolatum.
  • Section C Formulations with in Excess of 80% Combinations of Petrolatum and Oil, without Silicone and with No Water.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
US12/025,547 2006-11-14 2008-02-04 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses Abandoned US20080260655A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US12/025,547 US20080260655A1 (en) 2006-11-14 2008-02-04 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
PCT/IB2009/005032 WO2009098595A2 (fr) 2008-02-04 2009-02-04 Compositions pharmaceutiques et cosmétiques moussantes à base de pétrolatum, sensiblement non aqueuses et leurs utilisations
AU2009211147A AU2009211147A1 (en) 2008-02-04 2009-02-04 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
CA2714015A CA2714015C (fr) 2008-02-04 2009-02-04 Compositions pharmaceutiques et cosmetiques moussantes a base de petrolatum, sensiblement non aqueuses et leurs utilisations
EP09707299A EP2257276A2 (fr) 2008-02-04 2009-02-04 Compositions pharmaceutiques et cosmétiques moussantes à base de pétrolatum, sensiblement non aqueuses et leurs utilisations
US12/778,591 US8795635B2 (en) 2006-11-14 2010-05-12 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US14/189,559 US9682021B2 (en) 2006-11-14 2014-02-25 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85874706P 2006-11-14 2006-11-14
US89917607P 2007-02-02 2007-02-02
US91585907P 2007-05-03 2007-05-03
US11/940,290 US20080206155A1 (en) 2006-11-14 2007-11-14 Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
US12/025,547 US20080260655A1 (en) 2006-11-14 2008-02-04 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/940,290 Continuation-In-Part US20080206155A1 (en) 2006-11-14 2007-11-14 Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/778,591 Continuation US8795635B2 (en) 2006-11-14 2010-05-12 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses

Publications (1)

Publication Number Publication Date
US20080260655A1 true US20080260655A1 (en) 2008-10-23

Family

ID=40952509

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/025,547 Abandoned US20080260655A1 (en) 2006-11-14 2008-02-04 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US12/778,591 Active 2029-09-22 US8795635B2 (en) 2006-11-14 2010-05-12 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US14/189,559 Expired - Fee Related US9682021B2 (en) 2006-11-14 2014-02-25 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/778,591 Active 2029-09-22 US8795635B2 (en) 2006-11-14 2010-05-12 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US14/189,559 Expired - Fee Related US9682021B2 (en) 2006-11-14 2014-02-25 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses

Country Status (5)

Country Link
US (3) US20080260655A1 (fr)
EP (1) EP2257276A2 (fr)
AU (1) AU2009211147A1 (fr)
CA (1) CA2714015C (fr)
WO (1) WO2009098595A2 (fr)

Cited By (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2010143186A1 (fr) * 2009-06-08 2010-12-16 Otic Pharma Ltd. Préparations de mousse otique
US20110015229A1 (en) * 2009-01-06 2011-01-20 Jie Zhang Method of treating neuropathic pain
US20110207765A1 (en) * 2008-10-31 2011-08-25 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
CN101785766B (zh) * 2010-01-26 2011-10-19 江苏天济药业有限公司 一种利多卡因氯己定气雾剂
WO2011088333A3 (fr) * 2010-01-14 2011-11-24 Zars Pharma, Inc. Formulations pour anesthésie locale se solidifiant pour la gestion de la douleur
US20120039818A1 (en) * 2010-08-10 2012-02-16 Joyce Labs, LLC (Delaware corp.) Anti-chafing aerosol powder
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
WO2011121034A3 (fr) * 2010-04-01 2012-05-31 Pharmanest Ab Compositions pharmaceutiques sans eau appropriées à des anesthésiques locaux
US20120202891A1 (en) * 2009-04-29 2012-08-09 University Of Kentucky Research Foundation Cannabinoid-Containing Compositions and Methods for Their Use
WO2012099962A3 (fr) * 2011-01-18 2012-09-27 Vicus Therapeutics, Llc Compositions pharmaceutiques et leurs procédés de fabrication et d'utilisation
US20120322776A1 (en) * 2009-12-22 2012-12-20 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2013025449A1 (fr) * 2011-08-16 2013-02-21 Merck Sharp & Dohme Corp. Utilisation de matrice inorganique et de combinaisons de polymères organiques pour la préparation de dispersions amorphes stables
US20130123720A1 (en) * 2010-06-11 2013-05-16 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
CN103463532A (zh) * 2013-08-22 2013-12-25 岳冀 一种治疗疼痛型急性颈部淋巴结炎的中药制备方法
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
WO2015044857A1 (fr) * 2013-09-25 2015-04-02 Ranbaxy Laboratories Limited Composition de pulvérisation topique d'halobétasol
WO2015086241A1 (fr) * 2013-12-10 2015-06-18 Henkel Ag & Co. Kgaa Traitement capillaire contenant de l'huile et du polyéthylène glycol
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
WO2016077884A1 (fr) * 2014-11-18 2016-05-26 Sndr Pty Ltd Composition topique
CN105770237A (zh) * 2016-04-22 2016-07-20 广东红珊瑚药业有限公司 一种具有止痒、消炎功效的泡沫剂及其制备方法
US9408877B1 (en) 2013-04-12 2016-08-09 Marcia Patricia Cox Compositions and process for skin restoration
US9427605B2 (en) 2005-03-24 2016-08-30 Novan, Inc. Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
CN106045875A (zh) * 2016-06-25 2016-10-26 仇颖超 一种盐酸土霉素的制备方法
EP3097903A1 (fr) * 2015-05-28 2016-11-30 Beiersdorf AG Formulation cosmétique de viscosité élevée pulvérisable
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
AU2015224534B2 (en) * 2009-10-02 2017-06-08 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
LU92931B1 (fr) * 2015-12-24 2017-07-20 Pihuit S A Composition et méthode antiparasites
US9757397B2 (en) 2011-07-05 2017-09-12 Novan, Inc. Methods of manufacturing topical compositions and apparatus for the same
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2018040692A1 (fr) * 2016-08-29 2018-03-08 江苏四新界面剂科技有限公司 Procédé de préparation d'un émulsifiant polydiméthylsiloxane
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
CN107875083A (zh) * 2017-10-18 2018-04-06 福建恒安集团有限公司 一种抗尿布疹涂布剂及其制备方法
WO2018075841A1 (fr) * 2016-10-21 2018-04-26 The Procter & Gamble Company Dosage de shampooing concentré de mousse pour fournir des bénéfices de soins capillaires
WO2018075850A1 (fr) * 2016-10-21 2018-04-26 The Procter & Gamble Company Dosage de mousse destiné à distribuer un volume de dosage et une quantité de tensioactif souhaités par un consommateur dans un espace de formulation optimal
WO2018075845A1 (fr) * 2016-10-21 2018-04-26 The Procter & Gamble Company Shampooing à dosage concentrée de mousse pour améliorer le conditionnement des cheveux
WO2018075847A1 (fr) * 2016-10-21 2018-04-26 The Procter & Gamble Company Dosage de shampooing concentré de mousse désignant des avantages de volume des cheveux
US10039799B2 (en) * 2016-07-20 2018-08-07 Lillian Jenkins Princess lite
US20180280293A1 (en) * 2015-04-15 2018-10-04 Maruho Co., Ltd. Pharmaceutical composition for skin
EP3283051A4 (fr) * 2015-04-16 2019-01-02 Kate Somerville Skincare, LLC Compositions auto-moussantes et procédés
US10206947B2 (en) 2013-08-08 2019-02-19 Novan, Inc. Topical compositions and methods of using the same
WO2019036770A1 (fr) * 2017-08-24 2019-02-28 University Of South Australia Compositions antimicrobiennes et procédés d'utilisation
US10226483B2 (en) 2013-08-08 2019-03-12 Novan, Inc. Topical compositions and methods of using the same
CN109575264A (zh) * 2018-10-26 2019-04-05 东莞理工学院 一种以戊内酯为溶剂提取聚羟基脂肪酸酯的方法
US10265334B2 (en) 2011-07-05 2019-04-23 Novan, Inc. Anhydrous compositions
US10311575B2 (en) 2016-03-23 2019-06-04 The Procter And Gamble Company Imaging method for determining stray fibers
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US10322081B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
CN110035663A (zh) * 2016-05-11 2019-07-19 拜耳医药保健有限责任公司 热稳定的打成泡沫的制剂
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10426713B2 (en) 2017-10-10 2019-10-01 The Procter And Gamble Company Method of treating hair or skin with a personal care composition in a foam form
US10441519B2 (en) 2016-10-21 2019-10-15 The Procter And Gamble Company Low viscosity hair care composition comprising a branched anionic/linear anionic surfactant mixture
US10576026B2 (en) 2011-10-11 2020-03-03 Fallien Cosmeceuticals, Ltd. Sunscreen formulation
WO2020049086A1 (fr) * 2018-09-05 2020-03-12 Leo Pharma A/S Composition d'aérosol pharmaceutique
US10610561B2 (en) * 2008-08-18 2020-04-07 Zhongshan Hospital of Fudan University Ceramide production-accelerating agent
US10799434B2 (en) 2016-10-21 2020-10-13 The Procter & Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits
US10849864B2 (en) 2015-07-28 2020-12-01 Novan, Inc. Combinations and methods for the treatment and/or prevention of fungal infections
US10888505B2 (en) 2016-10-21 2021-01-12 The Procter And Gamble Company Dosage of foam for delivering consumer desired dosage volume, surfactant amount, and scalp health agent amount in an optimal formulation space
WO2021022056A1 (fr) 2019-07-31 2021-02-04 Foamix Pharmaceuticals Ltd. Compositions et procédés et leurs utilisations
US10912732B2 (en) 2017-12-20 2021-02-09 The Procter And Gamble Company Clear shampoo composition containing silicone polymers
US10912743B2 (en) 2016-03-02 2021-02-09 Novan, Inc. Compositions for treating inflammation and methods of treating the same
US10925689B2 (en) 2014-07-14 2021-02-23 Novan, Inc. Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same
US20210169928A1 (en) * 2019-07-22 2021-06-10 Erivan Bio, Llc Topical Exosome Compositions and Associated Methods
US11077194B2 (en) 2012-03-14 2021-08-03 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
US11116703B2 (en) 2017-10-10 2021-09-14 The Procter And Gamble Company Compact shampoo composition containing sulfate-free surfactants
US11116704B2 (en) 2017-10-10 2021-09-14 The Procter And Gamble Company Compact shampoo composition
US11116705B2 (en) 2017-10-10 2021-09-14 The Procter And Gamble Company Compact shampoo composition containing sulfate-free surfactants
US11129783B2 (en) 2016-10-21 2021-09-28 The Procter And Gamble Plaza Stable compact shampoo products with low viscosity and viscosity reducing agent
US11141370B2 (en) 2017-06-06 2021-10-12 The Procter And Gamble Company Hair compositions comprising a cationic polymer mixture and providing improved in-use wet feel
US11154467B2 (en) 2016-10-21 2021-10-26 The Procter And Gamble Plaza Concentrated shampoo dosage of foam designating hair conditioning benefits
US11166980B2 (en) 2016-04-13 2021-11-09 Novan, Inc. Compositions, systems, kits, and methods for treating an infection
US11224567B2 (en) 2017-06-06 2022-01-18 The Procter And Gamble Company Hair compositions comprising a cationic polymer/silicone mixture providing improved in-use wet feel
US11285171B2 (en) 2018-03-01 2022-03-29 Novan, Inc. Nitric oxide releasing suppositories and methods of use thereof
US11291616B2 (en) 2015-04-23 2022-04-05 The Procter And Gamble Company Delivery of surfactant soluble anti-dandruff agent
US20220117860A1 (en) * 2018-11-30 2022-04-21 3M Innovative Properties Company Topical antimicrobial microemulsions
US11318073B2 (en) 2018-06-29 2022-05-03 The Procter And Gamble Company Low surfactant aerosol antidandruff composition
US11446217B2 (en) 2016-03-03 2022-09-20 The Procter & Gamble Company Aerosol antidandruff composition
CN115463091A (zh) * 2022-10-27 2022-12-13 新基元(北京)医药科技有限公司 一种改善稳定性的米诺环素泡沫剂
US11602493B2 (en) 2017-05-11 2023-03-14 Beiersdorf Ag Gel formulations
US11612551B2 (en) 2016-05-11 2023-03-28 Formulated Solutions, Llc Whipped formulations
US11679073B2 (en) 2017-06-06 2023-06-20 The Procter & Gamble Company Hair compositions providing improved in-use wet feel
US11679065B2 (en) 2020-02-27 2023-06-20 The Procter & Gamble Company Compositions with sulfur having enhanced efficacy and aesthetics
US11771635B2 (en) 2021-05-14 2023-10-03 The Procter & Gamble Company Shampoo composition
US11819474B2 (en) 2020-12-04 2023-11-21 The Procter & Gamble Company Hair care compositions comprising malodor reduction materials
US11975021B1 (en) * 2023-10-09 2024-05-07 James Kojian Topical compositions comprising emulsified povidone iodine solutions and methods of preparation
US11980679B2 (en) 2019-12-06 2024-05-14 The Procter & Gamble Company Sulfate free composition with enhanced deposition of scalp active
US11986543B2 (en) 2021-06-01 2024-05-21 The Procter & Gamble Company Rinse-off compositions with a surfactant system that is substantially free of sulfate-based surfactants
US12226505B2 (en) 2018-10-25 2025-02-18 The Procter & Gamble Company Compositions having enhanced deposition of surfactant-soluble anti-dandruff agents
US12427099B2 (en) 2020-11-23 2025-09-30 The Procter & Gamble Company Personal care composition
US12458575B2 (en) 2021-12-09 2025-11-04 The Procter & Gamble Company Sulfate free personal cleansing composition comprising effective preservation

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080031907A1 (en) * 2002-10-25 2008-02-07 Foamix Ltd. Cosmetic and pharmaceutical foam
EP3360519B1 (fr) 2007-11-21 2020-11-18 Smith & Nephew plc Pansement de plaie
US8808259B2 (en) 2007-11-21 2014-08-19 T.J. Smith & Nephew Limited Suction device and dressing
GB0722820D0 (en) 2007-11-21 2008-01-02 Smith & Nephew Vacuum assisted wound dressing
US11253399B2 (en) 2007-12-06 2022-02-22 Smith & Nephew Plc Wound filling apparatuses and methods
US20130096518A1 (en) 2007-12-06 2013-04-18 Smith & Nephew Plc Wound filling apparatuses and methods
GB0723875D0 (en) 2007-12-06 2008-01-16 Smith & Nephew Wound management
GB0803564D0 (en) 2008-02-27 2008-04-02 Smith & Nephew Fluid collection
GB0902816D0 (en) 2009-02-19 2009-04-08 Smith & Nephew Fluid communication path
GEP20156281B (en) 2009-10-01 2015-05-11 Aptalis Pharmatech Inc Orally administered corticosteroid compositions
US9061095B2 (en) 2010-04-27 2015-06-23 Smith & Nephew Plc Wound dressing and method of use
GB201011173D0 (en) 2010-07-02 2010-08-18 Smith & Nephew Provision of wound filler
GB201020005D0 (en) 2010-11-25 2011-01-12 Smith & Nephew Composition 1-1
CN103403095B (zh) 2010-11-25 2016-12-14 史密夫及内修公开有限公司 组合物i – ii及其产品和用途
JP6068443B2 (ja) * 2011-04-27 2017-01-25 アイエスピー インヴェストメンツ インコーポレイテッドＩｓｐ Ｉｎｖｅｓｔｍｅｎｔｓ Ｉｎｃ． 透明ウェットスプレーおよびジェル
EP2734189B1 (fr) 2011-07-20 2018-08-22 Perrigo Israel Pharmaceuticals Ltd. Compositions de mousse huileuses topiques
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (fr) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Préparations et thérapies de substitution pour hormonothérapie naturelle combinée
US20150159066A1 (en) 2011-11-25 2015-06-11 Smith & Nephew Plc Composition, apparatus, kit and method and uses thereof
US8530409B1 (en) * 2012-06-12 2013-09-10 Dipexium Pharmaceuticals LLC Stable pexiganan formulation
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2968647B1 (fr) 2013-03-15 2022-06-29 Smith & Nephew plc Scellement de pansement et son utilisation
US20160120706A1 (en) 2013-03-15 2016-05-05 Smith & Nephew Plc Wound dressing sealant and use thereof
WO2015034678A2 (fr) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticostéroïde contenant des compositions de comprimés se désintégrant par voie orale pour œsophagite à éonisophiles
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US20160000694A1 (en) * 2014-07-03 2016-01-07 Gr8 Organics, Inc. Composition and system for manufacturing same
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
CN104324039A (zh) * 2014-10-20 2015-02-04 付茜 一种治疗人身体表面脂肪瘤的药剂及使用方法
CN104490871B (zh) * 2014-11-24 2017-01-04 江苏远恒药业有限公司 一种复方醋酸氯己定栓及其制备工艺方法
US12290599B2 (en) 2015-06-19 2025-05-06 Global Health Solutions Llc Oil-based wound care compositions and methods
US12433856B2 (en) 2015-06-19 2025-10-07 Global Health Solutions Llc Petrolatum-based compositions and methods of treatment for onychomycosis
KR102132543B1 (ko) 2015-06-19 2020-07-09 글로벌 헬스 솔루션즈, 엘엘씨 양이온성 살생물제를 포함하는 페트롤라툼-계 조성물
US11110071B2 (en) 2015-06-19 2021-09-07 Global Health Solutions Llc Petrolatum-based PHMB compositions and methods of treatment for onychomycosis
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Composition pharmaceutique d'hormone stéroïde
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
GB201615693D0 (en) 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations
WO2019175290A1 (fr) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis ou compositions dérivées du cannabis pour favoriser l'arrêt de la dépendance chimique
GB201813876D0 (en) 2018-08-24 2018-10-10 Antibiotx As Treatment
US10967197B2 (en) 2018-08-29 2021-04-06 Azulite, Inc. Phototherapy devices and methods for treating truncal acne and scars
BR112021008417A2 (pt) 2018-11-02 2021-09-14 UNION therapeutics A/S Salicilanilidas halogenadas para tratar os sintomas de dermatite
WO2020089467A1 (fr) 2018-11-02 2020-05-07 UNION therapeutics A/S Régime posologique
NL2025641B1 (en) * 2020-04-17 2023-06-22 Veloce Biopharma Llc Methods and compositions for improved treatment of sinus disease
BE1028968B1 (nl) 2020-12-29 2022-08-01 Usocore Nv Harde was zonder BHT
CA3237594A1 (fr) 2021-11-17 2023-05-25 Emmanuel Paul Jos Marie Everaert Produit de soins personnels contenant du petrolatum a base d'huile naturelle
KR20250007558A (ko) 2022-04-22 2025-01-14 보보 랩스 아이엔씨. 피부 장벽 보호 전달 시스템 및 이의 방법

Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2586287A (en) * 1948-12-11 1952-02-19 Colagte Palmolive Peet Company Aluminum sulfamate antiperspirant preparation
US2968628A (en) * 1958-10-17 1961-01-17 Shulton Inc Propellant composition
US3236457A (en) * 1963-08-21 1966-02-22 John R Kennedy Composite spray container assembly
US3298919A (en) * 1962-12-26 1967-01-17 Dow Corning Shaving cream containing polysiloxanes
US3301444A (en) * 1965-08-12 1967-01-31 Oel Inc Aerosol metering valve
US3303970A (en) * 1964-07-14 1967-02-14 Jerome Marrow Device for simultaneously dispensing from plural sources
US3334147A (en) * 1962-02-28 1967-08-01 Economics Lab Defoaming and surface active compositions
US3366494A (en) * 1967-02-15 1968-01-30 Du Pont Pressurized aerosol food emulsions
US3369034A (en) * 1964-04-27 1968-02-13 Eversharp Inc Process for separating saponifiables and unsaponifiables in marine animal oils
US3559890A (en) * 1968-09-03 1971-02-02 William R Brooks Foam dispenser
US3561262A (en) * 1967-10-26 1971-02-09 Magnaflux Corp Water soluble developer
US3563098A (en) * 1968-06-28 1971-02-16 Rex Chainbelt Inc Automatic quick release mechanism
US3787566A (en) * 1969-07-29 1974-01-22 Holliston Labor Inc Disinfecting aerosol compositions
US3865275A (en) * 1973-07-30 1975-02-11 Raymond Lee Organization Inc Apparatus for operating an aerosol can
US3866800A (en) * 1969-02-12 1975-02-18 Alberto Culver Co Non-pressurized package containing self-heating products
US4001391A (en) * 1969-04-18 1977-01-04 Plough, Inc. Means for depositing aerosol sprays in buttery form
US4001442A (en) * 1973-07-18 1977-01-04 Elastin-Werk Aktiengesellschaft Collagen-containing preparations
US4252787A (en) * 1976-12-27 1981-02-24 Cambridge Research And Development Group Anti-fertility composition and method
US4310510A (en) * 1976-12-27 1982-01-12 Sherman Kenneth N Self administrable anti-fertility composition
US4309995A (en) * 1980-01-28 1982-01-12 Sacco Susan M Vaginal irrigation apparatus
US4427670A (en) * 1980-03-27 1984-01-24 Mitsubishi Chemical Industries Limited Skin preparation
US4725609A (en) * 1983-11-21 1988-02-16 Burroughs Wellcome Co. Method of promoting healing
US4798682A (en) * 1985-06-18 1989-01-17 Henkel Kommanditgesellschaft Auf Aktien Oil-in-water emulsions with increased viscosity under shear stress
US4804674A (en) * 1986-03-26 1989-02-14 Euroceltique, S.A. Vaginal pharmaceutical composition
US4806262A (en) * 1985-08-14 1989-02-21 The Procter & Gamble Company Nonlathering cleansing mousse with skin conditioning benefits
US4808388A (en) * 1986-08-20 1989-02-28 Merz + Co. Gmbh & Co. Foamable creams
US4897262A (en) * 1988-03-22 1990-01-30 Playtex Jhirmack, Inc. Non-aerosol hair spray composition
US4902281A (en) * 1988-08-16 1990-02-20 Corus Medical Corporation Fibrinogen dispensing kit
US4981679A (en) * 1983-06-08 1991-01-01 Briggs Joseph H Method and composition for the treatment of burns
US4981845A (en) * 1988-09-09 1991-01-01 Chesebrough Pond's U.S.A. Co., Division Of Conopco, Inc. Cosmetic composition
US4981677A (en) * 1987-09-23 1991-01-01 L'oreal Petrolatum-containing aerosol foam concentrate
US4981367A (en) * 1989-07-28 1991-01-01 Stranco, Inc. Portable mixing apparatus
US4985459A (en) * 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4993496A (en) * 1987-07-06 1991-02-19 Total Walther Feuerschutz Gmbh Quick release valve for sprinkler head
US5082651A (en) * 1989-04-26 1992-01-21 Smith Kline & French Laboratories Limited Pharmaceutical compositions
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US5089252A (en) * 1982-01-15 1992-02-18 L'oreal Cosmetic composition for treating keratin fibres, and process for treating the latter
US5091111A (en) * 1990-09-19 1992-02-25 S. C. Johnson & Son, Inc. Aqueous emulsion and aersol delivery system using same
US5279819A (en) * 1991-03-18 1994-01-18 The Gillette Company Shaving compositions
US5286475A (en) * 1990-11-09 1994-02-15 L'oreal Anhydrous cosmetic composition in the aerosol form forming a foam
US5378730A (en) * 1988-06-09 1995-01-03 Alza Corporation Permeation enhancer comprising ethanol and monoglycerides
US5378451A (en) * 1989-10-19 1995-01-03 Dow B. Hickam, Inc. Topical medicinal pressurized aerosol compositions and method of preparation, method of use and article of manufacture thereof
US5380761A (en) * 1991-04-15 1995-01-10 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Transdermal compositions
US5384308A (en) * 1993-06-14 1995-01-24 Henkin; R. I. Composition and method for enhancing wound healing
US5385943A (en) * 1988-03-30 1995-01-31 Schering Aktiengesellschaft Use of topically applicable preparations for treatment of presbyderma
US5389676A (en) * 1991-03-22 1995-02-14 E. B. Michaels Research Associates, Inc. Viscous surfactant emulsion compositions
US5482965A (en) * 1991-03-19 1996-01-09 Rajadhyaksha; Vithal J. Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers for physiological active agents
US5491245A (en) * 1993-03-26 1996-02-13 Th. Goldschmidt Ag Method for the synthesis of amphoteric surfactants
US5597560A (en) * 1994-05-17 1997-01-28 Laboratorios Cusi, S.A. Diclofenac and tobramycin formulations for ophthalmic and otic topicaluse
US5603940A (en) * 1993-10-08 1997-02-18 L'oreal Oil-in-water emulsion which may be used for obtaining a cream
US5605679A (en) * 1994-06-03 1997-02-25 L'oreal Photoprotective/cosmetic compositions comprising at least one solid organic sunscreen compound and diphenylacrylate solvent therefor
US5716611A (en) * 1996-01-02 1998-02-10 Euro-Celtique, S.A. Emollient antimicrobial formulations containing povidone iodine
US5716621A (en) * 1996-07-03 1998-02-10 Pharmadyn, Inc. Nonocclusive drug delivery device and process for its manufacture
US5719122A (en) * 1992-10-20 1998-02-17 Smithkline Beecham Farmaceutici S.P.A. Pharmaceutical compositions containing a calcitonin
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5856452A (en) * 1996-12-16 1999-01-05 Sembiosys Genetics Inc. Oil bodies and associated proteins as affinity matrices
US5858371A (en) * 1997-02-05 1999-01-12 Panacea Biotech Limited Pharmaceutical composition for the control and treatment of anorectal and colonic diseases
US5866040A (en) * 1990-06-15 1999-02-02 Shiseido Company, Ltd. Complex and emulsified composition
US5865347A (en) * 1997-10-27 1999-02-02 William T. Wilkinson Multi-chamber dispenser for flowable materials
US5869529A (en) * 1994-07-20 1999-02-09 Agis Industries (1983) Ltd. Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus
US5871720A (en) * 1997-11-20 1999-02-16 Colgate-Palmolive Company Cosmetic compositions with DBS and functionalized silicones
US6019967A (en) * 1995-01-26 2000-02-01 Societe L'oreal S.A. Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
US6024942A (en) * 1996-02-09 2000-02-15 The Procter & Gamble Company Photoprotective compositions
US6030630A (en) * 1995-12-29 2000-02-29 Rhodia Chimie Cosmetic compositions for the hair or skin based on sulfone copolyesters with polyorganosiloxane units
US6168576B1 (en) * 1999-05-24 2001-01-02 Irene N. Reynolds Device for dispensing vaginal medication
US6171347B1 (en) * 1996-11-16 2001-01-09 Wella Aktiengesellschaft Compositions, methods and kits for reductively removing color from dyed hair
US6180669B1 (en) * 1996-11-12 2001-01-30 Tamarkin Pharmaceutical Innovation Ltd. Method for treatment of dermatological disorders
US6183762B1 (en) * 1997-05-27 2001-02-06 Sembiosys Genetics Inc. Oil body based personal care products
US6186367B1 (en) * 1999-10-19 2001-02-13 Valley Design Inc. Metered liquid squeeze dispenser
US6187290B1 (en) * 1994-12-06 2001-02-13 Giltech Limited Physiologically acceptable foamable formulation and foam
US6190365B1 (en) * 1999-06-21 2001-02-20 Chun Lim Abbott Vaginal douche applicator and method of vaginal deodorization using the same
US6189810B1 (en) * 1998-10-07 2001-02-20 Sergei Alexeevich Nerushai Method for aerosol spraying liquid perfume products
US6335022B1 (en) * 1998-12-17 2002-01-01 L'oreal Nanoemulsion based on oxyethylenated or non-oxyethylenated sorbitan fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields
US20020002151A1 (en) * 2000-05-23 2002-01-03 Showa Yakuhin Kako Co., Ltd. Minocycline-containing compositions
US20020004063A1 (en) * 1999-09-28 2002-01-10 Jie Zhang Methods and apparatus for drug delivery involving phase changing formulations
US6341717B2 (en) * 2000-04-01 2002-01-29 Megaplast Gmbh & Co. Kg Metering pump dispenser with at least two metering pumps
US20020013481A1 (en) * 1998-02-24 2002-01-31 Uwe Schonrock Use of flavones flavanones and flavonoids for protecting ascorbic acid and/or ascorbyl compounds from oxidation
US20030006193A1 (en) * 1999-09-06 2003-01-09 Katsunori Ikeda Apparatus for purifying nucleic acids and proteins
US6511655B1 (en) * 1999-08-16 2003-01-28 Beiersdorf Ag Cosmetic or dermatological preparations of the oil-in-water type
US6672483B1 (en) * 1999-02-05 2004-01-06 Rexam Sofab Dispenser for chemically unstable products
US6682726B2 (en) * 2001-04-30 2004-01-27 The Gillette Company Self-foaming shaving lotion
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20050002976A1 (en) * 2003-06-19 2005-01-06 The Procter & Gamble Company Polyol-in-silicone emulsions
US6843390B1 (en) * 2003-03-17 2005-01-18 Joe G. Bristor Multiple fluid closed system dispensing device
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
US20060018938A1 (en) * 1997-08-18 2006-01-26 Stephanie Neubourg Foam skin cream, use of the foam skin protection cream and a process of its preparation
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
USRE38964E1 (en) * 1995-01-09 2006-01-31 Becton Dickinson And Company One hand needle release system
US20070009607A1 (en) * 2005-07-11 2007-01-11 George Jones Antibacterial/anti-infalmmatory composition and method
US20070020213A1 (en) * 2002-10-25 2007-01-25 Foamix Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20070020304A1 (en) * 2002-10-25 2007-01-25 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US20070017696A1 (en) * 2005-07-22 2007-01-25 Hon Hai Precision Industry Co., Ltd. Multi-layer printed circuit board
US20080008397A1 (en) * 2006-07-04 2008-01-10 Pavel Kisilev Feature-aware image defect removal
US20080015263A1 (en) * 2002-02-27 2008-01-17 Bolotin Elijah M Compositions for delivery of therapeutics and other materials
US20080015271A1 (en) * 2006-07-14 2008-01-17 Stiefel Research Austrialia Pty Ltd Fatty acid pharmaceutical foam
US7645803B2 (en) * 2005-05-09 2010-01-12 Foamix Ltd. Saccharide foamable compositions
US20110002969A1 (en) * 2008-02-29 2011-01-06 Lipotec, S.A. Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors
US20110002857A1 (en) * 2003-08-04 2011-01-06 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam

Family Cites Families (1055)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1159250A (en) 1914-05-01 1915-11-02 Frank Moulton Vaginal irrigator.
US1666684A (en) 1926-01-15 1928-04-17 Carstens Mfg Co H Vaginal douche
US1924972A (en) 1929-04-15 1933-08-29 Carl J Beckert Stabilized egg product
US2085733A (en) 1935-07-15 1937-07-06 John C Bird Shaving cream
US2390921A (en) 1943-03-23 1945-12-11 Ethel Hudson Clark Applicator for facial creams
US2524590A (en) 1946-04-22 1950-10-03 Carsten F Boe Emulsion containing a liquefied propellant gas under pressure and method of spraying same
US2617754A (en) 1949-08-29 1952-11-11 Procter & Gamble Cosmetic cream
DE933486C (de) 1949-10-02 1955-09-29 Ibm Deutschland Elektromechanische Recheneinrichtung mit Zaehlwert-Einstellvorrichtung
US3062715A (en) 1953-11-18 1962-11-06 George S Pfaus Vaginal tablet
US2767712A (en) 1954-03-01 1956-10-23 Neil S Waterman Medicinal applicator
GB808104A (en) 1955-01-04 1959-01-28 Udylite Res Corp Electrodeposition of copper from aqueous alkaline cyanide solutions
GB808105A (en) 1956-06-15 1959-01-28 Ici Ltd New pharmaceutical compositions
US3092555A (en) 1958-04-21 1963-06-04 Roy H Horn Relatively collapsible aerosol foam compositions
US3144386A (en) 1958-05-09 1964-08-11 Merck & Co Inc Mastitis aerosol foam
US3178352A (en) 1959-02-27 1965-04-13 Erickson Roy Shaving method and composition therefor
US3141821A (en) 1959-03-17 1964-07-21 Lehn & Fink Products Corp Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis
US3004894A (en) 1959-04-07 1961-10-17 Upjohn Co Therapeutic composition comprising tetracycline and a dioxolane
GB922930A (en) 1959-09-21 1963-04-03 Sunnen Joseph Spermicidal composition and method of making same
US3142420A (en) 1959-11-09 1964-07-28 Neotechnic Eng Ltd Metering dispenser for aerosol with fluid pressure operated piston
US3092255A (en) 1960-02-05 1963-06-04 Robert F Hohman Sorting apparatus
US3067784A (en) 1960-04-14 1962-12-11 Esta Medical Lab Inc Adapter connecting aerosol container valve stem to dispenser for filling said dispenser
NL270627A (fr) 1960-10-26
US3154075A (en) 1960-11-02 1964-10-27 Norwich Pharma Co Vaginal applicator
GB998490A (en) 1961-06-03 1965-07-14 Albert Fritz Albach A foam projector
DE1926796U (de) 1961-10-12 1965-11-11 Heidolph Elektro K G Geblaese.
US3261695A (en) 1962-12-24 1966-07-19 Gen Foods Corp Process for preparing dehydrated foods
US3330730A (en) 1962-08-03 1967-07-11 Colgate Palmolive Co Pressurized emulsion quick breaking foam compositions
US3252859A (en) 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
US3244589A (en) 1962-10-26 1966-04-05 Sunnen Alkyl phenoxy polyethoxy ether spermicidal aerosol
US3383280A (en) 1963-01-09 1968-05-14 Miles Lab Dermatological abradant stick-type applicator
FR1355607A (fr) 1963-01-22 1964-03-20 Perfectionnements aux sondes canules et leurs applications
US3149543A (en) 1963-03-04 1964-09-22 Ingersoll Rand Co Non-lubricated piston
GB1026831A (en) 1963-05-31 1966-04-20 Mediline Ag Preparations for use in feminine hygiene
US3824303A (en) 1963-07-24 1974-07-16 Yardley Of London Inc Collapsible foam pre-electric shave lotion containing diester lubricants
GB1081949A (en) 1963-08-12 1967-09-06 Avon Prod Inc Improvements in cosmetic mask
US3333333A (en) 1963-08-14 1967-08-01 Rca Corp Method of making magnetic material with pattern of embedded non-magnetic material
US3263867A (en) 1963-12-26 1966-08-02 Valve Corp Of America Metering button-type aerosol actuator
US3395214A (en) 1964-01-09 1968-07-30 Scholl Mfg Co Inc Antiperspirant composition providing a readily collapsible sprayable foam
US3278093A (en) 1964-01-13 1966-10-11 Valve Corp Of America Metering and non-metering aerosol actuator button
US3395215A (en) 1964-10-15 1968-07-30 Colgate Palmolive Co Pressurized lotion composition
US3384541A (en) 1964-10-28 1968-05-21 William G. Clark Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants
US3263869A (en) 1964-11-03 1966-08-02 Calmar Inc Liquid dispenser with overcap
US3342845A (en) 1964-11-05 1967-09-19 Upjohn Co Terphenyl triisocyanates
US3419658A (en) 1965-01-25 1968-12-31 Du Pont Nonaqueous aerosol foams containing mineral oil
US3346451A (en) 1965-01-27 1967-10-10 S E Massengill Company Concentrated liquid lactic acid douche preparation containing aromatics
US3456052A (en) 1965-09-28 1969-07-15 Garrett Lab Inc Aerosol composition containing butoxymonoether of a polyoxyalkylene glycol
GB1121358A (en) 1965-10-21 1968-07-24 Bristol Myers Co Aerosol manufacture
US3849569A (en) 1965-12-02 1974-11-19 Glaxo Lab Ltd Composition containing procaine penicillin
BE692228A (fr) 1966-01-10 1967-07-05
US3401849A (en) 1966-05-24 1968-09-17 Robert L. Weber Low force metering valve
US3886084A (en) 1966-09-29 1975-05-27 Champion Int Corp Microencapsulation system
US3377004A (en) 1966-10-03 1968-04-09 Gen Mills Inc Metered dispensing container
GB1201918A (en) 1966-12-21 1970-08-12 Bespak Industries Ltd Improvements in or relating to valves for pressurised dispensers
US3527559A (en) 1967-01-05 1970-09-08 Standard Pharmacal Corp Dense aqueous aerosol foam depilatory compositions containing a mixture of alkaline metal and alkali metal thioglycolates and a fatty alcohol-alkylene oxide wax emulsifying agent
US3540448A (en) 1968-01-17 1970-11-17 Joseph Sunnen Rechargeable applicator for dispensing substances in a foam condition
DE1926796A1 (de) 1968-05-27 1970-03-19 Dudiuyt Jean Paul Verfahren zum Herstellen eines Gemisches aus einem Wirkstoff mit einer Traegerfluessigkeit zur Austreibung aus einem dichten Behaelter sowie Sonnenschutzmittel
US3878118A (en) 1968-09-06 1975-04-15 Wilkinson Sword Ltd Self-heating chemical compositions
US3667461A (en) 1968-11-05 1972-06-06 Paul A Zamarra Disposable syringe
CA975500A (en) 1969-02-06 1975-09-30 Joseph G. Spitzer Structures such as applicator pads for cleaning and other purposes, propellant compositions for forming the same, and process
US3966090A (en) 1969-02-17 1976-06-29 Dart Industries Inc. Package for dispensing an antiseptic composition
US3819524A (en) 1969-06-17 1974-06-25 Colgate Palmolive Co Cosmetic composition for thermal dispensing
US3577518A (en) 1969-07-18 1971-05-04 Nat Patent Dev Corp Hydrophilic hairspray and hair setting preparations
BE759520A (fr) 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
GB1351761A (en) 1971-02-04 1974-05-01 Wilkinson Sword Ltd Substituted p-menthane carboxamides and compositions containing them
GB1353381A (en) 1971-02-04 1974-05-15 Wilkinson Sword Ltd Substituted p-menthanes and compositions containing them
GB1351762A (en) 1971-02-14 1974-05-01 Wilkinson Sword Ltd Tobacco and tobacco-containing manufactures
CA958338A (en) 1971-03-08 1974-11-26 Chung T. Shin Antiperspirant powder aerosol compositions containing aluminum chloride and water soluble aluminum compounds and methods of preparation
US3770648A (en) 1971-07-12 1973-11-06 Bristol Myers Co Anhydrous aerosol foam
US3912667A (en) 1971-09-13 1975-10-14 Spitzer Joseph G Structures such as applicator pads for cleaning and other purposes, propellant compositions for forming the same and process
BE788788A (fr) 1971-09-13 1973-03-13 Treuhandvereinigung Ag Produit pour conserver, favoriser et retablir la chevelure et procede de fabrication de ce produit
SE358308B (fr) 1971-11-26 1973-07-30 Pharmacia Ab
US3997467A (en) 1971-11-26 1976-12-14 Pharmacia Aktiebolag Foam forming composition
CH569128B5 (fr) 1971-12-30 1975-11-14 Ciba Geigy Ag
US3963833A (en) 1972-06-02 1976-06-15 Colgate-Palmolive Company Antiperspirant composition and method containing a dihydro-benzofuran and an astringent metal salt
US3841525A (en) 1972-06-14 1974-10-15 N Siegel Aerosol spray device with cam activator
US3849580A (en) 1972-09-05 1974-11-19 American Home Prod Aerosol dispensing system for anhydrous edible fat compositions
US3751562A (en) 1972-09-22 1973-08-07 Princeton Biomedix Medicated gelled oils
US3970584A (en) 1973-02-14 1976-07-20 S. C. Johnson & Son, Inc. Aerosol package containing a foam-forming emulsion and propellent system
US4439416A (en) 1973-03-23 1984-03-27 Colgate-Palmolive Company Self-heating shaving composition
GB1423179A (en) 1973-05-16 1976-01-28 Wilkinson Sword Ltd Pressurised shaving foam dispensers
US4110426A (en) 1973-07-24 1978-08-29 Colgate-Palmolive Company Method of treating skin and hair with a self-heated cosmetic
US3929985A (en) 1974-01-18 1975-12-30 Richardson Merrell Inc Anhydrous candicidin foam compositions
DE2501548A1 (de) 1974-01-25 1975-07-31 Procter & Gamble Mundbehandlungsmittel
GB1457671A (en) 1974-01-31 1976-12-08 Wilkinson Sword Ltd Flavour
US3923970A (en) 1974-03-29 1975-12-02 Carter Wallace Stable aerosol shaving foams containing mineral oil
US3962150A (en) 1974-04-10 1976-06-08 Richardson-Merrell Inc. Foam producing cleansing compositions
US3953591A (en) 1974-04-29 1976-04-27 The Procter & Gamble Company Fatty acid, polysiloxane and water-soluble polymer containing skin conditioning emulsion
US3966632A (en) 1974-06-06 1976-06-29 G. D. Searle & Co. Vegetable oil emulsion
US4145411A (en) 1974-09-05 1979-03-20 Colgate-Palmolive Company Pressurized foaming shaving composition
JPS5729213B2 (fr) 1974-11-12 1982-06-21
US4052513A (en) 1974-12-13 1977-10-04 Plough, Inc. Stable topical anesthetic compositions
US3952916A (en) 1975-01-06 1976-04-27 Warner-Lambert Company Automatic dispenser for periodically actuating an aerosol container
US3970219A (en) 1975-03-03 1976-07-20 Spitzer Joseph G Aerosol containers for foaming and delivering aerosols and process
US4019657A (en) 1975-03-03 1977-04-26 Spitzer Joseph G Aerosol containers for foaming and delivering aerosols
US4018396A (en) 1975-05-05 1977-04-19 Bechtel International Corporation Embedded housing for ore crusher
US3993224A (en) 1975-09-08 1976-11-23 Aerosol Investments, Ltd. Spout for two-component resin dispenser
DE2608226A1 (de) 1976-02-28 1977-09-08 Haarmann & Reimer Gmbh Mittel mit physiologischer kuehlwirkung
IL49491A (en) 1976-04-29 1979-09-30 Rosenberg Peretz Quickly-attachable connector for plastic pipes
US4102995A (en) 1976-05-13 1978-07-25 Westwood Pharmaceuticals Inc. Tar gel formulation
US4124149A (en) 1976-07-19 1978-11-07 Spitzer Joseph G Aerosol container with position-sensitive shut-off valve
CA1089368A (fr) 1976-08-02 1980-11-11 Daniel C. Geary Preparation deodorante en baton, renfermant un alcool gras polyethoxylate
IL52045A (en) 1976-08-25 1979-12-30 Mundipharma Ag Sprayable germicidal foam compositions
US4083974A (en) 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
US4386104A (en) 1977-04-19 1983-05-31 Nazzaro Porro Marcella Process for the treatment of acne
IT1114950B (it) 1977-12-30 1986-02-03 Porro Marcella Composizioni per il trattamento e la terapia di acne
GB2004746B (en) 1977-10-03 1982-03-10 Scherico Ltd Stable hopical anaesthetic compositions
SE7713618L (sv) 1977-12-01 1979-06-02 Astra Laekemedel Ab Lokalanestetisk blandning
US4160827A (en) 1978-02-06 1979-07-10 The Upjohn Company Metronidazole phosphate and salts
US4229432A (en) 1978-04-19 1980-10-21 Bristol-Myers Company Antiperspirant stick composition
US4603812A (en) 1978-06-27 1986-08-05 The Dow Chemical Company Foam-generating pump sprayer
US4178373A (en) 1978-08-21 1979-12-11 William H. Rorer, Inc. Coal tar gel composition
US4214000A (en) 1978-10-30 1980-07-22 Johnson & Johnson Zinc salt of all-trans-retinoic acid for the treatment of acne
JPS5569682A (en) 1978-11-20 1980-05-26 Toyo Aerosol Kogyo Kk Foam shrinkable composition
US4213979A (en) 1978-12-18 1980-07-22 Plough, Inc. Stable sprayable hydrocortisone product
US4954487A (en) 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4439441A (en) 1979-01-11 1984-03-27 Syntex (U.S.A.) Inc. Contraceptive compositions and methods employing 1-substituted imidazole derivatives
US4226344A (en) 1979-02-06 1980-10-07 Booth, Inc. Constant flow valve actuator
CH639913A5 (en) 1979-03-16 1983-12-15 Aerosol Service Ag Container for receiving and delivering a liquid substance
US4230701A (en) 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4335120A (en) 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4278206A (en) 1979-04-13 1981-07-14 Ae Development Corporation Non-pressurized dispensing system
US4241048A (en) 1979-05-01 1980-12-23 Bristol-Myers Company Suspension composition of benzocaine
JPS55153712A (en) 1979-05-18 1980-11-29 Kao Corp Insulin pharmaceutical preparation and its production
US4268499A (en) 1979-06-07 1981-05-19 Dow Corning Corporation Antiperspirant emulsion compositions
US4241149A (en) 1979-07-20 1980-12-23 Temple University Canal clathrate complex solid electrolyte cell
DE2931469A1 (de) 1979-08-02 1981-02-26 Bayer Ag Oberflaechenversiegelte formkoerper aus zelligen polyurethan-elastomeren und verfahren zu deren herstellung
JPS5854931B2 (ja) 1979-09-04 1983-12-07 トヨタ自動車株式会社 ブロ−チ盤
US4271149A (en) 1979-09-21 1981-06-02 West Agro-Chemical, Inc. Germicidal iodine compositions with enhanced iodine stability
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
EP0032309A3 (fr) 1980-01-10 1981-08-05 Imperial Chemical Industries Plc Fabrication d'un constituant catalytique, catalyseur et son utilisation
SE8004580L (sv) 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
US4338211A (en) 1980-06-30 1982-07-06 The Procter & Gamble Company Liquid surfactant skin cleanser with lather boosters
US4508705A (en) 1980-07-02 1985-04-02 Lever Brothers Company Skin treatment composition
US4323582A (en) 1980-07-21 1982-04-06 Siegel Norman H Method of treating animals and humans for internal and external parasites
JPS5914282B2 (ja) 1980-07-31 1984-04-04 株式会社神戸製鋼所 拡管抽伸方法
US4329990A (en) 1980-08-07 1982-05-18 Sneider Vincent R Expanding swab applicator
US4325939A (en) 1980-09-22 1982-04-20 Richardson-Vicks Inc. Zinc derivatives and their use in dental compositions
US4305936A (en) 1980-10-09 1981-12-15 Dermik Laboratories Topical corticosteroid formulations
US4292250A (en) 1980-11-17 1981-09-29 Wisconsin Alumni Research Foundation Vitamin D derivatives
EP0052404B1 (fr) 1980-11-19 1987-05-27 THE PROCTER & GAMBLE COMPANY Composition pharmaceutique topique qui ne teint pas en jaune
JPS57501845A (fr) 1980-11-27 1982-10-14
DE3147726A1 (de) 1980-12-03 1982-06-24 Leo Pharmaceutical Products Ltd. A/S (Loevens kemiske Fabrik Produktionsaktieselskab), 2750 Ballerup Antibiotische komplexe, verfahren zu ihrer herstellung und pharmazeutische mittel, die diese verbindungen enthalten
US4352808A (en) 1980-12-12 1982-10-05 Schering Corporation 3-Aralkyloxy-2,3-dihydro-2-(imidazolylmethyl)benzo(b)thiophenes and related derivatives, their use as antimicrobials and pharmaceutical formulations useful therefore
US4323694A (en) 1981-04-13 1982-04-06 Finetex, Inc. Benzoic acid esters
US4522948A (en) 1981-04-24 1985-06-11 Syntex (U.S.A.) Inc. Spermicidal substituted 1-(cycloalkyl)alkylimidazoles
US4393066A (en) 1981-06-05 1983-07-12 Garrett David M Method for treatment of herpetic lesions
US4607101A (en) 1981-08-27 1986-08-19 Jaye-Boern Laboratories, Inc. Method of treating acne vulgaris with a composition containing carbamide peroxide
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US4469674A (en) 1981-09-03 1984-09-04 Richardson-Vicks Inc. Stable oral compositions containing zinc and fluoride compounds
US4440320A (en) 1981-11-30 1984-04-03 Wernicke Steven A Foam dispensing apparatus
LU83949A1 (fr) 1982-02-16 1983-09-02 Oreal Composition destinee au traitement des matieres keratiniques contenant au moins un polymere cationique et au moins un latex anionique
US4529605A (en) 1983-01-12 1985-07-16 Una E. Lynch Bathing oil composition
US4661340A (en) 1983-06-06 1987-04-28 Interkemia Vegyipari Gazdasagi Tarsasag Quail egg based stabilized foam compositions for cosmetic purposes
JPS601113A (ja) 1983-06-20 1985-01-07 Kao Corp 養毛・育毛料
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
GB8402748D0 (en) 1984-02-02 1984-03-07 Dunlop Ltd Intravaginal device
US4912124A (en) 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
NZ207341A (en) 1984-03-01 1988-02-29 Harvey Alex Ind Ltd Device containing chemical impregnants for insertion into a body cavity of an animal
US4628063A (en) 1984-03-08 1986-12-09 Dana P. Brigham Antiviral pharmaceutical preparations and methods for their use
US4574052A (en) 1984-05-31 1986-03-04 Richardson-Vicks Inc. Crackling aerosol foam
GB8416638D0 (en) 1984-06-29 1984-08-01 Beecham Group Plc Topical treatment and composition
EP0172139B1 (fr) 1984-08-06 1988-09-14 Ciba-Geigy Ag Procédé d'encollage de papier avec des agents d'encollage anioniques hydrophobes et des agents de rétention cationiques
US4595526A (en) 1984-09-28 1986-06-17 Colgate-Palmolive Company High foaming nonionic surfacant based liquid detergent
SE8404895L (sv) 1984-10-01 1986-03-17 Torkel Ingemar Fischer Medel for en overkenslighetstest
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
CA1261276A (fr) 1984-11-09 1989-09-26 Mark B. Grote Shampooings
US4701320A (en) 1984-11-29 1987-10-20 Lederle (Japan), Ltd. Composition stably containing minocycline for treating periodontal diseases
US4627973A (en) 1984-12-14 1986-12-09 Charles Of The Ritz Group Ltd. Skin mousse
AU5078885A (en) 1984-12-20 1986-06-26 Warner-Lambert Company Non-irritant detergent
US4673569A (en) 1985-02-12 1987-06-16 Faberge Incorporated Mousse hair composition
EP0194097B1 (fr) 1985-03-01 1990-04-25 The Procter & Gamble Company Mousse douce pour nettoyage
US5002680A (en) 1985-03-01 1991-03-26 The Procter & Gamble Company Mild skin cleansing aerosol mousse with skin feel and moisturization benefits
WO1986005389A1 (fr) 1985-03-18 1986-09-25 Product Resources International, Inc. Compositions moussantes exothermiques stables
US4639367A (en) 1985-03-18 1987-01-27 Product Resources International, Inc. Aerosol foam
US4752465A (en) 1985-09-20 1988-06-21 Product Resources International, Inc. Aerosol foam
US5094853A (en) 1985-04-26 1992-03-10 S. C. Johnson & Son, Inc. Method of preparing a water-soluble stable arthropodicidally-active foam matrix
US4965063A (en) 1985-05-24 1990-10-23 Irene Casey Cleaner and disinfectant with dye
US4672078A (en) 1985-07-03 1987-06-09 Schering-Plough Corporation Urea stabilized with a lactone in various pharmaceutical and cosmetic preparations
GB8519426D0 (en) 1985-08-01 1985-09-04 Ici Plc Composition for personal care products
EP0213827A3 (fr) 1985-08-14 1988-04-06 The Procter & Gamble Company Préparation nettoyante non-moussante à effet conditionnant pour la peau
AU6175586A (en) 1985-09-11 1987-03-12 Chesebrough-Pond's Inc. Petroleum jelly, mild detergent anhydrous base compositions
FR2591331A1 (fr) 1985-12-10 1987-06-12 Drevet Jean Baptiste Dispositif de distribution de fractions dosees d'un produit contenu dans un recipient pressurise
US4837378A (en) 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
JPS62241701A (ja) 1986-04-11 1987-10-22 Maeda Kogyo Kk 自転車用ハブのクイツクレリ−ズ装置
CA1291036C (fr) 1986-04-23 1991-10-22 Edwin I. Stoltz Administration de medicaments par voie nasale
DE3614515A1 (de) 1986-04-29 1987-11-05 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer medien
FR2598392B1 (fr) 1986-05-09 1988-08-26 Oreal Conditionnement pour deux recipients pressurises
PH25150A (en) 1986-06-05 1991-03-13 Ciba Geigy Ag Novel pharmaceutical preparation for topical application
US4770634A (en) 1986-06-11 1988-09-13 Pellico Michael A Method for treating teeth with foamable fluoride compositions
JPS62299423A (ja) 1986-06-18 1987-12-26 Mazda Motor Corp 車両用空気調和装置
US4837019A (en) 1986-08-11 1989-06-06 Charles Of The Ritz Group Ltd. Skin treatment composition and method for treating burned skin
US4906453A (en) 1986-08-12 1990-03-06 Jumpeer Nails, Inc. Mousse product
WO1988001502A1 (fr) 1986-09-05 1988-03-10 The Upjohn Company Composition de minoxydile non aqueuse de dissolution du sebum
WO1988001863A1 (fr) 1986-09-12 1988-03-24 The Upjohn Company Mousses pour l'apport de minoxidil
LU86585A1 (fr) 1986-09-15 1988-04-05 Oreal Composition sous forme de mousse aerosol a base d'un polymere derive de cellulose quaternise et de polymere anionique
JPH0778019B2 (ja) 1986-11-08 1995-08-23 久光製薬株式会社 泡状エアゾ−ル消炎鎮痛製剤
EP0270316A3 (fr) 1986-12-04 1989-12-06 Pfizer Inc. Compositions topiques contenant des imidazoles 1-substitués et des agents non-steroides anti-inflammatoires pour le traitement de l'acné
US4822613A (en) 1986-12-15 1989-04-18 S. C. Johnson & Son, Inc. Water-soluble foamable insecticidally-active compositions
US4822614A (en) 1986-12-19 1989-04-18 S. C. Johnson & Son, Inc. Bioactive film-forming composition for control of crawling insects and the like
US5389677B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US4863900A (en) 1987-01-15 1989-09-05 The Research Foundation Of State University Of New York Method for reducing viral transmission with poly-L-histidine
DE3704907A1 (de) 1987-02-17 1988-08-25 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
US4828837A (en) 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
AU1388388A (en) 1987-04-01 1988-10-06 Dak-Laboratoriet A/S Benzoic acid derivatives and use thereof
LU86839A1 (fr) 1987-04-10 1988-12-13 Oreal Composition cosmetique detergente et moussante,retardant le regraissage des cheveux
WO1988008316A1 (fr) 1987-04-21 1988-11-03 Chattan Nominees Pty. Ltd. Douche vaginale
FR2615173B1 (fr) 1987-05-13 1989-08-18 Valois Valve doseuse pour liquide charge d'un propulseur liquide ou gaz liquefie, utilisable en position inversee
US4867967A (en) 1987-06-04 1989-09-19 Crutcher Wilbert L Method for the treatment of pseudofolliculitis barbae
US4780309A (en) 1987-06-16 1988-10-25 Warner-Lambert Company Edible aerosol foam compositions and method of preparing same
US4849117A (en) 1987-06-17 1989-07-18 Sanitek Products, Inc. Concentrated composition for forming an aqueous foam
US4885282A (en) 1987-07-02 1989-12-05 Thornfeldt Carl R Treatment of hyperhidrosis, ichthyosis and wrinkling
US5196405A (en) 1987-07-08 1993-03-23 Norman H. Oskman Compositions and methods of treating hemorrhoids and wounds
US4847068A (en) 1987-08-06 1989-07-11 Johnson & Johnson Consumer Products, Inc. Skin care compositions
US4913893A (en) 1987-08-28 1990-04-03 Clairol Incorporated Aerosol hair setting composition containing an alginate
CA1273576A (fr) 1987-09-16 1990-09-04 Patrick A. Beauchamp Traitement topique des affections de la peau
US4784842A (en) 1987-09-25 1988-11-15 Jean London Therapeutic composition for treatment of cuts, burns and abrasions
US4772427A (en) 1987-12-01 1988-09-20 Colgate-Palmolive Co. Post-foaming gel shower product
US5143717A (en) 1987-12-30 1992-09-01 Code Blue Medical Corporation Burn foam and delivery system
ATE74003T1 (de) 1988-01-14 1992-04-15 Akzo Nv Waessriges pharmazeutisches praeparat.
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
JP2643217B2 (ja) 1988-01-22 1997-08-20 エーザイ株式会社 脂溶性物質水性液
LU87187A1 (fr) 1988-03-31 1989-10-26 Oreal Association de derives de pyrimidine et de derives d'acide salicylique pour induire et stimuler la croissance des cheveux et diminuer leur chute
US4873078A (en) 1988-04-22 1989-10-10 Plough, Inc. High-gloss, high-shine lipstick
GB8811409D0 (en) 1988-05-13 1988-06-15 Unilever Plc Cosmetic composition
US4827378A (en) 1988-06-15 1989-05-02 Rockwell International Corporation Jack coaxial connector EMI shielding apparatus
US5217707A (en) 1988-06-16 1993-06-08 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Pharmaceutical composition and process for the preparation thereof
EP0349875A3 (fr) 1988-07-07 1991-09-25 General Electric Company Compositions d'élastomères pouvant être peintes
US4950420A (en) 1988-08-31 1990-08-21 Nalco Chemical Company Antifoam/defoamer composition
US4855294A (en) 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
JPH02191223A (ja) 1988-10-04 1990-07-27 Otsuka Pharmaceut Co Ltd 鉄補給用発泡製剤
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5186857A (en) 1988-11-14 1993-02-16 Imaginative Research Associates, Inc. Self-foaming oil compositions and process for making and using same
GB8828013D0 (en) 1988-12-01 1989-01-05 Unilever Plc Topical composition
US4970067A (en) 1988-12-12 1990-11-13 Helene Curtis, Inc. Method and composition to condition hair and impart semi-permanent hair set retention properties
US5262407A (en) 1988-12-16 1993-11-16 L'oreal Use of salicylic derivatives for the treatment of skin aging
FR2640942A1 (en) 1988-12-23 1990-06-29 Suchard Sa Jacobs Container of the aerosol type for delivering, in the form of a foam, metered quantities of product, particularly of food product
DE68913693T3 (de) 1988-12-27 2004-01-22 Osaka Shipbuilding Co., Ltd. Aerosol-Zusammensetzung.
JP2960445B2 (ja) 1988-12-28 1999-10-06 株式会社大阪造船所 エアゾール用組成物
FR2641185B1 (fr) 1988-12-29 1991-04-05 Oreal Composition de rasage pour la peau a base de polyorganosiloxanes a fonction acyloxyalkyle et procede de mise en oeuvre
JP2741230B2 (ja) 1989-01-11 1998-04-15 株式会社コーセー 泡状無水化粧料
LU87449A1 (fr) 1989-02-09 1990-09-19 Oreal Procede de fabrication de mousses utilisables dans les domaines cosmetique et pharmaceutique et mousses obtenues par ce procede
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5019375A (en) 1989-03-14 1991-05-28 The Procter & Gamble Company Low residue antiperspirant creams
DE69030698T2 (de) 1989-03-17 1997-10-02 Taisho Pharmaceutical Co., Ltd., Tokio/Tokyo Aerosolzusammensetzung zur äusserlichen verwendung
US5221696A (en) 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
DE69020211T2 (de) 1989-04-05 1995-11-02 Kao Corp Kosmetische Doppelemulsionszusammensetzung.
US5204093A (en) 1989-04-06 1993-04-20 Victor Steven A Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same
US5071648A (en) 1989-04-06 1991-12-10 Merocel Corporation Polymeric broad-spectrum antimicrobial materials
US5618798A (en) 1989-04-20 1997-04-08 Bar-Shalom; Daniel Use of sucralfate to treat baldness
US5221534A (en) 1989-04-26 1993-06-22 Pennzoil Products Company Health and beauty aid compositions
US4874794A (en) 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
US5322683A (en) 1989-05-01 1994-06-21 Leonard Mackles Anhydrous aerosol foam
US5002540A (en) 1989-05-22 1991-03-26 Warren Kirschbaum Intravaginal device and method for delivering a medicament
GB8911853D0 (en) 1989-05-23 1989-07-12 Ici Plc Co2 blown integral skin foams
CA1337279C (fr) 1989-06-06 1995-10-10 Robert J. Borgman Traitement intravaginal d'infections vaginales au moyen de compositions a base de metronidazole tamponne
US5208031A (en) 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
JPH0310636A (ja) 1989-06-09 1991-01-18 Matsushita Electric Works Ltd 床下野菜保存庫
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
MX21452A (es) 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
US5560859A (en) 1989-07-26 1996-10-01 Pfizer Inc. Post foaming gel shaving composition
US5352437A (en) 1989-07-28 1994-10-04 Hisamitsu Pharmaceutical Co., Inc. Foamable aerosol preparation
JPH0383914A (ja) 1989-08-18 1991-04-09 W R Grace & Co ドラッグキャリアー
US5219877A (en) 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US5508033A (en) 1989-12-06 1996-04-16 Societe D'engrais Composes Mineraux Et Amendments Utilization of algae extract for the preparation of pharmaceutical, cosmetic, food or agricultural compositions
US5295984A (en) 1989-12-07 1994-03-22 Ultrafem, Inc. Vaginal discharge collection device and intravaginal drug delivery system
ES2217249T3 (es) 1989-12-07 2004-11-01 Instead, Inc. Metodo para recoger el flujo vaginal.
AU6974191A (en) 1989-12-20 1991-07-18 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
US4966779A (en) 1989-12-21 1990-10-30 Basf Corporation Stable, water miscible emulsion comprising a fat-soluble vitamin
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US4963351A (en) 1989-12-26 1990-10-16 Bhn Associates Shaving aid
US5100917A (en) 1989-12-29 1992-03-31 Merrell Dow Pharmaceuticals Inc. Novel a-nor-steroid-3-carboxylic acid derivatives
US5104645A (en) 1990-02-02 1992-04-14 The Proctor & Gamble Company Antidandruff shampoo compositions
SE9000485D0 (sv) 1990-02-09 1990-02-09 Pharmacia Ab Foamable composition for pharmaceutical use, use thereof and method of treatment
US5164367A (en) 1990-03-26 1992-11-17 Procyte Corporation Method of using copper(ii) containing compounds to accelerate wound healing
US5130121A (en) 1990-04-17 1992-07-14 Isp Investments Inc. Skin care compositions containing discrete microdroplets of an oil in water stabilized by in situ polymerization of water-soluble vinyl monomer
US5007556A (en) 1990-04-18 1991-04-16 Block Drug Company, Inc. Metering dispenser
US5156765A (en) 1990-05-15 1992-10-20 Fox Valley Systems, Inc. Aerosol foam marking compositions
US5112359A (en) 1990-06-04 1992-05-12 Clairol, Inc. Hair colorants
JPH0451958A (ja) 1990-06-18 1992-02-20 Mitsubishi Materials Corp 循環式トイレ汚物処理剤
US5034220A (en) 1990-06-20 1991-07-23 Gaf Chemicals Corporation Non-aerosol shaving gel
US5336692A (en) 1990-06-28 1994-08-09 Medicis Pharmaceutical Corporation Ointment base and method of use
IT1243379B (it) 1990-07-27 1994-06-10 Giuliani Spa Composizione farmaceutica adatta alla somministrazione rettale di principi attivi che esplicano un'azione di medicazione a livello del colon prevalentemente di tipo topico
US5108556A (en) 1990-09-14 1992-04-28 Minnesota Mining And Manufacturing Company Process for preparing tertiary perfluoroamines
US5114718A (en) 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
GB9021546D0 (en) 1990-10-04 1990-11-21 Beecham Group Plc Novel composition
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
DE9016291U1 (de) 1990-11-30 1991-03-28 Kali-Chemie Pharma Gmbh, 3000 Hannover Topisch applizierbare Diclofenac-Zubereitungen
WO1992011839A1 (fr) 1991-01-08 1992-07-23 Leonard Mackles Mousse d'aerosol anhydre
WO1992012717A2 (fr) 1991-01-15 1992-08-06 Composition contenant une tetracycline et utilisation pour inhiber l'angiogenese
US5227163A (en) 1991-01-18 1993-07-13 Clilco, Ltd. Lice-repellant compositions
DE4102506C2 (de) 1991-01-29 1999-11-25 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
WO1992013602A1 (fr) 1991-02-05 1992-08-20 Buil Juergen Agent extincteur et protecteur contre le feu
US5650554A (en) 1991-02-22 1997-07-22 Sembiosys Genetics Inc. Oil-body proteins as carriers of high-value peptides in plants
US5948682A (en) 1991-02-22 1999-09-07 Sembiosys Genetics Inc. Preparation of heterologous proteins on oil bodies
US6753167B2 (en) 1991-02-22 2004-06-22 Sembiosys Genetics Inc. Preparation of heterologous proteins on oil bodies
US5648380A (en) 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5658956A (en) 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5663208A (en) 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
IT1247138B (it) 1991-03-06 1994-12-12 Dompe Farmaceutici Spa Composizione farmaceutica idrofila contenente ketoprofene sale di lisina per uso topico.
JPH04282311A (ja) 1991-03-08 1992-10-07 Koike Kagaku Kk エアゾール型発泡性傷口消毒剤
AU658608B2 (en) 1991-03-25 1995-04-27 Astellas Pharma Europe B.V. Topical preparation containing a suspension of solid lipid particles
US5167950A (en) 1991-03-28 1992-12-01 S. C. Johnson & Son High alcohol content aerosol antimicrobial mousse
DE4110973A1 (de) 1991-04-05 1992-10-08 Haarmann & Reimer Gmbh Mittel mit physiologischem kuehleffekt und fuer diese mittel geeignete wirksame verbindungen
JP3100416B2 (ja) 1991-04-11 2000-10-16 オカモト株式会社 ムース状潤滑剤
IT1247529B (it) 1991-04-24 1994-12-17 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale
US5204090A (en) * 1991-05-30 1993-04-20 Bristol Myers Squibb Waterproof high-SPF sunscreen compositions
US5164357A (en) 1991-06-05 1992-11-17 Appleton Papers Inc. Thermally-responsive record material
FR2677544B1 (fr) 1991-06-14 1993-09-24 Oreal Composition cosmetique contenant un melange de nanopigments d'oxydes metalliques et de pigments melaniques.
DE4210165A1 (de) 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme
DE4127630A1 (de) 1991-08-21 1993-02-25 Bruno Jesswein Zweikomponenten-druckdose, insbesondere fuer 2k-schaeume
GB9118028D0 (en) 1991-08-21 1991-10-09 Secr Defence Brit Improved transdrmal formulations
JP2969398B2 (ja) 1991-09-12 1999-11-02 花王株式会社 無水泡沫清浄清拭剤
US5643600A (en) 1991-09-17 1997-07-01 Micro-Pak, Inc. Lipid vesicles containing avocado oil unsaponifiables
WO1993005755A1 (fr) 1991-09-27 1993-04-01 Nof Corporation Composition cosmetique et composition d'emulsion
GB2260079B (en) 1991-10-01 1995-08-09 American Cyanamid Co Pharmaceutical composition containing felbinac
US5230897A (en) 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
US5236707A (en) 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
AU3136593A (en) 1991-11-22 1993-06-15 Richardson-Vicks Inc. Combined personal cleansing and moisturizing compositions
DE4140474C2 (de) 1991-12-09 1995-07-13 Schuelke & Mayr Gmbh Hautpflegeadditiv
US5294365A (en) 1991-12-12 1994-03-15 Basf Corporation Hydroxypolyethers as low-foam surfactants
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
US5252246A (en) 1992-01-10 1993-10-12 Allergan, Inc. Nonirritating nonionic surfactant compositions
EP0552612A3 (en) 1992-01-22 1993-10-20 Hoffmann La Roche Methods for determining and isolating compounds which bind directly to nucleosolic proteins
JP3146052B2 (ja) 1992-01-31 2001-03-12 プレスコ株式会社 エアゾールマッサージ剤
US5318774A (en) 1992-02-28 1994-06-07 Richardson-Vicks Inc. Composition and method for imparting an artificial tan to human skin
EP0633940B1 (fr) 1992-04-02 2002-12-04 SemBioSys Genetics Inc. Elements cis de proteines des corps oleiferes, servant de signaux de regulation
US5344051A (en) 1992-04-27 1994-09-06 Insta-Foam Products, Inc. Two-component foam dispensing apparatus
ZA932947B (en) 1992-04-28 1993-10-27 Schering Plough Healthcare Applicator for semisolid medications
US5409706A (en) 1992-05-04 1995-04-25 Imaginative Research Associates, Inc. Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin and emollients such as oils and esters
US5254334A (en) * 1992-05-04 1993-10-19 Imaginative Research Associates, Inc. Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin amd emollients such as oils and esters
IL105595A0 (en) 1992-05-15 1993-09-22 Akzo Nv Applicator for introducing a cream-type substance into a woman's vagina
FI945411A7 (fi) 1992-05-18 1994-11-17 Procter & Gamble Viilentäviä koostumuksia
US5389305A (en) 1992-06-03 1995-02-14 Colgate Palmolive Co. High foaming nonionic surfactant base liquid detergent
JPH08501529A (ja) 1992-06-11 1996-02-20 セラテック・インコーポレイテッド 皮膚透過薬剤投与緩和のグリセリン使用
US5346135A (en) 1992-06-16 1994-09-13 Vincent Edward C Spraying apparatus for blending liquids in a gaseous spray system
US5300286A (en) 1992-07-14 1994-04-05 Dow Corning Corporation Silicone emulsion for personal care application
BR9306816A (pt) * 1992-07-28 1998-12-08 Procter & Gamble Composição farmaceutica para uso tópico contendo um polímero catiônico reticulado e um eter alcoxilado
FI933979A0 (fi) 1992-09-10 1993-09-10 Mcneil Ppc Inc Bioeroderbar anordning foer dosering av aktiva ingredienser
JPH08501553A (ja) 1992-09-14 1996-02-20 スミス・ウォルター・ピー 皮膚調整組成物，その応用及び製造
JPH06100414A (ja) 1992-09-18 1994-04-12 Osaka Aerosol Ind Corp エアゾール用組成物
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5413775A (en) 1992-09-29 1995-05-09 Amerchol Corporation Hairsprays and acrylic polymer compositions for use therein
WO1994008536A1 (fr) 1992-10-21 1994-04-28 Gynetech Laboratories, Inc. Systeme d'administration vaginale utilisant une eponge
EP0596304B1 (fr) 1992-10-31 1998-04-01 Th. Goldschmidt AG Compositions cosmétiques et pharmaceutiques
DE4238860A1 (de) 1992-11-19 1994-05-26 Medicon Gmbh Hautschutzmittel zum Schutz der menschlichen Haut
US5308643A (en) 1992-11-30 1994-05-03 Osipow Lloyd I Self-lather generating shaving compositions
JP3328344B2 (ja) 1992-12-22 2002-09-24 タイホー工業株式会社 発泡型洗浄艶出し剤の発泡状態保持時間を制御する方法
JPH06263630A (ja) 1993-03-10 1994-09-20 Lion Corp ビタミンａ類可溶化点眼剤
JPH06279228A (ja) 1993-03-30 1994-10-04 Kao Corp 発泡性組成物
US5326557A (en) 1993-04-06 1994-07-05 Dow Corning Corporation Moisturizing compositions containing organosilicon compounds
US5807571A (en) 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
DE69430917T2 (de) 1993-05-19 2003-03-20 Hisamitsu Pharmaceutical Co 3-l-MENTHOXY-PROPANE-1, 2-DIOL ALS LÖSUNGSVERMITTLER UND EXTERNE ZUBEREITUNG, DIE DIESEN ENTHÄLT
WO1994027562A1 (fr) 1993-05-21 1994-12-08 Henkel Corporation Composition de shampoing doux
JP3161869B2 (ja) 1993-05-24 2001-04-25 株式会社ダイゾー 油中水型エアゾール組成物およびその製法
US5635469A (en) 1993-06-10 1997-06-03 The Procter & Gamble Company Foaming cleansing products
US5447725A (en) 1993-06-11 1995-09-05 The Procter & Gamble Company Methods for aiding periodontal tissue regeneration
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5398846A (en) 1993-08-20 1995-03-21 S. C. Johnson & Son, Inc. Assembly for simultaneous dispensing of multiple fluids
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
FR2709666B1 (fr) 1993-09-07 1995-10-13 Oreal Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire.
JP2978043B2 (ja) 1993-09-16 1999-11-15 高砂香料工業株式会社 （２ｓ）−３−｛（１ｒ，２ｓ，５ｒ）−［ ５−メチル−２−（１−メチルエチル）シクロヘキシル ］オキシ｝−１，２−プロパンジオール，その製造方法および用途
US5766632A (en) 1993-10-01 1998-06-16 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception
US5578315A (en) 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
FR2713486B1 (fr) 1993-12-14 1996-02-09 Scophysa Nouvelles compositions pour mousses, notamment mousses rectales, et mousses ainsi obtenues.
WO1995017175A1 (fr) 1993-12-23 1995-06-29 The Procter & Gamble Company Compositions antimicrobiennes pour mouchoirs jetables
US5527822A (en) 1993-12-29 1996-06-18 Forest Laboratories, Inc. Method of treatment of traumatic brain injury
DE9422052U1 (de) 1994-01-04 1997-10-30 Adolf Würth GmbH & Co. KG, 74653 Künzelsau Befüllgerät zum Befüllen eines wiederbefüllbaren Ausgabebehälters und wiederbefüllbarer Ausgabebehälter
JP3530564B2 (ja) 1994-02-03 2004-05-24 株式会社ノエビア エアゾールフォーム化粧料
DE4405127A1 (de) 1994-02-18 1995-08-31 Henkel Kgaa Haarbehandlungsmittel
US5514367A (en) 1994-02-28 1996-05-07 Estee Lauder, Inc. Skin tanning compositions and methods for their preparation and use
US5925669A (en) 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
IL109230A (en) 1994-04-05 1998-08-16 Agis Ind 1983 Ltd Anti-fungal composition containing bifonazole and fluocinonide
US5658749A (en) 1994-04-05 1997-08-19 Corning Clinical Laboratories, Inc. Method for processing mycobacteria
US5429815A (en) 1994-04-11 1995-07-04 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Stable single-phase self-foaming cleanser
FR2719467B1 (fr) 1994-05-05 1996-05-31 Oreal Utilisation de flavonoïdes pour préserver et/ou renforcer les propriétés mécaniques des cheveux et procédé de protection des cheveux utilisant ces composés.
US5902574A (en) 1994-05-23 1999-05-11 The Gillette Company Shaving preparation for improved shaving comfort
US5545401A (en) 1994-06-02 1996-08-13 Shanbrom; Edward Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine
US6221381B1 (en) 1994-06-28 2001-04-24 The University Of British Columbia Enhancing milk production by adding to feed a nonionic surfactant coated on a carrier
MA23592A1 (fr) 1994-06-30 1995-12-31 Procter & Gamble Compositions pour les soins corporels contenant des copolymeres greffes elastomeres thermoplastiques
US5679324A (en) 1994-07-08 1997-10-21 The Procter & Gamble Co. Aerosol foamable fragrance composition
FR2722431B1 (fr) 1994-07-12 1996-09-13 Lir France Sa Distributeur double pour produits fluides
JP3173330B2 (ja) 1994-07-20 2001-06-04 トヨタ自動車株式会社 車両用ロックアップクラッチのスリップ制御装置
US5444092A (en) 1994-07-20 1995-08-22 Collins; Jerry Method and composition for treating psoriasis
GB9414699D0 (en) 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
US5512555A (en) 1994-07-21 1996-04-30 Merck & Co., Inc. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one
JP3241542B2 (ja) 1994-07-29 2001-12-25 高砂香料工業株式会社 （−）−ｎ−イソプレゴールの精製方法及びその方法で得られた（−）−ｎ−イソプレゴールを含有するシトラス系香料組成物
DE4428096A1 (de) 1994-08-09 1996-02-15 Wella Ag Zweikammerbehälter
US5547989A (en) 1994-08-19 1996-08-20 Schering-Plough Healthcare Products, Inc. Compositions for treating corns and calluses
US5656586A (en) 1994-08-19 1997-08-12 Rhone-Poulenc Inc. Amphoteric surfactants having multiple hydrophobic and hydrophilic groups
KR970705374A (ko) * 1994-08-26 1997-10-09 레이서 제이코버스 코넬리스 개인용 세정 조성물(personal cleansing compositions)
JP3558393B2 (ja) 1994-08-29 2004-08-25 株式会社ダイゾー 起泡性エアゾール組成物
US5976555A (en) 1994-09-07 1999-11-02 Johnson & Johnson Consumer Products, Inc. Topical oil-in-water emulsions containing retinoids
JP3604177B2 (ja) 1994-09-14 2004-12-22 日東電工株式会社 経皮吸収製剤
US5500211A (en) 1994-09-22 1996-03-19 The Gillette Company Soap-free self-foaming shave gel composition
US5905092A (en) 1994-09-27 1999-05-18 Virotex Corporation Reel/Frame Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction
US5955414A (en) 1994-10-05 1999-09-21 S. C. Johnson & Son, Inc. Cleaning foam having fluorinated stain repellent and low flammability
US5540853A (en) 1994-10-20 1996-07-30 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
AU3855695A (en) 1994-11-08 1996-05-31 Mochida Pharmaceutical Co., Ltd. External preparation for skin protection
US5567420A (en) 1994-11-16 1996-10-22 Mceleney; John Lotion which is temporarily colored upon application
US5788664A (en) 1994-11-30 1998-08-04 Scalise; Gaspare Suppository applicator
US5641480A (en) 1994-12-08 1997-06-24 Lever Brothers Company, Division Of Conopco, Inc. Hair care compositions comprising heteroatom containing alkyl aldonamide compounds
JP3355257B2 (ja) 1994-12-09 2002-12-09 太陽化学株式会社 化粧料
US5529770A (en) 1994-12-09 1996-06-25 West Agro, Inc. Viscous liquid conditioning topical germicides
DE4444238A1 (de) 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
DK0801554T3 (da) 1994-12-21 2003-08-04 Cosmederm Technologies Formuleringer og fremgangsmåder til reduktion af hudirritation
WO1996019921A1 (fr) 1994-12-23 1996-07-04 Commonwealth Scientific And Industrial Research Organisation Substance iodee biocide
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5534261A (en) 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
US5523078A (en) 1995-02-03 1996-06-04 Michael E. Baylin Method of preparing and composition for treatment of hair and scalp
US5587149A (en) 1995-02-06 1996-12-24 R.P. Scherer Corporation Topical application emulsions
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
FR2730930B1 (fr) 1995-02-27 1997-04-04 Oreal Utilisation d'inhibiteurs de no-synthase pour diminuer l'effet irritant cutane de produits utilises dans le domaine cosmetique ou pharmaceutique
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
US5558872A (en) 1995-03-07 1996-09-24 Healthpoint Medical Limited Partnership Gelled mineral oil skin protectant
US5618850A (en) 1995-03-09 1997-04-08 Focal, Inc. Hydroxy-acid cosmetics
US5783202A (en) 1995-03-14 1998-07-21 Soltec Research Pty. Ltd. Pediculicidal mousse composition for killing head lice
JP4065321B2 (ja) 1995-03-29 2008-03-26 塩野義製薬株式会社 水分活性を調節したゼラチンカプセル剤
JPH08277209A (ja) 1995-04-07 1996-10-22 Taisho Pharmaceut Co Ltd 育毛剤
US5585104A (en) 1995-04-12 1996-12-17 The Procter & Gamble Company Cleansing emulsions
EP0738510A3 (fr) 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
FR2733417B1 (fr) 1995-04-25 1997-06-06 Oreal Emulsion huile-dans-eau moussante a base de tensio-actifs non-ioniques, d'une phase grasse et d'un polymere cationique ou anionique reticule et utilisation en application topique
GB9510856D0 (en) 1995-05-27 1995-07-19 Cussons Int Ltd Cleaning composition
UY24246A1 (es) 1995-06-06 1996-06-14 Neutrogena Corp Vehiculos tropicos que contienen acido azelaico solubilizado y estabilizado
EP0833605A1 (fr) 1995-06-22 1998-04-08 Minnesota Mining And Manufacturing Company Compositions hydro-alcooliques stables
JP3542665B2 (ja) 1995-07-07 2004-07-14 株式会社資生堂 抗老化皮膚外用剤、コラーゲン架橋阻害皮膚外用剤及び抗紫外線皮膚外用剤
US5705472A (en) 1995-07-18 1998-01-06 Petroferm Inc. Neutral aqueous cleaning composition
FR2736824B1 (fr) 1995-07-18 1997-10-10 Fabre Pierre Dermo Cosmetique Composition capillaire a base de minoxidil a faible teneur en solvant gras
DE29512760U1 (de) 1995-08-08 1995-11-16 Wella Ag, 64295 Darmstadt Druckgasbehälter zum Abgeben von Schaum
TW504387B (en) 1995-09-06 2002-10-01 Kao Corp Emulsified, water-in-oil type composition and skin cosmetic preparation
US5881493A (en) 1995-09-14 1999-03-16 D. B. Smith & Co. Inc. Methods for applying foam
CN1062129C (zh) 1995-09-14 2001-02-21 徐荣祥 药物基质及其用途
JPH0984855A (ja) 1995-09-25 1997-03-31 Kyoto Yakuhin Kogyo Kk 直腸または膣への薬物投与用のエアゾール製剤
US6221823B1 (en) 1995-10-25 2001-04-24 Reckitt Benckiser Inc. Germicidal, acidic hard surface cleaning compositions
KR100450861B1 (ko) 1995-12-14 2005-03-16 다이쇼 세이야꾸 가부시끼가이샤 에어로졸제제
US5843411A (en) 1997-02-06 1998-12-01 Topix Pharmaceuticals Inc. Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
US5889028A (en) 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5912007A (en) 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
US6251369B1 (en) 1996-03-05 2001-06-26 Sultan Dental Products Dental fluoride foam
FR2745716B1 (fr) 1996-03-07 1998-04-17 Oreal Emulsions huile-dans-eau moussantes pressurisables ultrafines
WO1997039745A1 (fr) 1996-04-19 1997-10-30 Sloan-Kettering Institute For Cancer Research Utilisation de retinoides inhales dans la prevention du cancer
US5910382A (en) 1996-04-23 1999-06-08 Board Of Regents, University Of Texas Systems Cathode materials for secondary (rechargeable) lithium batteries
IT1283042B1 (it) 1996-05-21 1998-04-07 Condea Augusta Spa Composizioni cosmetiche deodoranti e/o antitraspiranti
US5797955A (en) 1996-06-11 1998-08-25 Walters; David J. Pressure application unit for positioning vertebra
US5833961A (en) 1996-06-25 1998-11-10 Inolex Investment Corporation Polyester-based suncreen formulations
US6204285B1 (en) 1996-07-01 2001-03-20 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
EP0939618B1 (fr) 1996-07-10 2002-09-11 Steris Inc. Produit de lavage pour la peau a base de triclosan et possedant une meilleure efficacite
DE19631221C2 (de) 1996-08-02 1999-07-01 Beiersdorf Ag Schaumförmige Lichtschutzzubereitungen mit einem Gehalt an wasserlöslichen Lichtschutzfiltersubstanzen und grenzflächenaktiven Substanzen
AU725954B2 (en) 1996-08-15 2000-10-26 Board Of Trustees Of Southern Illinois University, The Enhancement of antimicrobial peptide activity by metal ions
US5833963A (en) 1996-08-20 1998-11-10 Bristol-Myers Squibb Company Non-tacky and quick-drying aqueous-based antiperspirant compositions
US5837270A (en) 1996-08-26 1998-11-17 Burgess; Nelson Leon Topical anti-acne composition
EP0829259A1 (fr) 1996-09-04 1998-03-18 Warner-Lambert Company Gel ou mousse contenant des microperles ou des particules fines
US6271295B1 (en) 1996-09-05 2001-08-07 General Electric Company Emulsions of silicones with non-aqueous hydroxylic solvents
US5952392A (en) 1996-09-17 1999-09-14 Avanir Pharmaceuticals Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition
US7060253B1 (en) 1996-09-20 2006-06-13 Mundschenk David D Topical formulations and delivery systems
FR2754451B1 (fr) 1996-10-14 1998-11-06 Oreal Creme auto-moussante
WO1998017282A1 (fr) 1996-10-23 1998-04-30 Vertex Pharmaceuticals Incorporated Procedes d'utilisation d'un octosulfate de saccharose pour le traitement ou la prevention d'une infection a virus enveloppe
US6093408A (en) 1996-10-25 2000-07-25 The Procter & Gamble Company Skin care compositions
IT1287114B1 (it) 1996-10-31 1998-08-04 Recordati Chem Pharm Composizioni farmaceutiche antierpetiche per applicatori topici, contenenti aciclovir
WO1998019654A1 (fr) 1996-11-04 1998-05-14 The Procter & Gamble Company Composition de mousse pour les cheveux contenant une emulsion a la silicone
FR2755854B1 (fr) 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
US5906992A (en) 1996-11-21 1999-05-25 Colgate Palmolive Company Foam cleaning compositions
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
US5951544A (en) 1996-12-04 1999-09-14 Laser Industries Ltd. Handpiece assembly for laser apparatus
US5759579A (en) 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
US5695551A (en) 1996-12-09 1997-12-09 Dow Corning Corporation Water repellent composition
US5672634A (en) 1996-12-23 1997-09-30 Isp Investments Inc. Crosslinked PVP-I2 foam product
US5879469A (en) 1997-01-06 1999-03-09 Deeay Technologies Ltd. Dishwashing method and detergent composition therefor
US6582711B1 (en) * 1997-01-09 2003-06-24 3M Innovative Properties Company Hydroalcoholic compositions thickened using polymers
SE520811C2 (sv) 1997-01-17 2003-08-26 Ponsus Ab Hudskyddspreparat innehållande lipofila och hydrofila komponenter, förfarande för framställning och användning därav
ES2133090B1 (es) 1997-02-21 2000-04-01 Uriach & Cia Sa J Nuevo aplicador para la administracion de medicaciones semisolidas.
AP9901641A0 (en) 1997-02-11 1999-09-30 Bernard Salafsky Anti-parasitic action of N,N-Diethyl-m-toluamide (DEET) and formulations that prolong its activity in the skin.
WO1998036733A2 (fr) 1997-02-24 1998-08-27 Michael Albert Kamm Composition pharmaceutique a usage local contenant un agent cholinergique ou un inhibiteur calcique
JP3050289B2 (ja) 1997-02-26 2000-06-12 日本電気株式会社 出力バッファ回路の出力インピーダンス調整回路
US6433068B1 (en) 1997-03-07 2002-08-13 David S. Morrison Hydrocarbon gels as suspending and dispersing agents and products
FR2760637B1 (fr) 1997-03-11 1999-05-28 Fabre Pierre Dermo Cosmetique Extrait de goudron de houille a teneur reduite en hydrocarbures aromatiques, procede d'obtention et preparations dermo-cosmetiques
US5922331A (en) 1997-03-26 1999-07-13 Chanel, Inc. Skin cream composition
US5951989A (en) 1997-04-07 1999-09-14 Heymann; Warren R. Method for the treatment of dry skin
USH2043H1 (en) 1997-05-23 2002-08-06 The Procter & Gamble Company Skin care compositions
US6372234B1 (en) 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6599513B2 (en) 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
CN1084595C (zh) 1997-05-27 2002-05-15 塞姆柏奥希斯遗传学公司 油体的用途
US6217887B1 (en) 1997-06-04 2001-04-17 The Procter & Gamble Company Leave-on antimicrobial compositions which provide improved immediate germ reduction
JP3113610B2 (ja) 1997-06-04 2000-12-04 東洋ガスメーター株式会社 ガスメーター用伝送装置の取付具
EP0884045A1 (fr) 1997-06-06 1998-12-16 Pfizer Products Inc. Formulations autobronzantes de dihydroxyacetone à stabilité améliorée et conférant une administration accrue
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
AU729680B2 (en) 1997-06-13 2001-02-08 Taisho Pharmaceutical Co., Ltd. Aerosol preparation
JPH11111A (ja) 1997-06-13 1999-01-06 Kagoshima Pref Gov 養魚用飼料
FR2765799B1 (fr) 1997-07-08 1999-08-27 Oreal Composition brillante contenant des huiles aromatiques epaissies par un alkylether de polysaccharide
JP3553767B2 (ja) 1997-08-22 2004-08-11 三洋電機株式会社 移載介助装置
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
US5885581A (en) 1997-09-11 1999-03-23 Merz, Incorporated Composition and method for improvement of the appearance of scars
US5939376A (en) 1997-09-25 1999-08-17 Colgate Palmolive Company Liquid cleaning compositions containing an organic ester foam control agent
US6241971B1 (en) 1997-09-25 2001-06-05 The Procter & Gamble Company Hair styling compositions comprising mineral salt, lipophilic material, and low levels of surfactant
US6214318B1 (en) 1997-10-02 2001-04-10 Oms Holdings Llc Aerosol ointment compositions for topical use
FR2769299B1 (fr) 1997-10-03 1999-12-31 Oreal Ensemble de conditionnement et de distribution bi-produits
US6075056A (en) 1997-10-03 2000-06-13 Penederm, Inc. Antifungal/steroid topical compositions
AUPO983897A0 (en) 1997-10-17 1997-11-06 Soltec Research Pty Ltd Topical antifungal composition
US5961957A (en) 1997-10-20 1999-10-05 Mcanalley; Bill H. Foam compositions
US5911981A (en) 1997-10-24 1999-06-15 R.I.T.A. Corporation Surfactant blends for generating a stable wet foam
JP3450680B2 (ja) 1997-10-28 2003-09-29 高砂香料工業株式会社 パラ−メンタン−３，８−ジオールの製造方法
CA2306837C (fr) 1997-10-28 2007-05-08 Asivi, Llc. Traitement du dysfonctionnement sexuel chez la femme
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
ES2318233T3 (es) 1997-11-10 2009-05-01 Strakan International Limited Sistemas mejoradores de la penetracion y reductores de la irritacion que comprenden testosterona.
DE29720316U1 (de) 1997-11-17 1998-01-29 Raimund Andris Gmbh & Co Kg, 78052 Villingen-Schwenningen Zweikammer-Dosierspender
US5849042A (en) 1997-11-19 1998-12-15 Bristol-Myers Squibb Hair dye compositions containing 2,3 dialkyl-4-aminophenol and a 2-alkyl-1-naphthol
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
TWI225793B (en) 1997-12-25 2005-01-01 Ajinomoto Kk Cosmetic composition
DE19802206A1 (de) 1998-01-22 1999-07-29 Beiersdorf Ag Lipidreduzierte, fließfähige Zubereitungen
FR2774595A1 (fr) 1998-02-06 1999-08-13 Rech D Innovation Et De Dev Ce Emulsion pour l'administration transdermique de steroides
DE19805918A1 (de) 1998-02-13 1999-08-19 Beiersdorf Ag Lipidreduzierte Zubereitungen
US6110966A (en) 1998-02-20 2000-08-29 Medi-Cell Laboratories, Inc. Triple action complex
JP3514105B2 (ja) 1998-02-27 2004-03-31 ティアック株式会社 記録媒体記録再生装置
US6187763B1 (en) 1998-03-04 2001-02-13 Teijin Limited Activated vitamin D3 emulsion-type lotions
US6121210A (en) 1998-03-12 2000-09-19 Dap Products Inc. Foamable silicone oil compositions and methods of use thereof
US5990100A (en) 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
AUPP310798A0 (en) 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
US5919830A (en) 1998-04-30 1999-07-06 Gopalkrishnan; Sridhar Stable non-aqueous blends for personal care compositions
US6649175B1 (en) 1998-05-04 2003-11-18 Schering-Plough Healthcare Products, Inc. Skin barrier composition
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
FR2779637B1 (fr) 1998-06-15 2000-09-01 Oreal Compositions cosmetiques photoprotectrices, contenant un nanopigment d'oxyde metallique et un terpolymere acrylique et utilisation de ces compositions pour proteger les matieres keratiniques contre le rayonnement ultraviolet
US6706290B1 (en) 1998-07-06 2004-03-16 Olvai E. Kajander Methods for eradication of nanobacteria
FR2780879B1 (fr) 1998-07-09 2002-09-20 Oreal Composition cosmetique photoprotectrice contenant un tensio-actif anionique, un compose filtrant le rayonnement ultraviolet et un compose cationique ou zwitterionique amphiphile et son utilisation
US6146664A (en) 1998-07-10 2000-11-14 Shaklee Corporation Stable topical ascorbic acid compositions
US6124362A (en) 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth
US6071541A (en) 1998-07-31 2000-06-06 Murad; Howard Pharmaceutical compositions and methods for managing skin conditions
DE19835239A1 (de) 1998-08-04 2000-02-24 Johnson & Johnson Gmbh Schäumende Ölzubereitung und deren Verwendung
JP4017758B2 (ja) 1998-08-04 2007-12-05 高砂香料工業株式会社 冷感剤組成物
GB9817817D0 (en) 1998-08-14 1998-10-14 Unilever Plc Cosmetic composition
MXPA01001752A (es) 1998-08-20 2002-04-08 3M Innovative Properties Co Parche en aerosol y sistema de aplicacion de medicamento.
JP3712868B2 (ja) 1998-09-02 2005-11-02 株式会社カネボウ化粧品 エアゾール組成物
AUPP583198A0 (en) 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US6087310A (en) 1998-09-23 2000-07-11 Castrol Limited Skin cleaning compositions and uses comprising a polymer latex emulsion
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
AU760735B2 (en) 1998-09-28 2003-05-22 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
US6607716B1 (en) 1998-09-29 2003-08-19 Tech Labs, Inc. Pediculicidal compositions, a kit, and methods of use
US6287546B1 (en) 1998-10-09 2001-09-11 Colgate-Palmolive Company Shampoos with stabilizers
JP3876081B2 (ja) 1998-10-22 2007-01-31 東洋エアゾール工業株式会社 フォーム形成用エアゾール組成物
US6110477A (en) 1998-10-30 2000-08-29 Topix Pharmaceuticals Inc. Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US5980904A (en) 1998-11-18 1999-11-09 Amway Corporation Skin whitening composition containing bearberry extract and a reducing agent
US6344218B1 (en) 1998-11-23 2002-02-05 The Procter & Gamble Company Skin deodorizing and santizing compositions
DE19855097A1 (de) 1998-11-28 2000-05-31 Wella Ag Pigmenthaltiges, verschäumbares Gel
US20010006654A1 (en) 1998-12-09 2001-07-05 L'oreal Compositions and methods for treating hair and skin using aqueous delivery systems
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6087317A (en) 1998-12-10 2000-07-11 Dow Corning Corporation Particle size stable silicone emulsions
US6262128B1 (en) 1998-12-16 2001-07-17 3M Innovative Properties Company Aqueous foaming compositions, foam compositions, and preparation of foam compositions
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
JP2000191429A (ja) 1998-12-28 2000-07-11 Kao Corp 発泡性化粧料
EP1142588A4 (fr) 1998-12-28 2007-01-10 Taisho Pharmaceutical Co Ltd Preparation externe
FR2787703B1 (fr) 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6270781B1 (en) 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
EP1025836A1 (fr) 1999-02-08 2000-08-09 F. Hoffmann-La Roche Ag Composition de protection solaire
TWI262930B (en) 1999-02-10 2006-10-01 Mitsui Chemicals Inc High-durability flexible polyurethane cold molded foam and process for producing the same
US6224888B1 (en) 1999-02-12 2001-05-01 The Procter & Gamble Company Cosmetic compositions
US6423329B1 (en) 1999-02-12 2002-07-23 The Procter & Gamble Company Skin sanitizing compositions
JP3641152B2 (ja) 1999-02-17 2005-04-20 株式会社ヤクルト本社 皮膚外用剤
ATE253405T1 (de) 1999-02-26 2003-11-15 Wella Ag Vorrichtung zum mischen, aufschäumen und ausgeben von flüssigkeiten aus separaten druckgasbehältern
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
IL129102A0 (en) 1999-03-22 2000-02-17 J P M E D Ltd An emulsion
ES2298932T3 (es) 1999-03-31 2008-05-16 Firmenich Sa Composicion saborizante que contiene cubebol y por lo menos agente refrescante.
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6264964B1 (en) 1999-04-14 2001-07-24 Conopco, Inc. Foaming cosmetic products
WO2000062776A1 (fr) 1999-04-16 2000-10-26 Fujisawa Pharmaceutical Co., Ltd. Compositions antifongiques
US6284802B1 (en) 1999-04-19 2001-09-04 The Procter & Gamble Company Methods for regulating the condition of mammalian keratinous tissue
MXPA01010676A (es) 1999-04-23 2003-08-20 Leo Pharm Prod Ltd Composicion farmaceutica de vitamina d o un analogo de vitamina d y al menos un corticoesteroide.
US6433003B1 (en) 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
GB9909711D0 (en) 1999-04-27 1999-06-23 Unilever Plc Mousse forming hair treatment composition
FR2793479B1 (fr) 1999-05-10 2001-06-29 Lir France Sa Distributeur double pour produits fluides ou pateux
WO2000067754A1 (fr) 1999-05-12 2000-11-16 Nitromed, Inc. Activateurs nitroses et nitrosyles du canal potassique, compositions et utilisations
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6518228B1 (en) 1999-05-27 2003-02-11 Clairol Incorporated Ultra-mild, clear, aqueous, foamable skin cleanser
AU5067000A (en) 1999-05-28 2000-12-18 Unilever Plc Foamable shower oil composition
JP2000351726A (ja) 1999-06-08 2000-12-19 Lion Corp エアゾール製剤
JP2000354623A (ja) 1999-06-14 2000-12-26 Shiigeru Kk 消臭剤及び消臭スプレー
GB9913951D0 (en) 1999-06-15 1999-08-18 Unilever Plc Mousse-forming shampoo compositions
US6113888A (en) 1999-06-15 2000-09-05 Neutrogena Corporation Self-tanning mousse
KR100352088B1 (ko) 1999-06-21 2002-09-12 한미약품공업 주식회사 미녹시딜 함유 외용 에멀젼 조성물
US6524594B1 (en) 1999-06-23 2003-02-25 Johnson & Johnson Consumer Companies, Inc. Foaming oil gel compositions
JP2001002526A (ja) 1999-06-23 2001-01-09 Koike Kagaku Kk 泡沫エアゾール組成物
NL1012419C2 (nl) 1999-06-23 2000-12-28 Airspray Nv Spuitbus voor het afgeven van een vloeistof.
US6551604B1 (en) 1999-06-28 2003-04-22 The Procter & Gamble Company Skin care compositions
AU5764800A (en) 1999-07-01 2001-01-22 Johnson & Johnson Consumer Companies, Inc. Cleansing compositions
US6762158B2 (en) 1999-07-01 2004-07-13 Johnson & Johnson Consumer Companies, Inc. Personal care compositions comprising liquid ester mixtures
FR2795643B1 (fr) 1999-07-02 2004-06-11 Oreal Composition cosmetique raffermissante comprenant au moins un hydroxystilbene en association avec de l'acide ascorbique
JP4058199B2 (ja) 1999-07-06 2008-03-05 ポーラ化成工業株式会社 温感パック
EP1200054A1 (fr) 1999-07-15 2002-05-02 Playtex Products, Inc. Composition de protection solaire sous forme d'aerosol
US6548074B1 (en) 1999-07-22 2003-04-15 Elizabeth Arden Co., Division Of Conopco, Inc. Silicone elastomer emulsions stabilized with pentylene glycol
FR2796925B1 (fr) 1999-07-29 2001-10-05 Valois Sa Distributeur a tete de distribution articulee
AU7389300A (en) 1999-08-02 2001-02-19 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
US6303552B1 (en) 1999-08-04 2001-10-16 Napier International Technologies, Inc. Aerosol paint stripper compositions
WO2001013956A2 (fr) 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Utilisation d'huile d'emeu et de ses diverses fractions comme excipient pour des medicaments et des preparations antifongiques, antibacteriennes et antivirales
US6777591B1 (en) 1999-08-27 2004-08-17 Sembiosys Genetics Inc. Legume-like storage protein promoter isolated from flax and methods of expressing proteins in plant seeds using the promoter
US6308863B1 (en) 1999-09-02 2001-10-30 Owens-Brockway Plastic Products Inc. Dual chamber package for pressurized products
US6479058B1 (en) 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
JP4394775B2 (ja) 1999-09-03 2010-01-06 株式会社ダイゾー 油中水型泡状エアゾール組成物およびその製造方法
US6986883B2 (en) 1999-09-09 2006-01-17 Discus Dental, Inc. Increased peroxide content tooth bleaching gel
AU3887301A (en) 1999-09-20 2001-04-24 Procter & Gamble Company, The Article for the delivery of foam products
US6437006B1 (en) 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
FR2798849B1 (fr) 1999-09-29 2001-11-23 Oreal Composition de lavage des matieres keratiniques, a base d'un agent tensio actif detergent, d'un homopolymere de dialkyl diallyl ammonium et d'un terpolymere acrylique
US6790435B1 (en) 1999-10-01 2004-09-14 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Antiperspirant compositions comprising microemulsions
US6667045B2 (en) 1999-10-01 2003-12-23 Joseph Scott Dahle Topical applications for skin treatment
FR2799369B1 (fr) 1999-10-08 2001-12-21 Oreal Association d'escine et de sulfate de dextran et son utilisation
FR2799963B1 (fr) 1999-10-22 2002-07-19 Oreal Emulsions contenant au moins un filtre uv organique insoluble et une silicone organomodifiee non-filtrante
US6080394A (en) 1999-11-08 2000-06-27 Dow Corning Corporation Polar solvent-in-oil emulsions and multiple emulsions
US20030077301A1 (en) 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
UA66796C2 (uk) 1999-12-27 2004-06-15 Univ Nat Pharmaceutical Лікарський засіб "профезоль-пінний" для лікування променевих уражень шкіри
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
IL133969A0 (en) 2000-01-10 2001-04-30 Thixo Ltd Thixotropic compositions containing unsaturated oils and food products containing the same
US7001690B2 (en) 2000-01-18 2006-02-21 Valence Technology, Inc. Lithium-based active materials and preparation thereof
US6528033B1 (en) 2000-01-18 2003-03-04 Valence Technology, Inc. Method of making lithium-containing materials
FR2804015B1 (fr) 2000-01-21 2005-12-23 Oreal Nanoemulsion contenant des lipides amphiphiles et un polymere non ionique et utilisations
FR2804016B1 (fr) 2000-01-21 2006-07-28 Oreal Nanoemulsion contenant des lipides amphiphiles et un ester de peg et utilisations
US20020006435A1 (en) 2000-01-27 2002-01-17 Samuels Paul J. Transdermal anesthetic and vasodilator composition and methods for topical administration
US6780443B1 (en) 2000-02-04 2004-08-24 Takasago International Corporation Sensate composition imparting initial sensation upon contact
FR2804666B1 (fr) 2000-02-04 2002-06-14 Oreal Distributeur pour le stockage d'au moins deux composants et la distribution selective soit d'un constituant seul, soit de leur melange, et procede pour sa mise en oeuvre
NL1014389C2 (nl) 2000-02-15 2001-08-16 Dija Zeist Bv Bruiningspreparaat voor de huid.
US20040161447A1 (en) 2000-02-17 2004-08-19 Leonard Paul Liquid foam producing compositions and dispensing system therefor
EP3367268A1 (fr) 2000-02-22 2018-08-29 Nokia Technologies Oy Codage spatial et affichage d'informations
WO2001062214A1 (fr) 2000-02-22 2001-08-30 Color Access, Inc. Compositions cosmetiques aqueuses en gel
DE10008837A1 (de) 2000-02-25 2001-08-30 Henkel Kgaa Treibgashaltiges Zahnreinigungsmittel
DE10008896A1 (de) 2000-02-25 2001-08-30 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Benzotriazolderivaten und Alkylnaphthalaten
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
IL135222A (en) 2000-03-22 2005-06-19 Univ Ben Gurion Compositions containing molecular iodine
US6649571B1 (en) 2000-04-04 2003-11-18 Masi Technologies, L.L.C. Method of generating gas bubbles in oleaginous liquids
FR2807322B1 (fr) 2000-04-10 2004-02-20 Oreal Composition, notamment cosmetique, comprenant de l'acide ascorbique en association avec un derive d'acide ascorbique
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
JP2002012513A (ja) 2000-04-24 2002-01-15 Kanebo Ltd 尿素含有ホイップ状化粧料
US6358541B1 (en) 2000-05-03 2002-03-19 David S. Goodman Topical preparation for the treatment of hair loss
US6410036B1 (en) 2000-05-04 2002-06-25 E-L Management Corp. Eutectic mixtures in cosmetic compositions
CA2408137C (fr) 2000-05-05 2011-04-19 R.P. Scherer Technologies, Inc. Formulation d'emulsion a phase continue aqueuse contenant de l'hydroquinone et du retinol
US6433024B1 (en) 2000-05-08 2002-08-13 Karl F. Popp Topical anti-acne composition
AU2001248715B2 (en) 2000-05-08 2005-10-13 Pfizer Products Inc. Skin protectant spray compositions
FR2808685B1 (fr) 2000-05-12 2004-10-08 Sanofi Synthelabo Compositions pharmaceutiques pour administration transdermique d'agents anti-inflammatoires
JP2001326952A (ja) 2000-05-15 2001-11-22 Nec Corp 放送確認システム、放送確認方法及び装置、放送確認プログラムを記録した記録媒体
FR2809010B1 (fr) 2000-05-22 2002-07-12 Oreal Nanoemulsion a base de polymeres anioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
DE10028638A1 (de) 2000-06-09 2001-12-20 Schuelke & Mayr Gmbh Lagerstabile Zusammensetzungen von Glycerinmonoalkylethern
WO2001095728A1 (fr) 2000-06-13 2001-12-20 Fd Management, Inc. Composition cosmetique pour peau agressee par des conditions extremes
AU2001272015A1 (en) 2000-06-23 2002-01-08 Combe International Ltd. Stable foam for use in disposable wipe
US20020164381A1 (en) 2000-06-30 2002-11-07 Medicis Pharmaceutical Corporation Mitocidal compositions and methods
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
CA2313659A1 (fr) 2000-07-06 2002-01-06 Barry J. Barclay Compositions de complexe de la vitamine b qui protegent contre les lesions cellulaires causees par la lumiere ultraviolette
DE10033414B4 (de) 2000-07-08 2004-02-19 Wella Aktiengesellschaft Klares, zweiphasiges, schaumbildendes Aerosol-Haarpflegeprodukt
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
DE10035930A1 (de) 2000-07-21 2002-01-31 Clariant Gmbh Feinemulsionen
US20020035070A1 (en) 2000-07-26 2002-03-21 The Procter & Gamble Company Method of regulating hair growth using metal complexes of oxidized carbohydrates
FR2812191B1 (fr) 2000-07-28 2003-10-17 Oreal Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
JP4166931B2 (ja) 2000-08-02 2008-10-15 ポーラ化成工業株式会社 発熱フォーム化粧料
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6514487B1 (en) 2000-08-08 2003-02-04 Teresa Leigh Barr Foam and gel oat protein complex and method of use
WO2002015873A2 (fr) 2000-08-22 2002-02-28 The Procter & Gamble Company Compositions pour les soins personnels contenant un polymere elastomere adhesif et un colloide inorganique
US6299023B1 (en) 2000-08-24 2001-10-09 Miles Arnone Device for dispensing two substances in a user selectable ratio with replaceable cartridges
WO2002015860A1 (fr) 2000-08-24 2002-02-28 Tim Ioannides Antioxydant topique a base de vitamine c et procede de combinaison avec agent topique par l'utilisateur
FR2813189B1 (fr) 2000-08-31 2003-02-28 Oreal Creme cosmetique moussante pour le traitement des peaux grasses
AU2001290936A1 (en) 2000-09-14 2002-03-26 Quantum Energy Technologies Application of water nanoclusters to skin
CA2422356C (fr) 2000-09-21 2009-06-30 Taisho Pharmaceutical Co., Ltd. Suppositoire maintenu dans la partie inferieure du rectum
AUPR048600A0 (en) 2000-10-02 2000-10-26 Soltec Research Pty Ltd Pharmaceutical vehicle
DE10049147A1 (de) 2000-10-04 2002-04-25 Wella Ag Haarwachsprodukt mit Wachsen, nicht-flüchtigen Ölen und flüchtigen, hydrophoben Stoffen
FR2814959A1 (fr) 2000-10-09 2002-04-12 Menarini France Nouveau dispositif de pulverisation pour formes pharmaceutiques a base d'agent anti-inflammatoire et les formes ainsi realisees
US6547063B1 (en) 2000-10-10 2003-04-15 The Procter & Gamble Company Article for the delivery of foam products
GB2367809A (en) 2000-10-12 2002-04-17 Bespak Plc Metering valve with collapsible chamber
US6403069B1 (en) 2000-10-20 2002-06-11 Colgate-Palmolive Company High oil clear emulsion with elastomer
FR2815616B1 (fr) 2000-10-20 2003-01-24 Oreal Ensemble de distribution destine a la distribution extemporanee de deux produits
DE10058384B4 (de) 2000-11-24 2004-12-16 Wella Aktiengesellschaft Kosmetisches oder dermatologisches Mittel in Form eines cremigen Permanentschaums oder einer stabil aufgeschäumten Creme, deren Verwendung und Verfahren zur Herstellung des Mittels
US6299032B1 (en) 2000-11-27 2001-10-09 George W. Hamilton Disposable actuator with cap opener for aerosol cans
US6969521B1 (en) 2000-11-28 2005-11-29 Avon Products, Inc. Aerosol insect repellent composition having low VOC content and method of applying same to the skin
WO2002043490A1 (fr) 2000-11-28 2002-06-06 Avon Products, Inc. Compositions insectifuges moussantes
US6774100B2 (en) 2000-12-06 2004-08-10 Imaginative Research Associates, Inc. Anhydrous creams, lotions and gels
GB0030068D0 (en) 2000-12-11 2001-01-24 Lawrence Malcolm Highway vehicular traffic flow control
JP3497466B2 (ja) 2000-12-12 2004-02-16 高砂香料工業株式会社 温感組成物
US20060254597A1 (en) 2000-12-14 2006-11-16 40J's Llc Method of treatment of atrophic vaginitis by topical clitoral menthol or a related cooling compound
DE10063342A1 (de) 2000-12-19 2002-06-20 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen
US6749860B2 (en) 2000-12-22 2004-06-15 Kimberly-Clark Worldwide, Inc. Absorbent articles with non-aqueous compositions containing botanicals
US20040079361A1 (en) 2001-01-17 2004-04-29 Clayton Colin D. Medicinal aerosols
FR2819427B1 (fr) 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20030013692A1 (en) 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
BR0206980A (pt) 2001-02-05 2004-07-06 Michael Albert Kamm Uso de um modulador do tÈnus do músculo liso
DE10110336A1 (de) 2001-03-03 2002-09-12 Clariant Gmbh Tensidfreie kosmetische, dermatologische und pharmazeutische Mittel
IL157734A0 (en) 2001-03-06 2004-03-28 Cellegy Pharma Inc Pharmaceutical compositions for the treatment of urogenital disorders
MXPA03008108A (es) 2001-03-07 2003-12-12 Procter & Gamble Composicion topica que comprende un agente cosmetico enlazante de derivado aromatico funcional.
ES2224063T3 (es) 2001-03-26 2005-03-01 3M Innovative Properties Company Valvula dosificadora para un inhalador de dosis medidas que tiene flujo mejorado.
EP1372668B1 (fr) 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Methode permettant d'attenuer les reactions a des irritants cutanes
IL157771A0 (en) 2001-03-27 2004-03-28 Galen Chemicals Ltd Intravaginal drug delivery devices for the administration of an antimicrobial agent
CA2441730C (fr) 2001-03-29 2008-11-18 The Dial Corporation Compositions antibacteriennes pour soin cutane
JP2002302419A (ja) 2001-03-30 2002-10-18 Aldeep Cosmetics Japan Inc 化粧用組成物
JP2004525955A (ja) 2001-04-05 2004-08-26 コッラジェネックス ファーマシューチカルス インコーポレイテッド テトラサイクリン化合物およびテトラサイクリン誘導体の制御された伝達
US6848597B2 (en) 2001-04-18 2005-02-01 James A. Vlodek Methods and apparatus for extruding foam through orifices
US20030053980A1 (en) 2001-04-30 2003-03-20 The Gillette Company Shaving compositions containing highly lubricious water soluble polymers
US20020187181A1 (en) 2001-05-14 2002-12-12 3M Innovative Properties Company System for delivering cosmetics and pharmaceuticals
ITMI20011019A1 (it) 2001-05-17 2002-11-17 Carlo Ghisalberti Sostanze furiliche per uso topico
US20030017181A1 (en) 2001-05-31 2003-01-23 Rood Gloria A. Dermatological compositions and methods
US7270828B2 (en) 2001-06-20 2007-09-18 The Procter & Gamble Company Personal care composition comprising hydrophobic gel
MXPA03011927A (es) 2001-06-20 2004-03-26 Procter & Gamble Composicion para el cuidado personal que contiene una emulsion de poliol en silicona.
FR2826292B1 (fr) 2001-06-22 2004-01-23 Rhodia Chimie Sa Emulsions huile dans huile comprenant une silicone, dispersions de telles emulsions et utilisation
US6544562B2 (en) 2001-06-25 2003-04-08 Blistex Inc. Acne treatment including dual-package system
US6428772B1 (en) 2001-06-25 2002-08-06 Blistex Inc. Acne treatment composition with cooling effect
WO2003002082A1 (fr) 2001-06-26 2003-01-09 The Procter & Gamble Company Emulsions anhydres anti-transpirantes sous pression
JP2003012511A (ja) 2001-06-27 2003-01-15 Rohto Pharmaceut Co Ltd エアゾール組成物
JP4051412B2 (ja) 2001-06-27 2008-02-27 株式会社カネボウ化粧品 混合注出装置
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
WO2003005985A1 (fr) 2001-07-13 2003-01-23 The Procter & Gamble Company Compositions moussantes comprenant des agents d'ammonium quaternaire
DE10134786A1 (de) 2001-07-17 2003-02-06 Beiersdorf Ag Schäumbare Zubereitungen
WO2003013513A1 (fr) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Composition d'emulsion stable
DE10138495B4 (de) 2001-08-04 2004-11-11 Beiersdorf Ag Nachschäumende Zubereitungen und deren Verwendung
ATE469639T1 (de) 2001-08-08 2010-06-15 Dominguez Maria Antonia Garcia-Olmedo Injizierbarer schaum und neue pharmazeutische anwendungen dafür
JP4707279B2 (ja) 2001-08-09 2011-06-22 ポーラ化成工業株式会社 クールダウン効果を有するマッサージ用の化粧料
US7091243B2 (en) 2001-08-09 2006-08-15 Croda, Inc. Anti-irritants
EP1414716A1 (fr) 2001-08-11 2004-05-06 Aventis Pharma Limited Distributeur a aerosol pressurise
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030049218A1 (en) 2001-08-28 2003-03-13 Amit Patel Antiperspirant deodorant emulsion
DK1455888T3 (da) 2001-08-29 2009-08-24 Pharmakodex Ltd Topisk indgivelsesindretning
US6709663B2 (en) 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
US6479060B1 (en) 2001-09-04 2002-11-12 Healthpoint, Ltd. Elegant hydrogenated castor oil ointments
FR2829693B1 (fr) 2001-09-20 2004-02-27 Oreal Creme cosmetique moussante
DE10147820A1 (de) 2001-09-27 2003-04-10 Beiersdorf Ag Selbstschäumende, schaumförmige, nachschäumende oder schäumbare kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Wachsen bzw. bei Raumtemperatur festen und/oder halbfesten Lipiden
US7931533B2 (en) 2001-09-28 2011-04-26 Igt Game development architecture that decouples the game logic from the graphics logics
US20030185839A1 (en) 2001-10-05 2003-10-02 Podolsky Daniel K. Methods and compositions for treating dermal lesions
WO2003087277A2 (fr) 2001-10-10 2003-10-23 Exxonmobil Research And Engineering Company Huile pour engrenage non toxique et biodegradable
DE60230893D1 (de) 2001-10-26 2009-03-05 Taiyo Kagaku Kk Ölige schäumbare aerosolzusammensetzung
US20030082120A1 (en) 2001-10-26 2003-05-01 Milstein Harold J. Method for reducing systemic effects of aging, effects of aging on the skin, and incidence of skin damage from sun exposure using antibiotics of the tetracycline family
US7255869B2 (en) 2001-10-30 2007-08-14 The Procter & Gamble Company Anhydrous cosmetic compositions containing polyols
DE10154324A1 (de) 2001-11-06 2003-08-07 Merz Pharma Gmbh & Co Kgaa Topisch applizierbare Zusammensetzungen mit externer Wirkstoffdepotbildung, deren Herstellung sowie deren Verwendung
DE10155956A1 (de) 2001-11-09 2003-05-22 Beiersdorf Ag Selbstschäumende, schaumförmige, nachschäumende oder schäumbare kosmetische oder dermatologische Zubereitungen
JP2005513007A (ja) 2001-11-13 2005-05-12 ザ プロクター アンド ギャンブル カンパニー 特定の浸透圧保護剤によって安定化させた酵素を含有する組成物、及びパーソナルケアにおける前記組成物の使用方法
DE10155792A1 (de) 2001-11-14 2003-05-22 Beiersdorf Ag Selbstschäumende, schaumförmige, nachschäumende oder schäumbare kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Siloxanelastomeren
EP1565189A4 (fr) 2001-11-16 2006-11-02 Beatrice M Klysz Compositions anti-vieillissement pour le soin de la peau et leurs utilisations
DE10159002A1 (de) 2001-11-30 2003-06-18 Clariant Gmbh Verwendung von mehrphasigen Mittel zum Verschäumen aus Schaumspendern
FR2833246B1 (fr) 2001-12-06 2005-06-24 Beatrice France Touteau Dispositif pour actionner simultanement deux aerosols contenant deux produits a melanger au moment de leur utilisation
US6531118B1 (en) 2001-12-11 2003-03-11 Avon Products, Inc. Topical compositions with a reversible photochromic ingredient
MXPA04006017A (es) 2001-12-20 2005-06-08 Femmepharma Inc Suministro de farmacos por via vaginal.
US20030118515A1 (en) 2001-12-21 2003-06-26 Robert Jew Cosmetic composition containing carbon dioxide
SE0104421D0 (sv) 2001-12-21 2001-12-21 Ponsus Pharma Ab New composition
US6765001B2 (en) 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US20030129259A1 (en) 2001-12-28 2003-07-10 Avon Products, Inc. Topical lightening compostitions and methods of use
JP4549625B2 (ja) 2002-01-05 2010-09-22 株式會社アモーレパシフィック 人参サポニン代謝産物を有効成分とする微細乳化粒子及びその製造方法、並びにこれを含有する皮膚老化防止用の化粧料組成物
US7192601B2 (en) 2002-01-18 2007-03-20 Walker Edward B Antimicrobial and sporicidal composition
US6992049B2 (en) 2002-01-31 2006-01-31 Exxonmobil Research And Engineering Company Lubricating oil compositions
NZ517094A (en) 2002-02-08 2005-03-24 Advanced Animal Technology Ltd Improvements in and relating to substance delivery device
CN100396684C (zh) 2002-02-14 2008-06-25 基姆逊有限公司 铝和六亚甲基四胺复合物及其应用
US6589216B1 (en) 2002-02-20 2003-07-08 Abbott Research Group, Inc. Vaginal douches, vaginal douche applicators and methods of vaginal douching
US6682511B2 (en) 2002-02-21 2004-01-27 Robert Wallace Besoyan Brief protector
US6691898B2 (en) 2002-02-27 2004-02-17 Fomo Products, Inc. Push button foam dispensing device
WO2003075851A2 (fr) 2002-03-06 2003-09-18 Cellegy Pharmaceuticals, Inc. Compositions et methodes de traitement de troubles ano-rectaux
US20050281766A1 (en) 2002-03-11 2005-12-22 Avon Products, Inc. Method of improving the aesthetic appearance of epithelia
US6736860B2 (en) 2002-03-12 2004-05-18 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Gradual permanent coloring of hair using dye intermediates dissolved in alkaline water with fatty alcohol
CA2422244A1 (fr) 2002-03-14 2003-09-14 Homax Products, Inc. Systemes et methodes a aerosol pour le melange et la distribution de materiaux a deux elements
KR20050008659A (ko) 2002-03-19 2005-01-21 에어스프레이 인터내쇼날 비.브이. 분배 장치
US20030180347A1 (en) 2002-03-19 2003-09-25 W.F. Young, Incorporated Patch for the delivery of topical agents
WO2003082225A1 (fr) 2002-03-28 2003-10-09 Hakuto Co., Ltd. Procede de stabilisation de mousse pour mousse cosmetique
DE60308010D1 (de) 2002-04-12 2006-10-12 Dreamwell Ltd Kassetten bettsystem
US8192749B2 (en) 2003-04-16 2012-06-05 Galderma Laboratories Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US8846039B2 (en) 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US6875438B2 (en) 2002-04-27 2005-04-05 Aventis Pharma Deutschland Gmbh Preparations for topical administration of substances having antiandrogenic activity
CA2384922C (fr) 2002-05-03 2008-09-02 Purepharm Inc. Produit topique de glycopyrrolate pour reduire la transpiration
CA2500134A1 (fr) 2002-05-06 2003-11-13 Collagenex Pharmaceuticals, Inc. Procede de traitement simultane de mucosite et d'infection fongique
BR0309944A (pt) 2002-05-10 2005-02-09 Unilever Nv Composição aquosa de condicionamento de cabelos, processo para a preparação de uma composição aquosa, método para realçar a deposição de óleo de condicionamento insolúvel em água e uso de uma composição
US6783027B2 (en) 2002-05-15 2004-08-31 The Procter & Gamble Company Metered-dose underarm product and package
US20030215472A1 (en) 2002-05-16 2003-11-20 Bonda Craig A Methods and compositions employing a dialkyl amide
AU2003245295B2 (en) 2002-05-20 2008-01-03 Collagenex Pharmaceuticals, Inc. Methods of treating allergic reactions
JP4050094B2 (ja) 2002-05-28 2008-02-20 株式会社三谷バルブ 定量バルブ機構およびエアゾール製品
US6723309B1 (en) 2002-06-10 2004-04-20 Jeffrey Alan Deane Hair cleansing conditioner
US7763587B2 (en) 2002-06-13 2010-07-27 L'oreal S.A. Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process
FR2840903B1 (fr) 2002-06-13 2005-01-28 Oreal Derive de glucose et de vitamine f, compositions le comprenant et utilisations pour ameliorer l'etat des poils et des cheveux
US7163669B2 (en) 2002-06-19 2007-01-16 J.M. Huber Corporation Cosmetic compositions comprising calcium silicates
DE60335275D1 (de) 2002-06-26 2011-01-20 Daizo Co Ltd VERPACKUNGSBEHuLTER ZUM AUSTRAGEN VON MEHREREN INHALTEN, VERPACKUNGSPRODUKT MIT DEM VERPACKUNGSBEHuLRODUKTS
JP2004026605A (ja) 2002-06-27 2004-01-29 Asahi Fiber Glass Co Ltd ガラス繊維ヤーン用集束剤及びそれを用いたガラス繊維ヤーン
US20040002550A1 (en) 2002-06-28 2004-01-01 Mercurio Anthony Fred Post foaming compositions
US6785629B2 (en) 2002-07-02 2004-08-31 Agilent Technologies, Inc. Accuracy determination in bit line voltage measurements
JP3833972B2 (ja) 2002-07-08 2006-10-18 古河電気工業株式会社 ワイヤハーネスの組立システム
DE10233330B4 (de) 2002-07-22 2007-04-26 Sasol Germany Gmbh Mikroemulsion enthaltend UV-Lichtschutzfilter und/oder Antischuppenmittel
US7137536B2 (en) 2002-07-22 2006-11-21 Seaquist Perfect Dispensing Foreign, Inc. Inverted aerosol dispenser
US6897195B2 (en) 2002-07-24 2005-05-24 Nanjing Zhongshi Chemical Co. Composition of menthol and menthyl lactate, its preparation method and its applications as a cooling agent
US20020182162A1 (en) 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
FR2843373B1 (fr) 2002-08-12 2005-03-04 Jean Augustin Dispositif de conditionnement et d'application d'un produit sous forme fluide
US7939170B2 (en) 2002-08-15 2011-05-10 The Rockefeller University Water soluble metal and semiconductor nanoparticle complexes
AU2003260736B8 (en) 2002-08-26 2009-04-23 S.L.A. Pharma Ag A pharmaceutical composition
US6770607B2 (en) 2002-09-12 2004-08-03 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Viscoelastic cleansing gel with micellar surfactant solutions
US7906473B2 (en) 2002-09-13 2011-03-15 Bissell Homecare, Inc. Manual spray cleaner
GB0221697D0 (en) 2002-09-18 2002-10-30 Unilever Plc Novel compouds and their uses
US6968982B1 (en) 2002-09-18 2005-11-29 Burns Caleb E S Multiple-mist dispenser
US7179481B2 (en) 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
US6949037B2 (en) 2002-09-27 2005-09-27 Richard A. Enos Quick-release fastener for releasably attaching lacrosse stick head to shaft
FR2845672B1 (fr) 2002-10-09 2006-02-10 Airlessystems Distributeur de produit fluide
EP1567113A4 (fr) 2002-10-24 2006-11-08 G & R Pharmaceuticals Llc Preparations antifongiques
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20080317679A1 (en) 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US20160158261A1 (en) 2002-10-25 2016-06-09 Foamix Pharmaceuticals Ltd. Antibiotic Kit and Composition and Uses Thereof
US20050186142A1 (en) 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
CA2502986C (fr) 2002-10-25 2011-08-23 Foamix Ltd. Mousse cosmetique et pharmaceutique
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8119109B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20060193789A1 (en) 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
US20060233721A1 (en) 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20070292355A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US20120156144A1 (en) 2002-10-25 2012-06-21 Foamix Foamable Compositions, Kits and Methods for Hyperhidrosis
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20080031907A1 (en) 2002-10-25 2008-02-07 Foamix Ltd. Cosmetic and pharmaceutical foam
US20050205086A1 (en) 2002-10-25 2005-09-22 Foamix Ltd. Retinoid immunomodulating kit and composition and uses thereof
US20070292359A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
EP1556332B1 (fr) 2002-10-28 2016-10-05 Givaudan SA Solutions rafraichissantes et compositions les contenant
JP2004250435A (ja) 2002-11-21 2004-09-09 Dai Ichi Seiyaku Co Ltd 育毛用組成物
JP4282311B2 (ja) 2002-11-26 2009-06-17 三洋電機株式会社 製氷装置
AU2003293865A1 (en) 2002-12-12 2004-06-30 Allpresan Gesellschaft Zum Vertrieb Von Gesundheitsprodukten Fur Allergiker Mbh Stable foam cream
GB0229071D0 (en) 2002-12-13 2003-01-15 Unilever Plc Cosmetic method and composition for enhancing attractiveness
US20040191196A1 (en) 2002-12-16 2004-09-30 Dov Tamarkin Novel conjugate compounds and dermatological compositions thereof
FR2848847B1 (fr) 2002-12-18 2005-10-14 Coletica Composition cosmetique ou dermopharmaceutique comprenant une enzyme insoluble en milieu aqueux, ainsi que ses utilisations
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
FR2848998B1 (fr) 2002-12-20 2006-04-07 Oreal Dispositif de distributeur comportant des moyens permettant de distribuer deux produits dans des proportions variables
MXPA05007266A (es) 2003-01-02 2006-01-17 Femmepharma Holding Co Inc Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
WO2004064769A2 (fr) 2003-01-21 2004-08-05 Hector Herrera Methodes de production et d'utilisation d'agents d'administration topique
US7141237B2 (en) 2003-01-24 2006-11-28 Connetics Australia Pty Ltd. Pharmaceutical foam
US20040151756A1 (en) 2003-02-04 2004-08-05 Richards Anthony P. Edible low density high surface area drug vehicle, method of manufacturing low density high surface area drug vehicle
AU2004210201B2 (en) 2003-02-06 2009-10-08 Cipla Limited Topical immunotherapy and compositions for use therein
MXPA05008479A (es) 2003-02-12 2006-03-10 Connetics Australia Pty Ltd Espuma hidroalcoholica formadora de pelicula.
US6841547B2 (en) 2003-02-28 2005-01-11 Albert Einstein College Of Medicine Of Yeshevia University Method for decreasing low density lipoprotein
US20040175347A1 (en) 2003-03-04 2004-09-09 The Procter & Gamble Company Regulation of mammalian keratinous tissue using hexamidine compositions
GB0305010D0 (en) 2003-03-05 2003-04-09 Unilever Plc Changing colours
US7357950B2 (en) 2003-03-21 2008-04-15 Elizabeth Anne Mazzio Topical treatment for dyshidrosis (pompholyx) and dry skin disorders
US7488757B2 (en) 2003-03-24 2009-02-10 Becton, Dickinson And Company Invisible antimicrobial glove and hand antiseptic
US20040192754A1 (en) 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
DE10315936A1 (de) 2003-04-03 2004-10-28 Ing. Erich Pfeiffer Gmbh Austragsvorrichtung für zumindest ein Medium
GB0308585D0 (en) 2003-04-14 2003-05-21 Pz Cussons Int Ltd Cleaning composition
US20040229803A1 (en) 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
US20040220187A1 (en) 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
DE10319771B4 (de) 2003-05-02 2005-03-17 Koenig & Bauer Ag System zur Inspektion eines Druckbildes
JP2004353084A (ja) 2003-05-08 2004-12-16 Sanyo Electric Co Ltd 蒸発装置の固定部材
FR2854821B1 (fr) 2003-05-16 2006-12-08 Oreal Ensemble pour le conditionnement et la distribution d'un produit, notamment sous forme d'un echantillon
JP4232535B2 (ja) 2003-05-20 2009-03-04 セイコーエプソン株式会社 プリンタ整備システム、印刷制御サーバ、クライアント、それらに関する方法及びそれらに関するプログラム
US7222802B2 (en) 2003-05-23 2007-05-29 Meadwestvaco Corporation Dual sprayer with external mixing chamber
BR0318319A (pt) 2003-05-25 2006-07-18 Yuwan Wang métodos de preparação e formulações/composições sustentadas pelo uso de dimeticona como veìculo
US7186416B2 (en) 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US20070010580A1 (en) 2003-05-30 2007-01-11 Gianfranco De Paoli Ambrosi Formulation for chemical peeling
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
JP4018032B2 (ja) 2003-06-17 2007-12-05 高砂香料工業株式会社 毛髪及び身体洗浄剤組成物
EP1643990B8 (fr) 2003-06-18 2007-05-09 Galderma S.A. Composition pharmaceutique topique de teinte verte a base de metronidazole
US20050042182A1 (en) 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20070111956A1 (en) 2003-07-03 2007-05-17 Japan Science And Technology Agency Remedy for sarcoidosis and method of treating the same
US20070140999A1 (en) 2003-07-18 2007-06-21 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
EP1653932A1 (fr) 2003-07-24 2006-05-10 Ranbaxy Laboratories Limited Compositions a liberation modifiee de minocycline
US7226230B2 (en) 2003-07-28 2007-06-05 Raymond Liberatore Spreader
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
JP2007508243A (ja) 2003-08-04 2007-04-05 フォーミックス エルティーディー． 両親媒性コポリマーゲル化剤を含む泡坦体
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
ES2541488T3 (es) 2003-08-25 2015-07-21 Foamix Pharmaceuticals Ltd. Espuma farmacéutica penetrante
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
EP1663196A2 (fr) 2003-09-25 2006-06-07 DMI Biosciences, Inc. Methodes et produits faisant intervenir de l'acide n-acyl-l-aspartique
FR2860143B1 (fr) 2003-09-26 2008-06-27 Oreal Composition cosmetique comprenant un polymere sequence et une huile siliconee non volatile
US20050084551A1 (en) 2003-09-26 2005-04-21 Jensen Claude J. Morinda citrifolia-based oral care compositions and methods
PL1668105T3 (pl) 2003-09-29 2019-03-29 Deb Ip Limited Kompozycje żelopodobne i pieniące o dużej zawartości alkoholu
GB2406330B (en) 2003-09-29 2005-12-07 Bespak Plc A dispensing apparatus
WO2005032522A1 (fr) 2003-10-03 2005-04-14 Collegium Pharmaceutical, Inc. Mousses aerosol topiques
FR2860502B1 (fr) 2003-10-07 2007-09-14 Valois Sas Valve doseuse et dispositif de distribution de produit fluide comportant une telle valve
GB0323908D0 (en) 2003-10-11 2003-11-12 Nupharm Lab Ltd Pharmaceutical foam formulation
WO2005034903A1 (fr) 2003-10-14 2005-04-21 Showa Denko K.K. Agent a usage cutane externe contenant un sel d'un derive de l'acide ascorbique, procede de stabilisation de l'agent a usage cutane externe, et stabilisant
FR2860976B1 (fr) 2003-10-20 2006-02-10 Ravi Shrivastava Nouvelles compositions synergiques pour ameliorer la biodisponibilite et l'efficacite des acides gras polyinsatures pour le traitement des troubles du fonctionnement cerebral.
US7419498B2 (en) 2003-10-21 2008-09-02 Nmt Medical, Inc. Quick release knot attachment system
CN100475184C (zh) 2003-10-31 2009-04-08 宝洁公司 包含脱氢乙酸和护肤活性物质的护肤组合物
WO2005044214A1 (fr) 2003-11-06 2005-05-19 Unilever Plc Composition cosmetique amelioree comportant de la vitamine b3, de la vitamine b6 et un acide organique
US8157788B2 (en) 2003-11-06 2012-04-17 Paolo L. Manfredi Multi-site drug delivery platform
CA2544599A1 (fr) 2003-11-06 2005-05-26 Maria Emanuel Ryan Methodes de traitement de l'eczema
AU2006246425B2 (en) 2003-11-06 2012-03-22 Genencor International, Inc. Personal care compositions and methods for their use
EP1694283A1 (fr) 2003-11-17 2006-08-30 The Procter & Gamble Company Composition antitranspirante et applicateur associe
DE10354051A1 (de) 2003-11-17 2005-06-16 Beiersdorf Ag Spender mit kosmetischen Zubereitungen, die Hilfsmittel zur Gängighaltung des Spenders enthalten
WO2005049081A1 (fr) 2003-11-21 2005-06-02 Pfizer Products Inc. L'utilisation d'antibiotiques comme adjuvants de vaccins
US20050115988A1 (en) 2003-12-01 2005-06-02 Brian Law Multiple liquid foamer
US20050123496A1 (en) 2003-12-08 2005-06-09 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Self foaming non-aqueous personal wash cleansers with little or no surfactant
DE10361022A1 (de) 2003-12-23 2005-07-28 Merckle Gmbh Chem.-Pharm. Fabrik Topische Zubereitungen enthaltend Dimethylsulfoxid und Dexpanthenol
SG149075A1 (en) 2003-12-30 2009-01-29 Gilead Sciences Inc Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
ZA200507017B (en) 2004-02-04 2007-03-28 Foamix Ltd Cosmetic and pharmaceutical foam with solid matter
US7225518B2 (en) 2004-02-23 2007-06-05 Boston Scientific Scimed, Inc. Apparatus for crimping a stent assembly
JP4381169B2 (ja) 2004-02-27 2009-12-09 花王株式会社 毛髪化粧料
DK2656859T3 (en) 2004-03-03 2016-01-11 Revance Therapeutics Inc Topical application and transdermal delivery of the botulinum toxins
WO2005089582A2 (fr) 2004-03-18 2005-09-29 Bodypoint Designs, Inc. Support lateral pivotant et ensemble a liberation rapide pour dispositif de stabilisation sous-abdominale
DE102004016710B4 (de) 2004-04-05 2020-11-19 Greppmayr GmbH Formulierung zur Fußpflege
SI1734927T1 (sl) 2004-04-08 2012-09-28 Meda Pharma S A R L Pimekrolimusni penjen sestavek, ki vsebuje heksilenglikol, po izbiri oleil alkohol, dimetilizosorbid in/ali srednjeveriĹľne trigliceride
AU2005235308B2 (en) 2004-04-19 2011-12-01 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
NL1026031C2 (nl) 2004-04-23 2005-10-25 Airspray Nv Afgiftesamenstel.
WO2006131784A1 (fr) 2004-04-28 2006-12-14 Foamix Ltd. Mousses pour cavites corporelles
US20050244354A1 (en) 2004-04-30 2005-11-03 Sam Speron Oxygenated personal care products
JP2005314323A (ja) 2004-04-30 2005-11-10 Sato Pharmaceutical Co Ltd 育毛剤組成物
WO2005115336A2 (fr) 2004-05-15 2005-12-08 Collegium Pharmaceutical, Inc. Formulations pulverisables destinees au traitement d'etats dermiques inflammatoires aigus
US7083125B2 (en) 2004-05-17 2006-08-01 S.C. Johnson & Son, Inc. Detachable tube assembly
US7143909B2 (en) 2004-05-21 2006-12-05 Sonoco Development, Inc. Reconfigurable metered material dispenser
US8394394B2 (en) 2004-05-26 2013-03-12 L'oréal Mousse formulations
ITBO20040338A1 (it) 2004-05-28 2004-08-28 Progine Farmaceutici Srl Erogatore per nebulizzazione vaginale
US20050268416A1 (en) 2004-06-03 2005-12-08 Sommers J E Foldable lotion applicator
JP4368250B2 (ja) 2004-06-09 2009-11-18 ポーラ化成工業株式会社 ポスト・フォーム剤形の温感化粧料
FR2871698B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques et une phase huileuse
FR2871696B1 (fr) 2004-06-17 2006-11-10 Galderma Sa Composition topique pour le traitement du psoriasis
US8211449B2 (en) 2004-06-24 2012-07-03 Dpt Laboratories, Ltd. Pharmaceutically elegant, topical anhydrous aerosol foam
JP4355264B2 (ja) 2004-06-25 2009-10-28 ポーラ化成工業株式会社 温感非水フォーム化粧料
US7207655B2 (en) 2004-06-28 2007-04-24 Eastman Kodak Company Latency stirring in fluid ejection mechanisms
US6991789B2 (en) 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
US20060121073A1 (en) 2004-07-12 2006-06-08 Sandhya Goyal Topical gel formulation comprising insecticide and its preparation thereof
US7288692B2 (en) * 2004-07-14 2007-10-30 Exxonmobil Chemcial Patents Inc. Process for producing olefins
WO2006011046A1 (fr) 2004-07-19 2006-02-02 Warner-Lambert Company Llc Formulation pour stimuler la croissance des cheveux
WO2006010589A2 (fr) 2004-07-29 2006-02-02 Mipharm S.P.A. Mousse en gel post-moussant
JP4557624B2 (ja) 2004-07-29 2010-10-06 株式会社吉野工業所 定量注出器
US20060029565A1 (en) 2004-08-09 2006-02-09 The Gillette Company Self-heating shave foam product
JP5087773B2 (ja) 2004-08-12 2012-12-05 トリアクセス テクノロジーズ インコーポレイテッド 光信号検出回路及び方法
KR101243526B1 (ko) 2004-08-31 2013-03-20 스티펠 리서치 오스트레일리아 피티와이 리미티드 마이크로에멀젼 및 서브마이크론 에멀젼 방법 및 조성물
KR100623013B1 (ko) 2004-09-04 2006-09-19 김영대 나노에멀션, 그의 용도 및 제조방법
ES2729826T3 (es) 2004-09-23 2019-11-06 Arc Medical Devices Inc Composiciones farmacéuticas y métodos relacionados para inhibir adherencias fibrosas o enfermedad inflamatoria usando fucanos con bajo contenido de sulfato
WO2006035320A2 (fr) 2004-09-27 2006-04-06 Jan De Rijk Procedes et compositions de matieres pour le traitement de l'eau
FR2875797B1 (fr) 2004-09-30 2006-11-24 Oreal Ensemble de distribution destine a la distribution extemporanee de deux produits
BRPI0404595A (pt) 2004-10-26 2006-06-13 Natura Cosmeticos Sa nanoemulsão óleo-em-água, composição cosmética e produto cosmético compreendendo a mesma, processo para preparação da dita nanoemulsão
DE102004052986A1 (de) 2004-11-02 2006-05-04 Lindal Ventil Gmbh Vorrichtung zum Mischen von zwei unterschiedlichen Komponenten
US7350673B2 (en) 2004-11-19 2008-04-01 Glynntech, Inc. Metered dose squeeze dispenser
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
FR2880802B1 (fr) 2005-01-14 2008-12-19 Sederma Soc Par Actions Simpli Composition cosmetique ou dermopharmaceutique contenant un extrait d'euglene
WO2006081327A2 (fr) 2005-01-25 2006-08-03 University Of Vermont And State Agricultural College Petites molecules limitant la croissance fongique
BRPI0607038A2 (pt) 2005-01-28 2009-12-01 Basf Ag uso de polìmeros composições cosméticas para cabelo, e para pele, e, composição dermatólogica
US20060177392A1 (en) 2005-02-10 2006-08-10 William Walden Oil-based composition for acne
US20060193813A1 (en) 2005-02-11 2006-08-31 L'oreal Nanoemulsion containing a hydroxylated urea compound
GB0506141D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A topical compostion and its uses
WO2006099687A1 (fr) 2005-03-24 2006-09-28 Ensign Laboratories Pty Ltd Spray aerosol solaire
US20060222675A1 (en) 2005-03-29 2006-10-05 Sabnis Ram W Personal care compositions with color changing indicator
US20070069046A1 (en) 2005-04-19 2007-03-29 Foamix Ltd. Apparatus and method for releasing a measure of content from a plurality of containers
US20060285912A1 (en) 2005-04-19 2006-12-21 Foamix Ltd. Apparatus and method for releasing a measured amount of content from a container
WO2006122158A2 (fr) 2005-05-10 2006-11-16 Xanthone Plus International, Llc Compositions de soin de la peau contenant des xanthones
BRPI0609630A2 (pt) 2005-05-10 2010-04-20 Dermipsor Ltd composições e métodos para tratamento de doenças epidérmicas hiperproliferativas
ES2447301T3 (es) 2005-06-01 2014-03-11 Glaxosmithkline Intellectual Property Development Limited Formulación vitamínica
US20060272199A1 (en) 2005-06-02 2006-12-07 Bmc Manufacturing, Llc Aqueous gel candle for use with a warming device
US8211874B2 (en) 2005-06-03 2012-07-03 Galderma Laboratories Inc. Inhibition of thrombin generation
AU2006339311A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
WO2007085899A2 (fr) 2005-07-06 2007-08-02 Foamix Ltd. Compositions insecticides non inflammables et utilisations
US20070015738A1 (en) 2005-07-15 2007-01-18 Walker Stephen G Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells
EP2862561B1 (fr) 2005-07-18 2019-10-30 The Procter and Gamble Company Procédé de condionnement des cheveux avec une mousse aérosol crémeuse
WO2007085902A2 (fr) 2005-07-19 2007-08-02 Foamix Ltd. Composition moussante combinant un solvant polaire et un vecteur hydrophobe
US20080152596A1 (en) 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
ATE410997T1 (de) 2005-07-22 2008-10-15 Wella Ag Haarbehandlungsmethode mit einem trockenem schaum,der als ein mechanischer träger verwendet wird
EP1951200A2 (fr) 2005-08-09 2008-08-06 Nanobio Corporation Compositions de nano-émulsion ayant une activité anti-inflammatoire
CA2632183A1 (fr) 2005-08-25 2007-03-01 Philip R. Houle Solutions sensibilisantes ameliorees, systemes, et procedes d'utilisation
FR2890559B1 (fr) 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour la preparation
DE202006004676U1 (de) 2005-09-28 2007-02-08 Neubourg Skin Care Gmbh & Co. Kg Hautpflegeprodukte
EP2108360A3 (fr) 2005-10-24 2010-06-09 Collegium Pharmaceutical, Inc. Composition de mousse pharmaceutique topique
US20070134174A1 (en) 2005-11-03 2007-06-14 Christopher Irwin Personal care composition
JP2007131539A (ja) 2005-11-08 2007-05-31 Koike Kagaku Kk 冷感泡沫化粧料
US20070148194A1 (en) 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
JP4885529B2 (ja) 2005-12-08 2012-02-29 住友重機械工業株式会社 放射線検出ユニットおよび放射線検査装置
US20070160548A1 (en) 2005-12-13 2007-07-12 Playtex Products, Inc. Moisturizing sunless tanning composition
US20070142263A1 (en) 2005-12-15 2007-06-21 Stahl Katherine D Color changing cleansing composition
US20070148112A1 (en) 2005-12-28 2007-06-28 Avon Products, Inc. Foaming, color-changing topical composition and method of imparting a cosmetic effect
EP1981480A1 (fr) 2006-01-19 2008-10-22 Disphar International B.V. Composition moussante
US20070166273A1 (en) 2006-01-19 2007-07-19 Krivulka Joseph J Skin treatment educational kit
CA2645073A1 (fr) 2006-03-08 2007-09-13 Nuviance, Inc. Composition de medicament a liberation transdermique et compositions topiques pour application cutanee
US20070224143A1 (en) 2006-03-21 2007-09-27 Kamedis Ltd. Cosmetic and pharmaceutical foam carrier
US8580725B2 (en) 2006-03-22 2013-11-12 The Procter & Gamble Company Aerosol product comprising a foaming concentrate composition comprising particulate materials
US7252816B1 (en) 2006-03-29 2007-08-07 Dow Pharmaceutical Sciences Topical acne vulgairs medication with a sunscreen
AU2007273935B2 (en) 2006-03-31 2011-08-18 Stiefel Research Australia Pty Ltd Foamable suspension gel
WO2008075207A2 (fr) 2006-04-04 2008-06-26 Foamix Ltd. Composition expansible d'augmentation anti-infectieuse, et kits et utilisations de celle-ci
US20070264317A1 (en) 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
US20070281999A1 (en) 2006-05-31 2007-12-06 The Dial Corporation Alcohol-containing antimicrobial compositions having improved efficacy
JP4892282B2 (ja) 2006-06-09 2012-03-07 アルプス電気株式会社 電気接点用潤滑組成物
WO2008110872A2 (fr) * 2006-06-23 2008-09-18 Foamix Ltd. Compositions moussantes et kits comprenant un ou plusieurs parmi un agent de canal, un agent cholinergique, un donneur d'oxyde nitrique et des agents apparentés, et leurs utilisations
DK2494959T3 (en) 2006-07-05 2015-02-23 Foamix Pharmaceuticals Ltd Foam Bart dicarboxylsyrebærestof and pharmaceutical compositions thereof
NO343857B1 (no) 2006-07-18 2019-06-24 Meda Ab Immunresponsmodifiserende skumformuleringer
US20080031908A1 (en) 2006-07-25 2008-02-07 L'oreal Oily cosmetic composition in aerosol form
JP2008040899A (ja) 2006-08-08 2008-02-21 Fuji Xerox Co Ltd 印刷制御装置、プログラム及び方法
EA200970260A1 (ru) 2006-09-08 2009-08-28 Фоамикс Лтд. Окрашенная или окрашиваемая и вспениваемая композиция и пена
ES2315123B1 (es) 2006-09-25 2009-12-30 Divasa-Farmavic, S.A. Composiciones farmaceuticas estables de tetraciclinas en solucion, procedimiento para su obtencion y sus usos.
HUP0600765A2 (en) 2006-10-06 2008-10-28 Istvan Piller Container for stable carbondioxide foam, process for producing stable carbondioxide foam and method for using of foam
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
WO2009007785A2 (fr) 2006-11-14 2009-01-15 Foamix Ltd. Compositions d'émulsion pharmaceutiques moussantes, stables et non alcooliques, contenant un émollient onctueux et leurs utilisations
AU2007355106A1 (en) 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
CN101557796A (zh) 2006-12-15 2009-10-14 宝洁公司 护肤组合物
US20080153789A1 (en) 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
US20080292560A1 (en) 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
AU2008206982A1 (en) 2007-01-16 2008-07-24 Oystershell N.V. Foamable composition for killing arthropods and uses thereof
US20080188446A1 (en) 2007-02-02 2008-08-07 Warner Chilcott Company Inc. Tetracycline compositions for topical administration
WO2008097850A1 (fr) 2007-02-02 2008-08-14 Warner Chilcott Company, Inc. Compositions de tétracycline pour une administration topique
PT103661B (pt) 2007-02-23 2010-09-07 Hovione Farmaciencia S A Processo de preparação de minociclina base cristalina
GB0703909D0 (en) 2007-02-28 2007-04-11 Neuropharm Ltd Treatment of anxiety disorders
FR2915891B1 (fr) 2007-05-10 2012-05-11 Oreal Composition sous forme de mousse comprenant un polymere silicone
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009056991A2 (fr) 2007-09-04 2009-05-07 Foamix Ltd. Dispositif de distribution d'une composition expansible
US20090130029A1 (en) 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
WO2009069006A2 (fr) 2007-11-30 2009-06-04 Foamix Ltd. Peroxyde de benzoyle contenant de la mousse
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (fr) 2007-12-07 2009-06-11 Foamix Ltd. Porteurs, formulations, procédés pour formuler des agents actifs instables pour application externe et utilisations associées
CA2711703A1 (fr) 2008-01-08 2009-07-16 Foamix Ltd. Mousse de composition topique modifiant la sensation
AU2009205314A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8652443B2 (en) 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
RU2547441C2 (ru) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
US20120141384A1 (en) 2008-05-06 2012-06-07 Dov Tamarkin Antibacterial conjugated boronic acids and pharmaceutical compositions thereof
JP5070340B2 (ja) 2008-08-07 2012-11-14 シャープ株式会社 表示装置
KR101616663B1 (ko) 2008-08-08 2016-04-28 인터디지탈 패튼 홀딩스, 인크 버퍼 상태를 보고하기 위한 방법 및 장치
ATE500817T1 (de) 2008-12-23 2011-03-15 Intendis Gmbh Schäumbare zusammensetzung, die im wesentlichen frei von pharmazeutisch aktiven inhaltsstoffen ist, zur behandlung der menschlichen haut
JP5213734B2 (ja) 2009-01-22 2013-06-19 サンウエーブ工業株式会社 フラップ扉付きキャビネット
CA2752070C (fr) 2009-02-12 2017-11-28 Precision Dermatology, Inc. Compositions moussantes de peroxyde de benzoyle pour administration topique
AU2010217190B2 (en) 2009-02-25 2012-10-25 Mayne Pharma Llc Topical foam composition
WO2010124280A2 (fr) 2009-04-24 2010-10-28 New Century Pharmaceuticals, Inc. Onguent topique à base de sérum-albumine humaine pour le traitement de l'acné, du psoriasis, de la toxicité induite par egfr, le vieillissement prématuré de la peau et autres affections cutanées
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
PT104644B (pt) 2009-06-26 2012-11-06 Hovione Farmaciencia S A Formulação tópica contendo uma tetraciclina e método de tratamento de infecções cutâneas usando a mesma
US8255186B2 (en) 2009-07-09 2012-08-28 Air Liquide Large Industries U.S. Lp Presenting dynamic SCADA data
CA2769625C (fr) 2009-07-29 2017-04-11 Foamix Ltd. Compositions hydro-alcooliques moussantes non tensioactives, mousses legeres, et leurs utilisations
CA2769677A1 (fr) 2009-07-29 2011-02-03 Foamix Ltd. Compositions hydro-alcooliques moussantes a base d'agents non tensioactifs non polymeres, mousses legeres, et leurs utilisations
WO2011026094A2 (fr) 2009-08-31 2011-03-03 Collegium Pharmaceutical, Inc. Mousses aérosols stables destinées à la voie topique et comprenant un sel d'hypochlorite
US20140186269A1 (en) 2013-01-03 2014-07-03 Foamix Ltd. Vehicle compositions essentially free of pharmaceutically active agents for the improved treatment of acne and related disorders
US20140121188A1 (en) 2009-10-02 2014-05-01 Foamix Ltd. Compositions for the improved treatment of acne and related disorders
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
GB2474930B (en) 2009-10-02 2012-07-04 Foamix Ltd Topical tetracycline compositions
WO2011138678A2 (fr) 2010-05-04 2011-11-10 Foamix Ltd. Compositions, gels et mousses comprenant des modulateurs de rhéologie et leurs utilisations
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8735377B1 (en) 2010-02-04 2014-05-27 Susan Anna Sipos Methods of treating herpes zoster
US20110212035A1 (en) 2010-02-26 2011-09-01 Collegium Pharmaceutical, Inc. Emollient foams for treatment of dermatoses
WO2011115700A2 (fr) 2010-03-18 2011-09-22 Precision Dermatology, Inc. Mousses émollientes pour le traitement de dermatite séborrhéique
US8592380B2 (en) 2010-03-26 2013-11-26 Precision Dermatology, Inc. Aerosol foams comprising clindamycin phosphate
US20120070390A1 (en) 2010-04-21 2012-03-22 Phillips D Howard Topical drug delivery system with dual carriers
US8784780B2 (en) 2010-06-11 2014-07-22 Precision Dermatology, Inc. High oil-content emollient aerosol foam compositions
WO2012007843A2 (fr) 2010-07-12 2012-01-19 Foamix Ltd. Appareil et procédé pour éjecter une dose unitaire de contenu d'un récipient
US9289400B2 (en) 2010-08-11 2016-03-22 Drexel University D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
BR112013018352A2 (pt) 2011-01-19 2019-08-27 Laboratory Skin Care Inc composição de minociclina tópica e método
WO2013009586A1 (fr) 2011-07-08 2013-01-17 The Research Foundation Of State University Of New York Onguent topique de minocycline pour la suppression de réactions allergiques cutanées
JP2014532717A (ja) 2011-11-03 2014-12-08 プレシジョン ダーマトロジー インコーポレイテッドＰｒｅｃｉｓｉｏｎ Ｄｅｒｍａｔｏｌｏｇｙ， Ｉｎｃ． 反応性噴射剤を使用した安定な皮膚用エアゾールフォーム
US8801680B2 (en) 2012-03-14 2014-08-12 Becton, Dickinson And Company Angled retracting sheath for safety needle
IL225239A0 (en) 2012-03-15 2013-06-27 Meir Eini Compounds for the treatment of acne and related diseases
KR20140134712A (ko) 2012-03-22 2014-11-24 프리시전 더마톨로지, 인크. 시클로덱스트린 기재의 마이크로에멀젼 및 그의 피부과용 용도
CA2775393C (fr) 2012-05-02 2014-04-29 Samy Saad Formulations pharmaceutiques topiques non aqueuses
CA2878462A1 (fr) 2012-07-13 2014-01-16 Paratek Pharmaceuticals, Inc. Composes tetracycline destines a traiter des troubles neurodegeneratifs
PT106679B (pt) 2012-11-27 2015-03-25 Hovione Farmaciencia Sa Formulações tópicas de tetraciclinas, sua preparação e usos
CN105050584A (zh) 2013-02-28 2015-11-11 普雷西恩护肤公司 具有提高的生物利用度的皮质类固醇的局部制剂
WO2014134427A1 (fr) 2013-02-28 2014-09-04 Precision Dermatology, Inc. Régulation de la biodisponibilité d'ingrédients actifs dans des formulations topiques
WO2014151347A1 (fr) 2013-03-15 2014-09-25 Revance Therapeutics, Inc. Dérivés de la minocycline
CA2915206A1 (fr) 2013-06-17 2014-12-24 Contract Pharmaceuticals Limited Mousses non aerosol pour l'administration topique
US9474720B2 (en) 2013-11-04 2016-10-25 BioPharmX, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
US20160287614A1 (en) 2013-11-20 2016-10-06 Lupin Limited Stable Pharmaceutical Formulation(s) of Tetracycline Antibiotic
PT107433B (pt) 2014-01-28 2018-12-04 Hovione Farm S A Processo de redução e controlo do tamanho de partícula
WO2015153864A2 (fr) 2014-04-02 2015-10-08 Hopkins Patricia T Méthodes de traitement d'états inflammatoires

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2586287A (en) * 1948-12-11 1952-02-19 Colagte Palmolive Peet Company Aluminum sulfamate antiperspirant preparation
US2968628A (en) * 1958-10-17 1961-01-17 Shulton Inc Propellant composition
US3334147A (en) * 1962-02-28 1967-08-01 Economics Lab Defoaming and surface active compositions
US3298919A (en) * 1962-12-26 1967-01-17 Dow Corning Shaving cream containing polysiloxanes
US3236457A (en) * 1963-08-21 1966-02-22 John R Kennedy Composite spray container assembly
US3369034A (en) * 1964-04-27 1968-02-13 Eversharp Inc Process for separating saponifiables and unsaponifiables in marine animal oils
US3303970A (en) * 1964-07-14 1967-02-14 Jerome Marrow Device for simultaneously dispensing from plural sources
US3301444A (en) * 1965-08-12 1967-01-31 Oel Inc Aerosol metering valve
US3366494A (en) * 1967-02-15 1968-01-30 Du Pont Pressurized aerosol food emulsions
US3561262A (en) * 1967-10-26 1971-02-09 Magnaflux Corp Water soluble developer
US3563098A (en) * 1968-06-28 1971-02-16 Rex Chainbelt Inc Automatic quick release mechanism
US3559890A (en) * 1968-09-03 1971-02-02 William R Brooks Foam dispenser
US3866800A (en) * 1969-02-12 1975-02-18 Alberto Culver Co Non-pressurized package containing self-heating products
US4001391A (en) * 1969-04-18 1977-01-04 Plough, Inc. Means for depositing aerosol sprays in buttery form
US3787566A (en) * 1969-07-29 1974-01-22 Holliston Labor Inc Disinfecting aerosol compositions
US4001442A (en) * 1973-07-18 1977-01-04 Elastin-Werk Aktiengesellschaft Collagen-containing preparations
US3865275A (en) * 1973-07-30 1975-02-11 Raymond Lee Organization Inc Apparatus for operating an aerosol can
US4252787A (en) * 1976-12-27 1981-02-24 Cambridge Research And Development Group Anti-fertility composition and method
US4310510A (en) * 1976-12-27 1982-01-12 Sherman Kenneth N Self administrable anti-fertility composition
US4309995A (en) * 1980-01-28 1982-01-12 Sacco Susan M Vaginal irrigation apparatus
US4427670A (en) * 1980-03-27 1984-01-24 Mitsubishi Chemical Industries Limited Skin preparation
US5089252A (en) * 1982-01-15 1992-02-18 L'oreal Cosmetic composition for treating keratin fibres, and process for treating the latter
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US4981679A (en) * 1983-06-08 1991-01-01 Briggs Joseph H Method and composition for the treatment of burns
US4725609A (en) * 1983-11-21 1988-02-16 Burroughs Wellcome Co. Method of promoting healing
US4985459A (en) * 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4798682A (en) * 1985-06-18 1989-01-17 Henkel Kommanditgesellschaft Auf Aktien Oil-in-water emulsions with increased viscosity under shear stress
US4806262A (en) * 1985-08-14 1989-02-21 The Procter & Gamble Company Nonlathering cleansing mousse with skin conditioning benefits
US4804674A (en) * 1986-03-26 1989-02-14 Euroceltique, S.A. Vaginal pharmaceutical composition
US4808388A (en) * 1986-08-20 1989-02-28 Merz + Co. Gmbh & Co. Foamable creams
US4993496A (en) * 1987-07-06 1991-02-19 Total Walther Feuerschutz Gmbh Quick release valve for sprinkler head
US4981677A (en) * 1987-09-23 1991-01-01 L'oreal Petrolatum-containing aerosol foam concentrate
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4897262A (en) * 1988-03-22 1990-01-30 Playtex Jhirmack, Inc. Non-aerosol hair spray composition
US5385943A (en) * 1988-03-30 1995-01-31 Schering Aktiengesellschaft Use of topically applicable preparations for treatment of presbyderma
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5378730A (en) * 1988-06-09 1995-01-03 Alza Corporation Permeation enhancer comprising ethanol and monoglycerides
US4902281A (en) * 1988-08-16 1990-02-20 Corus Medical Corporation Fibrinogen dispensing kit
US4981845A (en) * 1988-09-09 1991-01-01 Chesebrough Pond's U.S.A. Co., Division Of Conopco, Inc. Cosmetic composition
US5082651A (en) * 1989-04-26 1992-01-21 Smith Kline & French Laboratories Limited Pharmaceutical compositions
US4981367A (en) * 1989-07-28 1991-01-01 Stranco, Inc. Portable mixing apparatus
US5378451A (en) * 1989-10-19 1995-01-03 Dow B. Hickam, Inc. Topical medicinal pressurized aerosol compositions and method of preparation, method of use and article of manufacture thereof
US5866040A (en) * 1990-06-15 1999-02-02 Shiseido Company, Ltd. Complex and emulsified composition
US5091111A (en) * 1990-09-19 1992-02-25 S. C. Johnson & Son, Inc. Aqueous emulsion and aersol delivery system using same
US5286475A (en) * 1990-11-09 1994-02-15 L'oreal Anhydrous cosmetic composition in the aerosol form forming a foam
US5279819A (en) * 1991-03-18 1994-01-18 The Gillette Company Shaving compositions
US5482965A (en) * 1991-03-19 1996-01-09 Rajadhyaksha; Vithal J. Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers for physiological active agents
US5389676A (en) * 1991-03-22 1995-02-14 E. B. Michaels Research Associates, Inc. Viscous surfactant emulsion compositions
US5380761A (en) * 1991-04-15 1995-01-10 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Transdermal compositions
US5719122A (en) * 1992-10-20 1998-02-17 Smithkline Beecham Farmaceutici S.P.A. Pharmaceutical compositions containing a calcitonin
US5491245A (en) * 1993-03-26 1996-02-13 Th. Goldschmidt Ag Method for the synthesis of amphoteric surfactants
US5384308A (en) * 1993-06-14 1995-01-24 Henkin; R. I. Composition and method for enhancing wound healing
US5603940A (en) * 1993-10-08 1997-02-18 L'oreal Oil-in-water emulsion which may be used for obtaining a cream
US5597560A (en) * 1994-05-17 1997-01-28 Laboratorios Cusi, S.A. Diclofenac and tobramycin formulations for ophthalmic and otic topicaluse
US5605679A (en) * 1994-06-03 1997-02-25 L'oreal Photoprotective/cosmetic compositions comprising at least one solid organic sunscreen compound and diphenylacrylate solvent therefor
US5869529A (en) * 1994-07-20 1999-02-09 Agis Industries (1983) Ltd. Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus
US6187290B1 (en) * 1994-12-06 2001-02-13 Giltech Limited Physiologically acceptable foamable formulation and foam
USRE38964E1 (en) * 1995-01-09 2006-01-31 Becton Dickinson And Company One hand needle release system
US6019967A (en) * 1995-01-26 2000-02-01 Societe L'oreal S.A. Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
US6030630A (en) * 1995-12-29 2000-02-29 Rhodia Chimie Cosmetic compositions for the hair or skin based on sulfone copolyesters with polyorganosiloxane units
US5716611A (en) * 1996-01-02 1998-02-10 Euro-Celtique, S.A. Emollient antimicrobial formulations containing povidone iodine
US6024942A (en) * 1996-02-09 2000-02-15 The Procter & Gamble Company Photoprotective compositions
US5716621A (en) * 1996-07-03 1998-02-10 Pharmadyn, Inc. Nonocclusive drug delivery device and process for its manufacture
US6180669B1 (en) * 1996-11-12 2001-01-30 Tamarkin Pharmaceutical Innovation Ltd. Method for treatment of dermatological disorders
US6171347B1 (en) * 1996-11-16 2001-01-09 Wella Aktiengesellschaft Compositions, methods and kits for reductively removing color from dyed hair
US5856452A (en) * 1996-12-16 1999-01-05 Sembiosys Genetics Inc. Oil bodies and associated proteins as affinity matrices
US5858371A (en) * 1997-02-05 1999-01-12 Panacea Biotech Limited Pharmaceutical composition for the control and treatment of anorectal and colonic diseases
US6183762B1 (en) * 1997-05-27 2001-02-06 Sembiosys Genetics Inc. Oil body based personal care products
US20060018938A1 (en) * 1997-08-18 2006-01-26 Stephanie Neubourg Foam skin cream, use of the foam skin protection cream and a process of its preparation
US5865347A (en) * 1997-10-27 1999-02-02 William T. Wilkinson Multi-chamber dispenser for flowable materials
US5871720A (en) * 1997-11-20 1999-02-16 Colgate-Palmolive Company Cosmetic compositions with DBS and functionalized silicones
US20020013481A1 (en) * 1998-02-24 2002-01-31 Uwe Schonrock Use of flavones flavanones and flavonoids for protecting ascorbic acid and/or ascorbyl compounds from oxidation
US6189810B1 (en) * 1998-10-07 2001-02-20 Sergei Alexeevich Nerushai Method for aerosol spraying liquid perfume products
US6335022B1 (en) * 1998-12-17 2002-01-01 L'oreal Nanoemulsion based on oxyethylenated or non-oxyethylenated sorbitan fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields
US6672483B1 (en) * 1999-02-05 2004-01-06 Rexam Sofab Dispenser for chemically unstable products
US6168576B1 (en) * 1999-05-24 2001-01-02 Irene N. Reynolds Device for dispensing vaginal medication
US6190365B1 (en) * 1999-06-21 2001-02-20 Chun Lim Abbott Vaginal douche applicator and method of vaginal deodorization using the same
US6511655B1 (en) * 1999-08-16 2003-01-28 Beiersdorf Ag Cosmetic or dermatological preparations of the oil-in-water type
US20030006193A1 (en) * 1999-09-06 2003-01-09 Katsunori Ikeda Apparatus for purifying nucleic acids and proteins
US20020004063A1 (en) * 1999-09-28 2002-01-10 Jie Zhang Methods and apparatus for drug delivery involving phase changing formulations
US6186367B1 (en) * 1999-10-19 2001-02-13 Valley Design Inc. Metered liquid squeeze dispenser
US6341717B2 (en) * 2000-04-01 2002-01-29 Megaplast Gmbh & Co. Kg Metering pump dispenser with at least two metering pumps
US20020002151A1 (en) * 2000-05-23 2002-01-03 Showa Yakuhin Kako Co., Ltd. Minocycline-containing compositions
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US6682726B2 (en) * 2001-04-30 2004-01-27 The Gillette Company Self-foaming shaving lotion
US20080015263A1 (en) * 2002-02-27 2008-01-17 Bolotin Elijah M Compositions for delivery of therapeutics and other materials
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20070020213A1 (en) * 2002-10-25 2007-01-25 Foamix Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20070020304A1 (en) * 2002-10-25 2007-01-25 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US6843390B1 (en) * 2003-03-17 2005-01-18 Joe G. Bristor Multiple fluid closed system dispensing device
US20050002976A1 (en) * 2003-06-19 2005-01-06 The Procter & Gamble Company Polyol-in-silicone emulsions
US20110002857A1 (en) * 2003-08-04 2011-01-06 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
US7645803B2 (en) * 2005-05-09 2010-01-12 Foamix Ltd. Saccharide foamable compositions
US20070009607A1 (en) * 2005-07-11 2007-01-11 George Jones Antibacterial/anti-infalmmatory composition and method
US20070017696A1 (en) * 2005-07-22 2007-01-25 Hon Hai Precision Industry Co., Ltd. Multi-layer printed circuit board
US20080008397A1 (en) * 2006-07-04 2008-01-10 Pavel Kisilev Feature-aware image defect removal
US20080015271A1 (en) * 2006-07-14 2008-01-17 Stiefel Research Austrialia Pty Ltd Fatty acid pharmaceutical foam
US20110002969A1 (en) * 2008-02-29 2011-01-06 Lipotec, S.A. Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Schmolka (A Review of Block Polymer Surfactants, March 1977, Journal of the American Oil Chemist's Society, Volume 54, pages 110-116) *

Cited By (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8741265B2 (en) * 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8703105B2 (en) 2003-08-04 2014-04-22 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8114385B2 (en) 2003-08-04 2012-02-14 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9427605B2 (en) 2005-03-24 2016-08-30 Novan, Inc. Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US10610561B2 (en) * 2008-08-18 2020-04-07 Zhongshan Hospital of Fudan University Ceramide production-accelerating agent
US20110207765A1 (en) * 2008-10-31 2011-08-25 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
US9012477B2 (en) 2009-01-06 2015-04-21 Nuvo Research Inc. Method of treating neuropathic pain
US20110015229A1 (en) * 2009-01-06 2011-01-20 Jie Zhang Method of treating neuropathic pain
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US20120202891A1 (en) * 2009-04-29 2012-08-09 University Of Kentucky Research Foundation Cannabinoid-Containing Compositions and Methods for Their Use
WO2010143186A1 (fr) * 2009-06-08 2010-12-16 Otic Pharma Ltd. Préparations de mousse otique
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US9737561B2 (en) 2009-08-21 2017-08-22 Novan, Inc. Topical gels and methods of using the same
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US10376538B2 (en) 2009-08-21 2019-08-13 Novan, Inc. Topical gels and methods of using the same
US11583608B2 (en) 2009-08-21 2023-02-21 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8865139B1 (en) * 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US12138311B2 (en) 2009-10-02 2024-11-12 Journey Medical Corporation Topical tetracycline compositions
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
AU2015224534B2 (en) * 2009-10-02 2017-06-08 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US20120322776A1 (en) * 2009-12-22 2012-12-20 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
WO2011088333A3 (fr) * 2010-01-14 2011-11-24 Zars Pharma, Inc. Formulations pour anesthésie locale se solidifiant pour la gestion de la douleur
AU2011205730C1 (en) * 2010-01-14 2014-10-09 Nuvo Research Inc. Solid-forming local anesthetic formulations for pain control
US10603293B2 (en) 2010-01-14 2020-03-31 Crescita Therapeutics Inc. Solid-forming local anesthetic formulations for pain control
US20120022158A1 (en) * 2010-01-14 2012-01-26 Zars Pharma, Inc. Solid-forming local anesthetic formulations for pain control
US10751305B2 (en) 2010-01-14 2020-08-25 Crescita Therapeutics Inc. Solid-forming topical formulations for pain control
US9693976B2 (en) * 2010-01-14 2017-07-04 Crescita Therapeutics Inc. Solid-forming local anesthetic formulations for pain control
AU2011205730B2 (en) * 2010-01-14 2014-05-29 Nuvo Research Inc. Solid-forming local anesthetic formulations for pain control
US10350180B2 (en) * 2010-01-14 2019-07-16 Crescita Therapeutics Inc. Solid-forming local anesthetic formulations for pain control
CN101785766B (zh) * 2010-01-26 2011-10-19 江苏天济药业有限公司 一种利多卡因氯己定气雾剂
CN102892408A (zh) * 2010-04-01 2013-01-23 帕玛内斯特公司 适于局部麻醉剂的无水药物组合物
WO2011121034A3 (fr) * 2010-04-01 2012-05-31 Pharmanest Ab Compositions pharmaceutiques sans eau appropriées à des anesthésiques locaux
US10130640B2 (en) * 2010-06-11 2018-11-20 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US20130123720A1 (en) * 2010-06-11 2013-05-16 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
US10688108B2 (en) 2010-06-11 2020-06-23 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10716799B2 (en) 2010-06-11 2020-07-21 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10660908B2 (en) 2010-06-11 2020-05-26 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10617698B2 (en) 2010-06-11 2020-04-14 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
US9119781B2 (en) * 2010-06-11 2015-09-01 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US20150313919A1 (en) * 2010-06-11 2015-11-05 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
US20150335575A1 (en) * 2010-06-11 2015-11-26 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
US10682364B2 (en) 2010-06-11 2020-06-16 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
US9566286B2 (en) * 2010-06-11 2017-02-14 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US20170065618A1 (en) * 2010-06-11 2017-03-09 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
US20120039818A1 (en) * 2010-08-10 2012-02-16 Joyce Labs, LLC (Delaware corp.) Anti-chafing aerosol powder
US8778406B2 (en) * 2010-08-10 2014-07-15 Joyce Labs, Llc Anti-chafing aerosol powder
WO2012099962A3 (fr) * 2011-01-18 2012-09-27 Vicus Therapeutics, Llc Compositions pharmaceutiques et leurs procédés de fabrication et d'utilisation
US10265334B2 (en) 2011-07-05 2019-04-23 Novan, Inc. Anhydrous compositions
US9757397B2 (en) 2011-07-05 2017-09-12 Novan, Inc. Methods of manufacturing topical compositions and apparatus for the same
US10500220B2 (en) 2011-07-05 2019-12-10 Novan, Inc. Topical compositions
WO2013025449A1 (fr) * 2011-08-16 2013-02-21 Merck Sharp & Dohme Corp. Utilisation de matrice inorganique et de combinaisons de polymères organiques pour la préparation de dispersions amorphes stables
US10588832B2 (en) 2011-10-11 2020-03-17 Fallien Cosmeceuticals, Ltd. Foamable sunscreen formulation
US10576026B2 (en) 2011-10-11 2020-03-03 Fallien Cosmeceuticals, Ltd. Sunscreen formulation
US11077030B2 (en) 2011-10-11 2021-08-03 Fallien Cosmeceuticals, Ltd. Sunscreen formulation
US11911491B2 (en) 2011-10-11 2024-02-27 Fallien Cosmeceuticals, Ltd. Sunscreen formulation
US11077194B2 (en) 2012-03-14 2021-08-03 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
US11285098B2 (en) 2013-02-28 2022-03-29 Novan, Inc. Topical compositions and methods of using the same
US10258564B2 (en) 2013-02-28 2019-04-16 Novan, Inc. Topical compositions and methods of using the same
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US9408877B1 (en) 2013-04-12 2016-08-09 Marcia Patricia Cox Compositions and process for skin restoration
US10226483B2 (en) 2013-08-08 2019-03-12 Novan, Inc. Topical compositions and methods of using the same
US10828323B2 (en) 2013-08-08 2020-11-10 Novan, Inc. Topical compositions and methods of using the same
US10206947B2 (en) 2013-08-08 2019-02-19 Novan, Inc. Topical compositions and methods of using the same
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
CN103463532A (zh) * 2013-08-22 2013-12-25 岳冀 一种治疗疼痛型急性颈部淋巴结炎的中药制备方法
WO2015044857A1 (fr) * 2013-09-25 2015-04-02 Ranbaxy Laboratories Limited Composition de pulvérisation topique d'halobétasol
WO2015086241A1 (fr) * 2013-12-10 2015-06-18 Henkel Ag & Co. Kgaa Traitement capillaire contenant de l'huile et du polyéthylène glycol
US10736839B2 (en) 2014-07-11 2020-08-11 Novan, Inc. Topical antiviral compositions, delivery systems, and methods of using the same
US11040006B2 (en) 2014-07-11 2021-06-22 Novan, Inc. Topical antiviral compositions, delivery systems, and methods of using the same
US12403087B2 (en) 2014-07-11 2025-09-02 Ligand Pharmaceuticals Incorporated Topical antiviral compositions, delivery systems, and methods of using the same
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US10322081B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US11723858B2 (en) 2014-07-11 2023-08-15 Novan, Inc. Topical antiviral compositions, delivery systems, and methods of using the same
US10925689B2 (en) 2014-07-14 2021-02-23 Novan, Inc. Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same
WO2016077884A1 (fr) * 2014-11-18 2016-05-26 Sndr Pty Ltd Composition topique
US20180280293A1 (en) * 2015-04-15 2018-10-04 Maruho Co., Ltd. Pharmaceutical composition for skin
EP3283051A4 (fr) * 2015-04-16 2019-01-02 Kate Somerville Skincare, LLC Compositions auto-moussantes et procédés
US11291616B2 (en) 2015-04-23 2022-04-05 The Procter And Gamble Company Delivery of surfactant soluble anti-dandruff agent
US10561586B2 (en) * 2015-05-28 2020-02-18 Beiersdorf Ag Sprayable high viscosity cosmetic formulation
US20160346173A1 (en) * 2015-05-28 2016-12-01 Beiersdorf Ag Sprayable high viscosity cosmetic formulation
US11547641B2 (en) * 2015-05-28 2023-01-10 Beiersdorf Ag Sprayable high viscosity cosmetic formulation
EP3097903A1 (fr) * 2015-05-28 2016-11-30 Beiersdorf AG Formulation cosmétique de viscosité élevée pulvérisable
US10849864B2 (en) 2015-07-28 2020-12-01 Novan, Inc. Combinations and methods for the treatment and/or prevention of fungal infections
LU92931B1 (fr) * 2015-12-24 2017-07-20 Pihuit S A Composition et méthode antiparasites
US10912743B2 (en) 2016-03-02 2021-02-09 Novan, Inc. Compositions for treating inflammation and methods of treating the same
US11446217B2 (en) 2016-03-03 2022-09-20 The Procter & Gamble Company Aerosol antidandruff composition
US10311575B2 (en) 2016-03-23 2019-06-04 The Procter And Gamble Company Imaging method for determining stray fibers
US11166980B2 (en) 2016-04-13 2021-11-09 Novan, Inc. Compositions, systems, kits, and methods for treating an infection
CN105770237A (zh) * 2016-04-22 2016-07-20 广东红珊瑚药业有限公司 一种具有止痒、消炎功效的泡沫剂及其制备方法
US11612551B2 (en) 2016-05-11 2023-03-28 Formulated Solutions, Llc Whipped formulations
CN110035663A (zh) * 2016-05-11 2019-07-19 拜耳医药保健有限责任公司 热稳定的打成泡沫的制剂
US11622922B2 (en) 2016-05-11 2023-04-11 Formulated Solutions, Llc Whipped formulations
US11826440B2 (en) 2016-05-11 2023-11-28 Formulated Solutions, Llc Thermal-stable whipped formulations
US11964035B2 (en) 2016-05-11 2024-04-23 Beiersdorf Ag Whipped gel formulations
US12138332B2 (en) 2016-05-11 2024-11-12 Formulated Solutions, Llc Whipped formulations
US12161737B2 (en) 2016-05-11 2024-12-10 Formulated Solutions, Llc Whipped formulations
CN106045875A (zh) * 2016-06-25 2016-10-26 仇颖超 一种盐酸土霉素的制备方法
US10039799B2 (en) * 2016-07-20 2018-08-07 Lillian Jenkins Princess lite
WO2018040692A1 (fr) * 2016-08-29 2018-03-08 江苏四新界面剂科技有限公司 Procédé de préparation d'un émulsifiant polydiméthylsiloxane
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10799434B2 (en) 2016-10-21 2020-10-13 The Procter & Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits
WO2018075850A1 (fr) * 2016-10-21 2018-04-26 The Procter & Gamble Company Dosage de mousse destiné à distribuer un volume de dosage et une quantité de tensioactif souhaités par un consommateur dans un espace de formulation optimal
CN109843252A (zh) * 2016-10-21 2019-06-04 宝洁公司 指定毛发体积有益效果的浓缩型洗发剂泡沫剂型
US10653590B2 (en) 2016-10-21 2020-05-19 The Procter And Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits comprising an anionic/zwitterionic surfactant mixture
WO2018075838A1 (fr) * 2016-10-21 2018-04-26 The Procter & Gamble Company Dosage de shampooing concentré de mousse pour fournir des bénéfices de soins capillaires
WO2018075847A1 (fr) * 2016-10-21 2018-04-26 The Procter & Gamble Company Dosage de shampooing concentré de mousse désignant des avantages de volume des cheveux
WO2018075845A1 (fr) * 2016-10-21 2018-04-26 The Procter & Gamble Company Shampooing à dosage concentrée de mousse pour améliorer le conditionnement des cheveux
US11129783B2 (en) 2016-10-21 2021-09-28 The Procter And Gamble Plaza Stable compact shampoo products with low viscosity and viscosity reducing agent
WO2018075841A1 (fr) * 2016-10-21 2018-04-26 The Procter & Gamble Company Dosage de shampooing concentré de mousse pour fournir des bénéfices de soins capillaires
US11141361B2 (en) 2016-10-21 2021-10-12 The Procter And Gamble Plaza Concentrated shampoo dosage of foam designating hair volume benefits
US11154467B2 (en) 2016-10-21 2021-10-26 The Procter And Gamble Plaza Concentrated shampoo dosage of foam designating hair conditioning benefits
US10842720B2 (en) 2016-10-21 2020-11-24 The Procter And Gamble Company Dosage of foam comprising an anionic/zwitterionic surfactant mixture
US11202740B2 (en) 2016-10-21 2021-12-21 The Procter And Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits
US10441519B2 (en) 2016-10-21 2019-10-15 The Procter And Gamble Company Low viscosity hair care composition comprising a branched anionic/linear anionic surfactant mixture
CN109862943A (zh) * 2016-10-21 2019-06-07 宝洁公司 用于提供毛发护理有益效果的浓缩型洗发剂泡沫剂型
CN109862941A (zh) * 2016-10-21 2019-06-07 宝洁公司 用于提供毛发护理有益效果的浓缩型洗发剂泡沫剂型
CN109862944A (zh) * 2016-10-21 2019-06-07 宝洁公司 用于以最佳制剂空间递送消费者所需的剂型体积和表面活性剂量的泡沫剂型
US10888505B2 (en) 2016-10-21 2021-01-12 The Procter And Gamble Company Dosage of foam for delivering consumer desired dosage volume, surfactant amount, and scalp health agent amount in an optimal formulation space
US11602493B2 (en) 2017-05-11 2023-03-14 Beiersdorf Ag Gel formulations
US11224567B2 (en) 2017-06-06 2022-01-18 The Procter And Gamble Company Hair compositions comprising a cationic polymer/silicone mixture providing improved in-use wet feel
US11679073B2 (en) 2017-06-06 2023-06-20 The Procter & Gamble Company Hair compositions providing improved in-use wet feel
US11141370B2 (en) 2017-06-06 2021-10-12 The Procter And Gamble Company Hair compositions comprising a cationic polymer mixture and providing improved in-use wet feel
WO2019036770A1 (fr) * 2017-08-24 2019-02-28 University Of South Australia Compositions antimicrobiennes et procédés d'utilisation
US10426713B2 (en) 2017-10-10 2019-10-01 The Procter And Gamble Company Method of treating hair or skin with a personal care composition in a foam form
US11992540B2 (en) 2017-10-10 2024-05-28 The Procter & Gamble Company Sulfate free personal cleansing composition comprising low inorganic salt
US11129775B2 (en) 2017-10-10 2021-09-28 The Procter And Gamble Company Method of treating hair or skin with a personal care composition in a foam form
US11904036B2 (en) 2017-10-10 2024-02-20 The Procter & Gamble Company Sulfate free clear personal cleansing composition comprising low inorganic salt
US11607373B2 (en) 2017-10-10 2023-03-21 The Procter & Gamble Company Sulfate free clear personal cleansing composition comprising low inorganic salt
US11116705B2 (en) 2017-10-10 2021-09-14 The Procter And Gamble Company Compact shampoo composition containing sulfate-free surfactants
US11116704B2 (en) 2017-10-10 2021-09-14 The Procter And Gamble Company Compact shampoo composition
US11116703B2 (en) 2017-10-10 2021-09-14 The Procter And Gamble Company Compact shampoo composition containing sulfate-free surfactants
CN107875083A (zh) * 2017-10-18 2018-04-06 福建恒安集团有限公司 一种抗尿布疹涂布剂及其制备方法
US10912732B2 (en) 2017-12-20 2021-02-09 The Procter And Gamble Company Clear shampoo composition containing silicone polymers
US11285171B2 (en) 2018-03-01 2022-03-29 Novan, Inc. Nitric oxide releasing suppositories and methods of use thereof
US11318073B2 (en) 2018-06-29 2022-05-03 The Procter And Gamble Company Low surfactant aerosol antidandruff composition
WO2020049086A1 (fr) * 2018-09-05 2020-03-12 Leo Pharma A/S Composition d'aérosol pharmaceutique
US12226505B2 (en) 2018-10-25 2025-02-18 The Procter & Gamble Company Compositions having enhanced deposition of surfactant-soluble anti-dandruff agents
CN109575264A (zh) * 2018-10-26 2019-04-05 东莞理工学院 一种以戊内酯为溶剂提取聚羟基脂肪酸酯的方法
CN109575264B (zh) * 2018-10-26 2021-09-28 亿科优生物降解材料研究院(广东)有限公司 一种以戊内酯为溶剂提取聚羟基脂肪酸酯的方法
US20220117860A1 (en) * 2018-11-30 2022-04-21 3M Innovative Properties Company Topical antimicrobial microemulsions
US20210169928A1 (en) * 2019-07-22 2021-06-10 Erivan Bio, Llc Topical Exosome Compositions and Associated Methods
WO2021022056A1 (fr) 2019-07-31 2021-02-04 Foamix Pharmaceuticals Ltd. Compositions et procédés et leurs utilisations
US11980679B2 (en) 2019-12-06 2024-05-14 The Procter & Gamble Company Sulfate free composition with enhanced deposition of scalp active
US11679065B2 (en) 2020-02-27 2023-06-20 The Procter & Gamble Company Compositions with sulfur having enhanced efficacy and aesthetics
US12427099B2 (en) 2020-11-23 2025-09-30 The Procter & Gamble Company Personal care composition
US11819474B2 (en) 2020-12-04 2023-11-21 The Procter & Gamble Company Hair care compositions comprising malodor reduction materials
US11771635B2 (en) 2021-05-14 2023-10-03 The Procter & Gamble Company Shampoo composition
US12409125B2 (en) 2021-05-14 2025-09-09 The Procter & Gamble Company Shampoo compositions containing a sulfate-free surfactant system and sclerotium gum thickener
US11986543B2 (en) 2021-06-01 2024-05-21 The Procter & Gamble Company Rinse-off compositions with a surfactant system that is substantially free of sulfate-based surfactants
US12458575B2 (en) 2021-12-09 2025-11-04 The Procter & Gamble Company Sulfate free personal cleansing composition comprising effective preservation
CN115463091A (zh) * 2022-10-27 2022-12-13 新基元(北京)医药科技有限公司 一种改善稳定性的米诺环素泡沫剂
WO2025080295A1 (fr) * 2023-10-09 2025-04-17 Kojian Md James Compositions topiques comprenant des solutions émulsifiées de povidone iodée et procédés de préparation
US11975021B1 (en) * 2023-10-09 2024-05-07 James Kojian Topical compositions comprising emulsified povidone iodine solutions and methods of preparation

Also Published As

Publication number Publication date
WO2009098595A2 (fr) 2009-08-13
CA2714015A1 (fr) 2009-08-13
US8795635B2 (en) 2014-08-05
US20140248219A1 (en) 2014-09-04
EP2257276A2 (fr) 2010-12-08
US9682021B2 (en) 2017-06-20
AU2009211147A1 (en) 2009-08-13
WO2009098595A3 (fr) 2009-11-12
US20100221195A1 (en) 2010-09-02
CA2714015C (fr) 2017-03-21

Similar Documents

Publication Publication Date Title
US9682021B2 (en) Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US11103454B2 (en) Wax foamable vehicle and pharmaceutical compositions thereof
US20080206155A1 (en) Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
US9439857B2 (en) Foam containing benzoyl peroxide
US10821077B2 (en) Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9622947B2 (en) Foamable composition combining a polar solvent and a hydrophobic carrier
US9549898B2 (en) Oil and liquid silicone foamable carriers and formulations
US20070292359A1 (en) Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20080152596A1 (en) Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
EP2029106A2 (fr) Vecteur expansible à base de polypropylène glycol et compositions pharmaceutiques associées
WO2007085902A2 (fr) Composition moussante combinant un solvant polaire et un vecteur hydrophobe
IL196363A (en) Foams as carriers of dicarboxylic acids and will be used as pharmaceuticals
US20130189195A1 (en) Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: FOAMIX LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAMARKIN, DOV;FRIEDMAN, DORON;ZIV, ENBAL;AND OTHERS;REEL/FRAME:020914/0485;SIGNING DATES FROM 20080409 TO 20080429

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: FOAMIX PHARMACEUTICALS LTD., ISRAEL

Free format text: CHANGE OF NAME;ASSIGNOR:FOAMIX LTD.;REEL/FRAME:033446/0129

Effective date: 20140601